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 Abstract 
Rhodiola rosea, Eleutherococcus senticosus, Epimedium and Panax species have been 
used in complementary and alternative medicine for thousands of years and are used 
worldwide for their range of curative effects.  In order for any herb preparation to be 
considered medicinally effective, it must be given at a sufficient dosage level, as well, for 
therapeutic purposes, the correct plant species is most important.  Due to the lack of quality 
control, many herb-containing products that are made available to consumers on the 
market today may contain misidentified plant species, counterfeit ingredients, an 
insufficient quantity of the known active compounds and spiking with marker compounds.  
Therefore, better regulation and effective control of commercial herbal products are 
needed. 
There are three major aims for this research programme: 
1) Development of analytical methods for the detection of major biological marker 
compounds of Rhodiola rosea, Eleutherococcus senticosus, Epimedium and Panax species 
and establishment of their HPLC profiles. 
2) The developed methods from above to be used to evaluate raw materials and 
commercial products containing the Rhodiola rosea, Eleutherococcus senticosus, Epimedium 
and Panax species. 
3) Establish Rapid Resolution Liquid Chromatography methods for each single herb and 
analyze multiple chemical constituents simultaneously in formulated products containing 
Rhodiola rosea, Eleutherococcus senticosus, Epimedium and Panax species. 
 
 4) To determine if the proposed developed methods are practical for use, and 
furthermore, with respect to selected commercial products to clarify that their content 
matches the claim on their label. 
 Traditionally, single marker compounds are used for the evaluation and 
determination of herbs.  This presents a restriction and consequently many counterfeit 
products are found on the market.  Therefore HPLC profile analysis for the multiple chemical 
constituent is needed for a more accurate identification of herb species and provides 
significance for the analysis of formulated products.  R. rosea, E. senticosus, Epimedium and 
Panax species were included in this study as these four herbs are often used in different 
mixture combinations to make the so-called “energy formula”.  This includes the 
simultaneous analysis of up to twenty active ingredients from these four herbs, namely, 
salidroside, tyrosol, eleutheroside B, E, rosarin, rosavin, rosin, rosiridin, Rg1, Re, epimedin A, 
B, C, icariin, Rb1, Rc, Rb2 and Rd. 
A rapid and effective method for the determination of phenylpropanoids, 
phenylethanol and monoterpenoids from R. rosea, eleutherosides B and E from E. 
senticosus, flavonol glycosides from Epimedium species and ginsenosides from Panax 
species in one injection using the reverse-phase Rapid Resolution Liquid Chromatography 
was successfully developed and used to evaluate the botanical combination.  This 
breakthrough example will lead the industry to optimum quality control methods, especially 
for formulated botanical products.  As well, the results will provide herbalists with more 
confidence in accepting the so-called “standardized botanical extracts”.  This developed 
method can simultaneously analyse Rhodiola, Eleutherococcus, Epimedium and Panax 
containing products to ensure the correct species . 
 Keywords:   Rhodiola rosea, Eleuthercoccus senticosus, Epimedium, Panax species, ginseng, 
Panax quinquefolius, RRLC, ginsenosides, rosavins, HPLC profile, eleutheroside, flavonol 
glycoside 
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Chapter 1  Introduction 
Herbs have been used widely long before the curative function of herbs was 
acknowledged.  Our ancestors experienced the healing powers of plants, but never 
understood the basis of these actions.  About 3000 BC, the properties of medicinal plants 
were written about and noted in many cultures, such as Egypt, Middle East, India and China, 
but to them, these uses of plants were related to magical qualities.  By 500 BC, medicine 
started separating from the spiritual world.  Hippocrates, a Greek “father of medicine”, was 
one of the first to claim this, and thought that all illnesses were of natural cause rather than 
spells and magic.  By the 2nd century, the trade in plants used as medicines flourished and, 
therefore, many authors attempted to record their possible uses to treat ailments and 
diseases.  Dioscorides, in the 1st century AD, successfully wrote one of the first herbal 
medicine books, De Materia Medica.  Another renowned author, Galen, also proposed his 
theory of the four humors around 131 – 200 AD (Chevallier 1996). 
There is no doubt that modern medicine is able to save lives and relieve symptoms 
but the shortage of modern medicine prevails in times of, for example, war or access to 
synthetic medicines is limited to developed countries due to the expensive cost of such 
products.  After thousands of years of experience, it is clear that herbal medicine still plays a 
great role in relieving the symptoms of many ailments. Currently, herbal medicines are 
available widely and in some countries are also used in conjunction with modern medicine 
where they may provide usually a safer, more gentle and tolerable means to relieve 
symptoms or heal sickness (Chevallier 1996). 
While herbal medicines are usually safe to use, some plant products may produce 
side effects or even toxic effects (Chevallier 1996).  The effect of herbal medicines in the 
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body depends on the chemical constituents of the plant.  Traditionally, plants were 
consumed as food. Our ancestors came to realize that some herbs had medicinal properties 
to offer.  Traditional Chinese Medicinal (TCM) theory believes in bringing harmonious 
interactions and holism of our body to the environment, nature and universe, and 
emphasizing the holism of body, mind, and spirit as well as the systems, organs, tissues and 
functions of our body.  Even a single herb contains multiple related secondary metabolites 
and it is believed that all of these secondary metabolites contribute to provide a combined 
effect.  For example, berberine from the crude extract of Coptis chinensis Franch. is not the 
only compound to provide an anti–inflammatory effect, other proto-type quaternary 
alkaloids within the extract all contribute towards this this effect (Wei et al. 1991). 
 Current knowledge informs us that active compounds are responsible for a plant’s 
medicinal properties.  Some of the main types of constituents could be divided into the 
following classes of compounds: mucilage (polysaccharides that soak up water to produce a 
lining on the mucous membranes of the digestive tract to protect it against irritation, acidity 
and inflammation) (Chevallier 1996), phenols (usually used to reduce inflammation, e.g.  
salicylic acid) (Macedo et al. 2006), tannins (improve resistance to infection) (Min et al. 
2005), coumarins (often used as anti-coagulant and sunscreen agents, muscle relaxants and 
fragrance enhancers due to its ability to increase the flavour perception) (Chevallier 1996, 
Felter et al. 2006), anthraquinones (gives colour to fruits and flowers of plants and many are 
associated with laxative action) (Khan and Han 2003, Schorkhuber et al. 1998), 
glucosinolates (help increase blood flow, remove build up of waste products and reduce 
thyroid hormone production) (Chevallier 1996), volatile oils (provide anti-inflammatory 
effects) (Qi et al. 2011, Aqel 1991), saponins (aid the absorption of nutrients) (Chevallier 
1996, Francis  et al. 2002), cardiac glycosides (strengthen and improve rate of contraction of 
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the heart muscle especially in heart failure, help transfer fluids from circulatory system to 
urinary tract and therefore aid in lowering blood pressure, ie. diuretics) (Chevallier 1996, 
Gleitz and Peters 1997), cyanogenic glycosides (provide a sedative and relaxing effect on the 
heart and body muscles) (Chevallier 1996), alkaloids (used to treat some types of cancer, ie. 
Prostate cancer, reduce muscle spasms, relieve pain and dry up body secretions, ie.  
diarrhea) and minerals such as iron (helps maintain levels for body to function effectively, ie. 
prevent anaemia). 
 The demand for herbal drugs is increasing exponentially; the more articles and books 
published on its usage and effectiveness, the higher the demand (Ma 2009).  Therefore, the 
direction of the development of the natural health product market has been influenced by 
the demand of the products.  In the early 1990’s, herbs used in commercial natural health 
products sold on the North American market consisted of the original herb or its extract by 
ratio; for example, making 5 kg of raw herb into 1 kg of extract through extraction process, 
this is the so called standardization.  Quality control aims to meet a product labels claim by 
using available analytical methods.  This has usually been set against a single marker 
compound as the standard for the identification and quantification of the herbs or extracts 
(Ma 2009) and is not ideal in the context of herbal products.  Panax species are well known 
popular herbs that are available on the natural health product market which illustrates this.  
Three major species, namely, P. quinquefolius L, P. ginseng C.A. Meyer and P. notoginseng 
Burkill., contain the same or similar active compounds, but their function varies depending 
on the TCM theory.  There is variation in the relative content ratio of the compounds in 
these species and a HPLC method has been developed, providing chromatograms that 
profile each of the species (Ma et al. 1996).  Ma et al. also identified and confirmed that 
approximately 35% of the P. quinquefolius products found on the market do not meet their 
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respective label claim, for example, many products claim P. quinquefolius on their label, but 
on testing were determined to contain P. ginseng.  This lack of discrimination arises usually 
because only the glycosides Rg1 and Rb1 are used as standards (Ma et al. 1995, Chinese 
pharmacopeia 2005).  A considerable number of botanical extracts sold to the public are 
spiked with synthetic compounds or other plants species which contains the marker 
compound (Ma et al. 1995).  Hence, verification of plant species based on one or two 
compound is not sufficient for its identification and the full spectrum of chemical 
constituents is required to be taken into consideration for the identification of extracts by 
means of their HPLC profiles (Ma et al. 1996, Ma et al. 2011b).  Rapid Resolution Liquid 
Chromatography (RRLC), a relatively new technique that is easy, fast and reliable was 
introduced 3-5 years ago.  It has been proven that with RRLC, there is up to five times more 
sensitivity, as well 60% more resolution and the analyses are 20 times faster compared to 
conventional HPLC.   It offers unlimited possibilities for automated method development, as 
well as its ability to analyse thousands of samples per day it is definitely an asset to the 
pharmaceutical industry, as the characteristics of the herbs show many different chemical 
constituents (Agilent Website 2009).  The majority of natural health products sold on the 
market are formulated herb-based product and, therefore, a fast, simple and simultaneous 
RRLC analytical method is crucial for such identification. 
 There are many recent publications on optimum growth conditions such as the origin 
of growth, processing methodologies and best season for harvesting for each TCM as well as 
botanical herb (Ma et al. 1996).  Consequently, establishing an effective analytical method 
and analysing multi – chemical constituents rapidly became an important issue in the quality 
control of botanical products.  The main reason for the analysis is to set up a standard which 
leads to a better understanding of each herb’s chemical composition as well as any changes 
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relating to each chemical compound from degradation within formulated products.  For 
example, as reported by Ma et al. in 2011, chlorogenic acid present in Lonicera japonica 
Thunb. will degrade if left overnight in neutral to basic conditions (Ma et al. 2011c).   This 
understanding allows improvement of its harvesting procedure yielding a higher 
concentration of active compounds, and retaining the concentration of active compounds in 
extracts during manufacturing procedures. 
 In general, in the natural health product market, there are three main problems with 
manufactured semi – finished and finished products: first of all, lack of adequate quality 
control of active compounds found in herbs; second of all, the content of active compounds 
not meeting its label claim nor meeting the concentration and species requirement set for 
the international market; and third of all, the species claimed on the label is not the one 
presented in the product. A similar problem in the dairy market is that of melamine which 
has been used for protein adulteration and has caused several deaths in babies (The Times 
2008).   Many of these problems results from spiking the product with other chemical 
compounds or collection and use of wrong plant species (Wei et al. 1991).  The lack of 
proper quality control management has caused the general public to have low confidence in 
products containing natural herbal extracts.  Hence to cultivate trust in natural health 
products, government regulatory affairs department and international pharmacopoeia 
commissions are working collaboratively to try to set up the international recognized 
standard in the industry. 
In addition, quality has safety and efficacy implications with regard to the available 
natural products, especially when formulated products and TCM retail product are 
commonly seen on the market (Marles 2012).  Therefore, Health Canada indicates that all 
finished products sold in Canada are mandatory to be in compliance with the Natural Health 
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Product Regulations, which includes Good Manufacturing Practice (GMP) for all procedures 
for the process of manufacturing the finished product.  As one of the leading Canadian 
phytopharmaceutical research team in the natural health product field, the development of 
analytical methods proposed in this study have been in collaboration with both Chinese 
Pharmacopoeia and American Herbal Pharmacopeia and have been correlated with the 
demand of products on the natural health product market.  
The current research project has focused on a popular “energy formula”, which 
contains four herbs, namely, Rhodiola rosea L., Epimedium species, Panax quinquefolius L. 
and Eleutherococcus senticosus Maxim., that is available in the European and North 
American natural health product markets.  All of these four herbs are adaptogens, and their 
main function is to provide resilience with minimal disturbances to the normal physiological 
functions of the organism, increasing resistance when the organism is under wide range of 
harmful factors, such as, physical, chemical and biological nature factors, as well normalizes 
the organism irrespective of the direction of the preceding pathological changes (Brekhman 
and Dardymov 1968).  
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1.1 Rhodiola L. Species 
Species of the genus Rhodiola L. have properties as adaptogens and belong to the 
Crassulaceae family.  The Rhodiola species prefer mountainous habitats and are found all 
over the world in such areas as the Himalayas, parts of Southwest China, Altai Mountains 
across Mongolia into Siberia, extending to Iceland and British Isles across Scandinavia and 
the Alps and other such regions such as the Carpathian Mountains (Darbinyan et al. 2000, 
Komarov 1939, Hegi 1963).  As well, many Rhodiola species have been discovered in Alaska, 
Canada, northern mountains of United States (Hegi 1963) where they generally grow 
naturally in a circumpolar distribution in dry sandy ground at high altitudes (Ma et al.2008).  
Before World War II, some Rhodiola species were originally listed within different genera in 
a sub-family Sedoidae (Hegi 1963) and later they were classified into a sub-genus under a 
larger genus Sedum containing around 10 species.  Hegi identified around 50 species of 
Rhodiola and placed them into a separate genus (Hegi 1963).   
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Figure 1.1:  Photographs showing Rhodiola rosea plant flowering stage and its roots. 
 
There are more than 200 species of Rhodiola that have been identified.  At least 20 
of these species are used in traditional Chinese medicine, including R. crenulata, R. alterna, 
R. brevipetiolata, R. kirilowii, R. quadrifida, R. sachalinensis and R. sacra (Kelly 2001).   
Among all the Rhodiola L. species, R. rosea has been extensively researched as an adaptogen 
with various health-promoting effects and was first mentioned in 77 A.D. by the Greek 
physician, Dioscorides, in the De Materia Medica for its medicinal applications (Mell 1938). 
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This plant reaches a maximum of around 70 cm and produces yellow blossoms (Figure 2.1).  
It is a perennial plant with a thick rhizome and a rose-like fragrance when cut, therefore it is 
commonly known as the rose, golden or arctic root (Khanum et al.2005).    Between 1725 to 
1960, various medicinal applications of R. rosea also appeared in scientific literature 
publications from Germany, Sweden, Norway, France, Soviet Union and Iceland (Linnaeus 
1754, Linnaeus 1749, Linnaeus 1725, Linnaeus 1768, Commission Nationale de la 
Pharmacopee Francaise 1974, Sandberg 1998, Mashkovskij 1976) and, not too long ago, in 
Nunavik, Canada, a new arctic population of R. rosea was found (Avula et al.2009).  Interest 
in R. rosea has been fairly extensive since 180 published articles have featured this plant 
since 1960.  However, most of these publications have been in Scandinavian and Slavic 
languages and this had hindered the spread of this knowledge to the rest of the Western 
world. 
 
For centuries it has been claimed that only family members of a mountain Siberian 
village knew the secret passage to harvesting R. rosea and methods for extracting its active 
ingredients (Saratikov et al.1987).  For the first time since 1969, R. rosea was included as an 
official Russian medicine by the Committee of Soviet Ministry of Health. They described it 
for use as a stimulant for fatigue, infectious illness, psychiatric and neurological conditions, 
to increase attention span, memory, and work productivity.  Since then, in Swedan, R. rosea 
has been recognized for its anti-fatigue and psycho-stimulant properties, and as an herbal 
medicinal product (Sandberg 1998).  In Denmark, R. rosea is recognized as a botanical drug 
known to increase mental work capacity, strength and a psycho-stimulant (Sandberg 1998). 
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Rhodiola species have been known to improve resistance in a variety of organisms 
against different environmental stress conditions (Linnaeus 1749), therefore, increasing the 
life span of organisms (Linnaeus 1725) by decreasing liver toxicity and anticancer activity 
(Linnaeus 1768), antioxident activity (Commission Nationale de la Pharmacopee Francaise 
1974), antidiabetic activity (Sandberg 1998), and enhancement of learning and memory 
(Mashkovskij 1976). For centuries, they have also been used by Asians and Eastern 
Europeans to extend longevity, resistance to altitude sickness and to treat fatigue, anaemia, 
gastrointestinal ailments, impotence, infections, physical endurance, and nervous system 
disorders (Linnaeus 1749).  According to Linnaeus, R. rosea can also diminish vaginal 
discharge, hysteria, treatment of hernia and headache (Linnaeus 1749).   
 
A number of studies have shown that R. rosea can increase the bioelectrical activity 
of the brain and as well can enhance learning based on emotionally positive reinforcement 
and in contrast, relatively large doses were found to have a sedative effect. It has been 
evaluated to have a stimulating effect causing the release of neurotransmitters namely, 
norepinephrine, dopamine, serotonin and nicotinic cholinergic, otherwise these compounds 
are primarily involved with thinking, analyzing, evaluating, calculating, planning, attention, 
memory, learning, and storing, storage and retrieval of information function within the 
brain (Darbinyan et al. 2000, Saratikov et al. 1987a, Kurkin et al. 1985a, Kurkin et al. 1986, 
Saratikov 1974, Saratikov et al. 1967, Spasov et al. 2000a, Spasov et al. 2000b, Saratikov et 
al. 1987b, Petkov et al. 1990, Baranov et al. 1994, Komar et al. 1981, Stancheva et al. 1987, 
Lazarova et al. 1986, Petkov et al. 1986, Saratikov et al. 1978, Marina  et al. 1968). 
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The cholinergic system uses the neurotransmitter acetylcholine and enables retrieval 
of memory, but when agents block the acetylcholine interaction then memory is affected.  R. 
rosea reverses this blockage and therefore increases memory function (Marina and 
Alekseeva 1968, Furmanowa et al. 1998). It can also improve memory by increasing 
tolerance to physical and emotional stress. Emotional stress is a main factor that can 
interfere with the function of memory. Therefore, R. rosea can benefit both immediate 
memory performance and as well as long-term preservation of brain function (Furmanowa 
et al. 1998, Joseph et al. 1999).  Clinical studies to evaluate the beneficial effects of R. rosea 
were conducted on 53 healthy subjects and 412 patients with neuroses and asthenic 
syndromes.  50 mg was administered three times a day for a period of ten days to four 
months.  Approximately 60% of the patients who had symptoms such as fatigue, headache 
and weakness, were reported to have been alleviated of these symptoms (Krasik et al.1970a, 
Krasik et al. 1970b, Saratikov and Krasnov 1987c). 
 
Not only does R. rosea benefit mental fatigue, but it has also been shown to promote 
physical endurance in a study with 42 master level skiers.  After taking either R. rosea 
extract or a placebo, out of the 42 master level skiers, the skiers that had taken the R. rosea 
extract were able to perform with less arm tremor and better coordination.  After 30 
minutes of rest time, the group that had taken R. rosea had a heart rate of only 104-106% 
over the baseline, whereas the placebo group had heart rate of 128.7% over the baseline.  
Overall, R. rosea significantly improved recovery time, strength, endurance, cardiovascular 
measure and coordination (Saratikov et al. 1987d). 
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Clinical studies have demonstrated that R. rosea is able to improve an individuals’ 
ability to deal with stress, which usually involves catecholamines, serotonin and endorphins.  
The serotonin system is very important for a body to deal with stress, and R. rosea has been 
shown to increase the release of serotonin in the brain and therefore decrease stress.  As 
well, it increases stress tolerance by adjusting the opioid and catcholamine release levels 
(Lishmanov et al. 1987, Maslova et al. 1994). 
 
R. rosea also relieves cardio-stress.  Studies have shown that it is able to prevent 
reduction in levels of myocardial catecholamines and cyclic adenosine monophosphate 
(cAMP), and thus reduce stress associated damage to the heart tissue (Lishmanov et al. 
1987, Maslova et al. 1994, Maimeskulova et al. 1997). One clinical study showed that 
subjects taking an adaptogen formula consisting of 50 mg R. rosea root extract, 100 mg of 
eleuthero root extract and 150 mg of schisandra fruit extract, improved the contractility 
strength of their heart muscle (Baranov 1994).   
 
The International Classification of Diseases (ICD-10) by the World Health 
Organization recognises neurasthenia with symptoms such as: exhaustion after minor 
mental effort, fatigue after minor physical effort, muscle pains, dizziness, tension headaches, 
sleep disturbance, inability to relax, irritability, inability to recover through rest.  Relaxation 
and enjoyment does not occur in the presence of organic mental disorders, affective 
disorders or panic, or generalized anxiety disorder (U.S. Department of Health and Human 
Services 1992).  A clinical study was conducted among 27 students, physicians and scientists 
between the age of 19 – 46 to take 10 drops of R. rosea tincture once or twice a day for 2 – 
3 weeks a few days before intense intellectual work.  Results showed that R. rosea was able 
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to help improve the neurasthenia symptoms (Kraski et al. 1970).  Studies have also shown 
that a single dose of R. rosea will not improve these symptoms but, with prolonged use, it 
has improved perception and processing of information even more than Eleutherococcus 
senticosus, another herb with similar functions as R. rosea (Darbinyan et al. 2000). 
 
Like many adaptogens, R. rosea also enhances thyroid function. It is able to do so 
without the side effect of hyperthyroidism (Maslova et al 1994).  Other favourable effects of 
R. rosea that have been demonstrated in rats are muscle building, gonad strengthening and 
egg maturation (Gerasimova 1970). 
 
R. rosea also has the ability to protect the nervous system from oxidative damage 
from free radicals.  Phenolic compounds are known to have strong antioxidant properties 
and R. rosea is well known for its high content in phenolic compounds (Furmanowa et al. 
1998, Bolshakova et al. 1997).  Anti-cancer drugs such as cyclophophaminde, rubomycin and 
adriamycin are known to be a hematotoxic or hepatotoxic.  Udintsev et al. and Borovskaya 
et al. were able to show, using an animal model, that R. rosea is able to decrease the toxicity 
of anti-cancer drugs and also to enhance the anticarcinogenic properties of the drugs 
(Borovskaya et al. 1988, Udintsev et al. 1991, Udintsev et al. 1992). 
 
R. rosea has been demonstrated to possess low levels of toxicity, but this only occurs 
with an intake of 235,000 mg dosage (Udintsev et al. 1991). The regular dosage on available 
preparations is only 200 – 600 mg/day, therefore, the margin of safety is quite large 
(Udintsev et al. 1991). Overall, R. rosea is found to display beneficial properties and is safe 
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for internal use, but there are reports of some patients becoming agitated, jittery or over 
activated (Brown et al.2002).   
 
1.1.1 Chemical Constituents of Rhodiola L. Species 
More than forty chemical constituents occurring in Rhodiola L. species have been 
identified.  These belong to diverse groups of natural products:  triterpenes, monoterpeoids, 
cyanoglycosides, phenolic acids, flavonoids, phenylpropanoids and phenylethanoids.  Some 
of these have been investigated and reported as potential active compounds (figure 1.2) 
(Yousef et al. 2006, Kurkin et al. 1985b, Zapesochnaya et al.1982, Du et al.1994, Zuo et al. 
2007, Akgul et al. 2004). 
 Triterpenes:  daucosterol, beta-sitosterol 
 Monoterpenoids:  rosiridol, rosaridin 
 Phenolic acids:  chlorogenic acid, hydroxycinnamic acid, gallic acid 
 Flavonoids:  rodiolin, rodionin, rodiosin, acetylrodalgin, tricin 
 Phenylpropanoids:  rosavin, rosin, rosarin 
 Phenylethanol:  salidroside, tyrosol 
Standardization of R. rosea root extracts was first undertaken in 1970 with salidroside as 
the principle pharmacological compound (Saratikov et al. 1987).  Therefore, all of the R. 
rosea extracts and tinctures were recommended by the Russian Pharmacopoeia Committee 
to standardize to a minimum of 0.8% salidroside (Kurkin et al. 1985a).  After 10 years, the 
demand for R. rosea increased drastically, and the quality and effectiveness of these herbs 
declined due to some of the R. rosea being substituted by other Rhodiola species containing 
salidroside (Kurkin et al. 1985b).  In 1986, it was discovered that R. rosea comprises a unique 
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chemical composition in comparison to other species of Rhodiola, namely, the presence of 
rosavin, rosin and rosarin, also known as rosavins (Kurkin et al. 1986, Dubichev et al. 1991, 
Ganzera et al. 2001).  Salidroside was then reported to be present in all species of Rhodiola 
and as well as Salix triandra L., Vaccinium vitis-idaea L. and Rhododendron species.  Hence, it 
was considered that standardization against salidroside is not suitable for the identification 
of R. rosea (Bridel et al. 1926, Thieme 1969a, Thieme 1969b).  In 1989, it was established 
that rosavins are the markers for R. rosea extracts, but also acknowledged that they are not 
the only pharmacological active ingredients in the plant.  Consequently, R. rosea extract is 
now standardized with both salidroside and the rosavins with a ratio of 3:1 as represented 
by their naturally occurring proportions (The Russian Federation Ministry of Health and 
Medical Industry 1989). 
 
Figure 1.2:  Chemical structures of 6 bioactive compounds in R. rosea roots: (1) salidroside, 
(2) tyrosol, (3) rosarin, (4) rosavin, (5) rosin  (6) rosiridin.      
 
1.1.2 Methods used for the analysis of active compounds occurring in Rhodiola species 
A variety of methods have been used to analyze the active constituents in Rhodiola L. 
species, such as, TLC, GC, HPLC, and capillary zone electrophoresis (Table 1.1). Among these 
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techniques, HPLC has been considered to be the most effective method to evaluate and 
analyze the active compounds of Rhodiola species simultaneously because some 
compounds cannot be analyzed by GC/MS due to their thermal instability, high polarity, or 
high molecular weight (proteins, peptides, nucleic acids, oligosaccharides).  
By means of HPLC and a C18 reverse phase column, salidroside was shown to occur 
in R. crenulatae and is detailed in the 2010 Chinese Pharmacopeia (Chinese Pharmacopeia 
2010).  Mao et al. (2007) used the microwave – assisted extraction (MAE) followed by high 
performance liquid chromatographic analysis on an Agilent HPLC 1100 with a photodiode 
array detector for the quantification of salidroside and tyrosol.  A Shimadzu LC – 6A HPLC 
system was used by Peng et al. for the identification of just salidroside (Peng et al. 2009). In 
contrast, a LC/MS system used by Yu et al. consisted of Shimadzu LC – 10AD HPLC series 
liquid chromatography and a Shimadzu LC/MC – 2010A single quadrupole mass 
spectrometer for the analysis of salidroside from R. rosea (Yu et al. 2008).   High – speed 
counter – current chromatography was used by Li and Chen for the purpose of isolation and 
purification of salidroside from R. sachalinensis A. Bor. (Li et al. 2001).  Han et al. used a 
different model (GS 20) of this analytical technique, but for the purification of salidroside 
from R. crenulata (Han et al. 2002).  In 2003, Tolonen et al. used a sensitive 2690 Alliance LC 
and Micromass Quattro II triple – quadruple MS system for identification of salidroside, 
sachaliside 1, rosin, 4-methoxycinnamyl-O-β-glucopyranoside, rosarin, rosavin, cinnamyl-(6’-
O-β-xylopyranosyl)- O-β-glucopyranoside, 4-methoxy-cinnamyl-(6’-O-α-arabinopyranoxyl)- 
O-β-glucopyranoside, rosiridin and benzyl- O-β-glucopyranoside from R. rosea (Tolonen et al. 
2003a).  In the same year, Tolonen et al. also published an HPLC method in conjunction with 
the aforementioned work using a Waters 996 PDA detector for the quantification of 
salidroside and rosavin from R. rosea L. extract (Tolonen et al. 2003b).  Chang et al. used an 
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on – line SPE – LC – MS/MS method with Agilent 1100 series LC system with a Biosystems 
Sciex API 3000 tandem mass spectrometer for the quantification of salidroside (Chang et al. 
2007).  Waters 2690 Alliance HPLC system was used as well by Petsalo et al., but in 
conjugation with LCT TOF mass spectrometer for the identification of flavonoids herbacetin, 
gossypetin and kaempferol found in R. rosea plants (Petsalo et al. 2006).  Ganzera et al. 
used the Waters Alliance 2690 HPLC system with a 996 photodiode array detector for the 
analysis of five marker compounds found in R. rosea, namely, salidroside, rosarin, rosavin, 
rosin and rosiridin (Ganzera  et al. 2001).  Capillary electrophoresis (CE) was used for the 
separation of Rhodiola L. species because of its speed efficiency, reproducibility, ultra – 
small sample volume and little consumption of solvents, when coupled with electrochemical 
detection; it gives high selectivity of electroactive analytes and high sensitivity.  
Zapesochnaya and Kurkin identified three cinnamyl alcohol glycosides, namely, rozin, 
rosavin and rosarin using ethanol for extraction from rhizomes of R. rosea (Zhou et al. 2007).  
In 2002 Rohloff used steam distillation and headspace solid – phase micro – extraction with 
gas chromatography – mass spectrometry to gain detailed information about the 
composition of terpenic and volatile components found in rhizomes of R. rosea (Rohloff 
2002). 
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Table 1.1:  Comparison of different techniques used for the identification and analysis of Rhodiola L. species 
Article Technique/Method Apparatus Used Mobile Phase Parameters 
2010 Chinese 
Pharmacopeia (Chinese 
Pharmacopoeia 
Commission 2010) 
HPLC with C18 
Reverse phase 
column 
HPLC with C18 Reverse 
phase column 
methanol: water (15:85) 275 nm, 10 µL, 
Mao et al. (Mao et al. 
2007) 
MAE and HPLC with 
photodiode array 
detector 
Agilent 1100 HPLC with 
Zorbax SDB – C18 Column 
(150 x 4.6 mm, 5.0 µm) and 
SB – C18 guard column (4.6 
x 12.5mm) 
80% aqueous methanol: water 
(20:80) 
1.0 mL/min, 10 µL, 25 °C, 190 – 800 
nm 
Peng et al. (Peng et al. 
2009) 
HPLC Shimadzu LC – 6A LC with 
Shim – pack ODS (150 x 4.6 
mm, 5 µm) and Shimadzu 
LC – 6A system with 
Pehnomenex ODS (250 x 10 
mm, 8 µm) 
methanol: water (15:85); 
methanol: water (11:89) 
1.0 mL/min, 25 °C, 20 µL, 275 nm 
Yu et al. (Yu et al. 2008) LC/MS Shimadzu LC – 10AD HPLC 
and Shimadzu LC/MS – 
2010A single quadrupole 
mass spectrometer with 
Shim – pack ODS (250 x 2.0 
mm, 4.6 µm) 
Methanol: 100 µM ammonium 
chloride (25:75) 
40 °C, 0.2 mL/min for HPLC; curve 
dissolution line and block 
temperature were at 250 °C and 
200 °C, respectively, nebulizer gas 
(nitrogen) had a flow rate of 1.5 L/min 
and drying gas at 4.0 L/min. Probe 
voltage, CDL voltage and detector 
voltage at – 4.5 kV, 10 V and 1.6 kV, 
respectively 
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Li and Chen (Li et al. 2001) High – speed 
counter – current 
chromatography 
High – speed counter – 
current chromatography 
n-butanol: ethyl acetate: water 
(2:3:5) 
2.0 mL/min, 276 nm 
Han et al. (Han et al. 2002) High – speed 
counter – current 
chromatography 
Model GS 20 analytical high 
– speed counter – current 
chromatography and 
preparative HSCCC on 
Model FS10A2 multilayer 
coil planet centrifuge with a 
PTEE multilayer coil of 110 
m x 1.6 mm 
water: acetonitrile (19:1) 35 °C, 1.0 mL/min, 280 nm, 
Tolonen et al. (Tolonen et 
al. 2003a) 
LC/MS 2690 Alliance LC with 
Waters Polarity 2.1 x 50 
mm, 3 µm column and 
Synergi Max – RP 2.0 x 4.0 
mm pre-column 
Starts out with 90% A (water, 
0.1% formic acid, 0.02% formic 
acid + 10 mM ammonium 
acetate, 10 mM ammonium 
acetate)-5% B (Acetonitrile)-5% 
C (methanol) and changed 
linearly to 76% A-12% B-12% C 
within a range of 16 mins 
35 °C, 5 µL, 0.3 mL/min for HPLC, m/z 
range of 80 – 530, positive and 
negative capillary voltages were 3.4 
and – 3.2 kV, sample cone voltages 
were 22 V and - 20 V, extraction cone 
voltage were 4 and – 3 V, respectively, 
nebulising and drying gas (nitrogen) 
were 201/h and 400/h, desolvation 
temp was 320 °C, source temp was 
150 °C and column flow rate was 0.3 
mL/min 
Tolonen et al. (Tolonen et 
al. 2003b) 
HPLC Waters 2690 Alliance HPLC 
system with Xterra RP 18 
column (2.1 x 50 mm, 3.5 
µm) 
10 mM ammonium acetate pH 
6.95 (A) – acetonitrile (B) at a 
gradient elution of 0 – 4 mins, 0 
– 1% A, 4 – 38 mins, 1 – 9% A 
20 µL, 276 and 254 nm, 26 °C, 0.6 
mL/min 
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Chang et al. (Chang et al. 
2007) 
On – line SPE – LC – 
MS/MS 
Agilent 1100 LC with Agilent 
TC – C18 reverse – phase 
column (4.6 x 150 mm, 5 
µm)  
Position 1: 10 mM ammounium 
acetate containing 0.1% formic 
acid (A): acetonitrile (B) 
(70:30), Position 2: 0-1.5 mins, 
30% B, 2 mins, 70% B, 2 – 4 
min, 70% B, 4.1 min, 30% B, 4.1 
– 5 mins, 30% B. 
100 µL, 1.5 mL/min 
Petsalo et al. (Petsalo et 
al. 2006) 
HPLC – MS Waters 2690 Alliance HPLC 
system with Waters 
Symmetry C18 column (2.1 
x 100 mm, 3.5 µm) with 
Phenomenex Luna C18 pre-
column (2.0 x 4.0 mm); LCT 
TOF mass spectrometer 
with ESI LockSpray ion 
source 
0.1 % formic acid (A) and 
acetonitrile (B) at a linear 
gradient from 5 to 40% B 
within 60 mins 
30 °C, 10 -20 µL, 276 and 254 nm, 0.3 
mL/min for HPLC; capillary voltage of 
3.5 and – 3.5 kV, cone voltage at 25 
and – 35 kV, desolvation and source 
temperature at 220 and 150 °C, 
respectively, drying gas (nitrogen) 
flow rate at 850 L/h  
Ganzera et al. (Ganzera et 
al. 2001) 
HPLC Waters Alliance 2690 HPLC 
system equipped with a 996 
photodiode array detector 
were used with a 
Phenomenex Luna C18 
column (150 x 4.6 mm, 5 
µm) 
25 mM phosphate buffer pH 
7.0 (A) and acetonitrile (B) at a 
gradient of 0 – 30 mins, 5 – 
20% B 
10 µL, 205 nm, 1 mL/min, 60 °C 
Zapesochnaya and Kurkin 
(Zhou et al. 2007) 
CE – ED Capillary electrophoresis – 
electrochemical detection 
N/A 7.5 – 6.2 ppm region 
Rohloff (Rohloff 2002) GC – MS Virian Star 3400 CX gas 
Chromatography with 
Saturn 3 mass spectrometer 
and Chrompack CP – Wax 
52 CB (30 x 0.32 mm x 0.25 
µm) 
N/A For oil samples the oven initially at 
60 °C and increase 2 °C/min until it 
reaches 210 °C then held for 5 mins, 
the injector, transfer line and detector 
temperatures were 220, 210 and 
175 °C, respectively 
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1.2 Eleutherococcus senticosus (Araliaceae) 
The New Royal Horticultural Society Dictionary of Gardening (1992) noted that there 
are approximately 30 different species of Eleutherococcus. These species grow to about 2 – 
7 meters tall, their stems are erect, sparingly branched and covered in thorns that point 
backwards.  The fine prickly leaves of this plant are three to five foliate, petioles to 
approximately 12 cm (Figure 1.3).  These shrub-looking plants grow in the eastern parts of 
Asia, such as East of Russia, the Amur Region, Primorksy Krai, Sakhalin, as well as Northeast 
China, Korea and Japan.  Eleutherococcus came from the Greek word eleutheros, meaning 
“free” and kokkos meaning “pip” or “seed”.  Between the 1950 – 1960’s, the availability of 
wild P. ginseng was in extremely short supply, partly compounded by its long cultivation 
time.  This prompted the Russians to search for a new source that can display similar 
pharmacological activity and ‘tonic ‘ properties (Bretschneider 1898, Brekhman 1968). 
Eleutherococcus senticosus (Rupr. & Maxim.), the only Eleutherococcus species that grows in 
Russia, also known as Siberian ginseng is thought to possess habit and gross morphology 
which are similar to P. ginseng.  The name Siberian ginseng was given to E. senticosus due its 
first exportation from Siberia, since then the designation has persisted, but the species was 
never referred to as Siberian ginseng by the Russian people.  E. senticosus is also referred to 
by other names, “eleuthero”, “eleutherokokk” or “eleutherococcus”. Eleutherococcus was 
first discovered in 1830 by a physician, Porphyrii Yevdokimovich Kirilov.  Many plant 
specimens, including E. senticosus and P. ginseng were plants collected by Kirilov 
(Bretschneider 1898).  In 1968, Brekhman reported that E. senticosus has identical or even 
superior pharmacological effects compared to P. ginseng (Brekhman 1968).  Coincidently, 
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both E. senticosus and P. ginseng have been reported to be “adaptogens” due to their ability 
to ‘non-specifically increase resistance’ (Brekhman 1968).   
 
 
 
 
Figure 1.3:  Photograph showing Eleutherococcus senticosus flowering branch and shrub. 
 
Adaptogens have been viewed to have the ability to normalize immune responses of 
an organism to various stresses (Mowrey 1993, Rege et al. 1999).  It acts as a protection 
against harmful radicals, as well as acts synergistically with other antioxidants, and 
therefore, it can maintain, prevent or maybe even treat certain diseases (Sies 1994). For 
example, adaptogens could help sustain the health of those who have been diagnosed with 
AIDS or other immune deficiency syndromes (Peterhans 1994).  E. senticosus was reported 
to have the ability to synthesise betulinic acid, which provides anti-carcinogenic and anti-
viral effects, as well as many anti-oxidative compounds (Zhao 1993, Yasukawa et al. 1991). 
Packer et al. also noted that E. senticosus also provides a protective anti-oxidative 
effect after extensive exercise at a high altitude, under external stress. It increases the 
production of oxygen species as the result of compensating the lack of oxygen in the outside 
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environment, resulting from the anti-oxidative effect of vitamin E and other anti-oxidants 
contained in plant extracts (Packer et al. 1994). 
E. senticosus has also been proposed to display aphrodisiac effects.  Phenolic 
compounds in E. senticosus have a similar or maybe even identical effect to Viagra, they 
temporarily inhibit nitric oxide as a result of cyclic GMP signal transduction inhibition 
(Mowrey 1993, Goldstein et al.1998, Ratsch 1997). 
E. senticosus and Panax species are both classified within the family Araliaceae, but 
they have very different chemical compositions.  In 1968, Brekhman reported that E. 
senticosus contains secondary compounds such as lignans, saponins, coumarins, vitamins, 
various sugars etc., whereas Panax species contains mostly saponins (Brekhman 1968).  
Not only do E. senticosus and Panax species differ in their chemical compounds, but 
their pharmacological effects do not overlap completely.  For example, they both help 
increase the ability to do physical and mental work, help recover more quickly and fully 
from serious diseases (Brekhman 1968, Mowrey 1993).  As well, they display similar 
properties of anti-cancer and anti-oxidative effects.  In contrast, the anti-stress activity, 
decrease in tonic pain, overcoming impotence and adverse effects from morphine are all 
associated with P. ginseng and are properties that E. senticosus does not exhibit (Mogil et al. 
1998, Kim et al.1998a, Yoshimura et al. 1998, Kim et al. 1998c).  
 
1.2.1. Chemical Constituents of E. senticosus 
 In the late 1950 – 1960, Brekhman et al. investigated the pharmacological effects of 
E. senticosus (Brekhman 1968). Between 1970 – 1980, they examined the chemical 
composition of the active compounds in the plant and concluded that the two most 
important compounds are eleutheroside B and E (details provided below). Harvesting during 
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the spring and autumn yields the greatest concentration of these eleutherosides. 
Ogasawara et al. noted in 1998 that it is very useful to quantify the production of these 
secondary metabolites as they provide better understanding of the pharmacological effects 
of the new drugs for development which may then be adjusted to the needs to each patient 
(Ogasawara et al. 1998).  As well, the concentration of these secondary metabolites is very 
important for the determination of efficacy and safety. When their amount is altered 
significantly, over-consumption may lead to lack of activity, altered activity or even toxicity 
(Ogasawara et al.1998). 
  
Eleutherosides of Eleutherococcus are divided into two different classes, namely, 
triterpenoidal saponins which includes eleutherosides I, K, L and M composed of glycosides 
of olenolic acid, as well as the phenylpropane derivatives which include glycosylated 
eleutherosides B, B1, D and E ((-) syringoresinol)  (Wagner 1980, Sonnenborn et al. 1993).  In 
1994, Lewis and Davin suggested that lignans such as sesamin, syringoresinol etc, are 
secondary products of E. senticosus which have been evolutionarily-derived by elaboration 
of the phenylpropanoid pathway to protect the plant from harmful free radicals that cause 
cancer, and hence the display of anti-cancer properties in plants by E. senticosus (Lewis et al. 
1994).  Some of the chemical constituents that occur in the plant and their reported 
beneficial physiological/pharmacological properties are given below. 
 
1. Eleutheroside B (Syringin) 
This has been shown to improve white blood cell count and thrombocyte count 
which were previously damaged by radiation in mice, as well as inhibiting 
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immunohaemolysis of antibody-coated sheep erythrocytes by guinea pig serum (Ruijun et al. 
1990, Kapil et al.1997). 
 
Figure 1.4:  Chemical structure of syringin. 
 
2. Eleutheroside B4 (Sesamin) 
 Sesamin reduced the risk of atherosclerosis in humans, as well decreased the group 
of mammary cancerous cells in female rats after 12 weeks of intake (Hirata et al.1996, 
Hirose et al.1992, Nonaka et al. 1997). 
  
Figure 1.5:  Chemical structure of sesamin. 
 
3. β-Sitosterol-3β-D-gluco-pyranoside 
 This compound has been found to inhibit growth of human colon cells by activating 
the sphingomyelin cycle, thus producing anti-inflammatory, anti-pyretic, anti-hyperglycemic 
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effects as well as reducing the absorption of cholesterol (Awad et al. 1998, Gupta et al. 1980, 
Heinemann et al. 1993, Ivorra et al. 1988). 
 
Figure 1.6:  Chemical structure of β-sitosterol-3β-D-gluco-pyranoside 
 
4. Eleutheroside B1 (Isofraxidin) 
 Eleutheroside B1, also known as isofraxidin, displays anti-cancer activity and 
stimulates liver bile when administered at 25 mg/kg (Borris et al.1980, Danielak et al.1973). 
 
Figure 1.7:  Chemical structure of eleutheroside B1, isofraxidin. 
 
5. Caffeic acid and Caffeic acid ethyl ester 
 Caffeic Acid displays anti-oxidative, anti-tumour, anti-gout, anti-bacterial, prevents 
hepatitis and anti-xanthine oxidase activity (Cha et al.1995, Soliman et al.1998, Aziz et 
al.1998, Radtke et al. 1998, Kaul et al.1998).  The ethyl ester of caffeic acid confers anti-
oxidative protection to single stranded DNA breaks in Chinese hamster V79 cells after 
damage caused by hydrogen peroxide (Nokayama et al.1996). 
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Figure 1.8:  Chemical structure of caffeic acid caffeic acid ethyl ester. 
 
6. Coniferyl aldehyde 
 Coniferyl aldehyde possesses anti-oxidative effects against skin damaged induced by 
UV light-derived hydroxyl radicals (Taira et al.  1992). 
 
Figure 1.9:  Chemical structure of coniferyl aldehyde. 
  
1.2.2. Methods demonstrated to be feasible for the analysis of active compounds 
occurring in Eleutherococcus species 
 
1.2.2.1. Thin – Layer Chromatography – Densitometry  
 Vanhaelen and Vanhaelen-Fastre focused on the analysis of the roots of E. senticosus, 
P. ginseng and Picrorrhizakurroai using thin-layer chromatographic (TLC) analysis linked with 
densitometry.  A high speed TLC-scanner CS-920 with 1.2 x 1.2 mm beam was used.  TLC 
plates precoated with silica gel 60F254 (10 x 20 cm; Art. 5729; for HPTLC, Art. 5642; E. Merck) 
and saturated mobile phase tanks.  Solutions were spotted 15 mm from the lower edge of 
the plates and developed with a complex mixture of 1, 2-dichloroethane-ethanol-methanol-
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water (65:22:22:7), and the compounds detected by spraying with  1% vanillin ethanolic 
solution and a 5% sulphuric acid ethanolic solution in a 1:1 ratio, then heated at 120 °C for 
2.5 min and measured at 530 nm.  Three compounds were associated to form a band and 
the distance between the spots were 3 mm (Vanhaelen and Vanhaelen-Fastre 1984). 
 
1.2.2.2. High Performance Liquid Chromatography 
Vanhaelen and Vanhaelen-Fastre, in addition to the thin-layer chromatographic (TLC) 
technique, also established an isocratic elution method for HPLC system for the roots of E. 
senticosus, P. ginseng and Picrorrhiza kurroai (Vanhaelen and Vanhaelen-Fastre 1984). Since 
then an HPLC gradient elution method has been reported in the 2009 United States 
Pharmacoepia that is based on determination of the content of eletherosides B and E 
(Members of the USP Dietary Supplements and Food Ingredients Expert Committees 2009).  
Zgorka and Kawka identified free phenolic acids, namely, protocatechuic, chlorogenic, p 
hydroxybenzoic, vanilic, caffeic, syringic, p coumaric and ferulic as occurring in the roots of E. 
senticosus by means of the Hewlett – Packard model 1050 LC reverse  phase high 
performance liquid chromatography (Zgorka et al. 2001).  In 2006 Feng et al. used a Waters 
Alliance 2487 HPLC with a 2996 photodiode array detector for the identification of 
eleutheroside B and E (Feng et al.2006).  A modified HPLC method that quantitatively 
evaluates the three main bioactive constituents in E. senticosus, namely, elutherosides B-,E, 
and isofraxidin by means of a SPD – M10A VP diode array detector has been proposed by 
Zhu et al. (Zhu et al. 2011).  Lucio – Gutierrez et al. proposed a fast identification method for 
the purpose of authentication of E. senticosus by using a scanning monochromator NIR 
Systems model 5000 spectrometer to provide a near infrared spectral fingerprint (Lucio-
Gutierrez et al. 2011).  See Table 1.2 for more detailed information. 
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Table 1.2:  Comparison of methods used for the identification and analysis of Eleutherococcus senticosus 
Article Method Apparatus Used Mobile Phase Parameters 
Vanhaelen and Vanhaelen 
– Fastre (Vanhaelen et al. 
1984) 
TLC and 
HPLC 
High speed TLC-scanner CS-920 used 
to scan a precoated silica gel 60F254 
plates from E. Merck 
1,2 – dichloroethane:ethanol: 
methanol:water (65:22:22:7) and 
water-ethanol-acetic acid (85:16:1) 
1.1 mL/min, 530 nm and 235 nm, 
120 °C 
2009 USP HPLC HPLC with 4.0 mm x 25 cm column, 5 
µm packing 
water:acetonitrile 95:5 (A): 
acetonitrile:water 60:40 (B) 0 – 5 
mins, 3% B, 5 – 30 mins, 3 – 40% B, 
30 – 31 mins, 40 – 95% b, 31 – 45 
mins, 95% B, 45 – 45.1 mins, 95 – 
3% B, 45.1 – 60 mins, 3% B 
1.0 mL/min, 220 nm 
 
 
 
 
 
Zgorka and Kawka (Zgorka 
et al. 2001) 
HPLC HP model 1050 LC and a stainless 
steel column 200 x 4.6 mm, 5 µm and 
HP 1100 HPLC with a Symmetry 
column 250 x 4.6 mm, 5 µm 
methanol:water:acetic acid 
(23:77:1), methanol:0.001M 
phosphoric acid (23:77) 
1 mL/min, 254 nm, 20 µL, 30 °C 
Feng et al. (Feng et al. 
2006) 
HPLC Waters Alliance 2487 HPLC and 2996 
photodiode array detector with a 
Kromasil ODS column 250 x 4.6 mm, 
5 µm 
water (A) and acetonitrile (B) at a 
gradient elution of 0 to 15 mins 90 
– 80% A, 15 – 40 mins, 80 – 50% A 
0.8 mL/min, 220 nm  for 
eleutheroside E and 206 nm for 
eleutheroside B, 10 µL, 25 °C 
Zhu et al. (Zhu et al. 2011) HPLC HPLC system with a SPD – M10A VP 
diode array detector with a Waters 
XTerra phenyl (4.6 mm x 150 mm, 3.5 
µm) coumn 
acetonitrile (A) and 20 mM 
NaH2PO4 at pH 4.3 (B) with a 
gradient condition of 0 – 5 mins, 8 
– 13% A, 5 – 39 Mins, 13 – 30% A 
0.8 mL/min, 207 nm for 
eletheroside E, 264 for 
eleutheroside B and 340 nm for 
isofraxidin, 10 µL,  40 °C 
Lucio-Gutierrez et al. 
(Lucio-Gutierrez et al. 
2011) 
NIR scanning monochromator 
NIRSystems model 5000 
spectrometer 
N/A Spectra were collected over the 
spectral region of 1100 – 2498 nm 
with a resolution of 2 nm.  
Samples were scanned in 40 mm 
diameter 10 mm thickness  
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1.3 Epimedium L. (Berberidaceae) 
Epimedium L. species were first discovered in the early 1700’s. Historically they have 
been referred to by many different names, such as,  Barrenwort, Bishop’s Hat, Fairy Wings, 
Horny Goat Weed, Xian-linpi, Yangheye, Rowdy Lamb Herb and Yin Yang Huo (Ma et al. 
2011a).  They are also called the three branches-nine leaves grass because of their 
appearance (Ma et al. 2011a). Epimedium species grows very low on the ground. Their 
stems spread above the soil as a deciduous, perennial plant equipped with leathery leaves.  
The name Bishop’s Hat come from the shape of their flowers, they bloom in a variety of 
colours, such as purple, pink, rose, yellow or white (Ma et al. 2011a).  Epimedium plants are 
tough, lasting perennials ideal for providing a beautiful cover for the ground during spring 
(Ma et al. 2011a).  Figure 1.10 below shows the leaves and flowers of an Epimedium species 
and also the dense covering of the ground by the plant. The stems are characteristically 
branched into three with a leaf on each branch.  
  
Figure 1.10: Photographs showing leaves, flowers and ground cover by Epimedium species. 
Epimedium L. species are distributed in the central parts of China, such as Sichuang, 
Hunan and Hubei provinces, as well as Japan, Russia, Indian, Southern Europe and Bulgaria. 
They normally grow on cliffs under moist forests near streams and wet lands, prefer acidic 
soils, and no direct sunlight. Therefore, during dry and hot seasons, Epimedium species must 
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be watered to protect the major constituents within the plant (Ying et al. 2001, Zhang et al. 
2003). Thirteen species of Epimedium were reported to be growing in China by 1975 (Yen 
1975).  This number was extended by 1980 to twenty nine (Stearn 1990, Stearn 1997a, 
Stearn 1997b, Stearn 1993a, Stearn 1996, Stearn 1995, Stearn 1993b, Stearn 1990, Orgisn 
1996, He et al. 1996).  By 1987, around 56 species had been documented (Guo et al. 1987).  
Currently, more than fifteen species of Epimedium are used extensively in Traditional 
Chinese Medicine, but only five of these species are recorded in the Chinese pharmacopoeia 
to possess medicinal use, namely, E. bravicornum Maxim., E. sagittatum (Sieb. Et Zucc) 
Maxim., E. koreanum Nakai, E. pubescens Maxim. and E. wushanense T.S. Ying  (Chinese 
Pharmacopoeia Commission 2010); therefore, on the commercial market, it is not necessary 
to specifically categorize each species.    
 
The stems and leaves of Epimedium species have been used for more than 2000 
years in Traditional Chinese Medicine and Japanese Kampo for its warming or “Yang” tonic 
which provides great therapeutic properties for the Kidney (Chinese Pharmacopoeia 
Commission  2010, Xiao et al. 1993), enhances the immune system (Hu 1997), increase 
sperm production in the reproductive system and therefore useful for sexual enhancement 
(Markarova et al. 2007, Niu 1989), stimulates cerebral and peripheral circulation to 
decreases chances of memory loss, chronic tiredness and numbness (Meng et al. 1996, 
Tadano et al. 1992), induces dilation of coronary blood vessels to improve conditions such 
as hypertension and angina in the cardiovascular system (Yu et al. 1992), and improves 
osteoporosis and menstrual irregularity (Wang et al. 2004, Meng et al. 2005).  In Korea, E. 
koreanum has been used traditionally for spermatorrhoea, impotence and forgetfulness (Liu 
et al. 1984).  The roots of Epimedium species are also widely used as anti-rheumatic 
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medicine in Chinese folk medicines (China Herb Compilation 1975).    Traditionally, 
Epimedium is usually steeped in water or macerated in wine, but nowadays, more 
convenient ways with the herb incorporated in formulations such as tablets and capsules 
are available. 
 
Since the Han dynasty (202 BC – 220 AD), Epimedium plants, such as, E. sagittatum 
have been used for its “Yang” tonic in treating “Coldness” and male impotence (erectile 
dysfunction) (Chinese Pharmacopoeia Commission 2010, Xiao et al.1993, Li et al. 1991).  The 
intake of Epimedium plants can improve the symptoms of deficiency in “Yang” by facilitating 
the pituitary gland(s)-glandular system and inducing glucocorticoid release, thus increasing 
the level of testosterone and oestradiol and reducing lutinizing hormones (Wang et al. 2004).  
In 2009, Chen found that the major chemical constituents of Epimedium plants exhibit an 
inhibitory effect on phosphodiesterase-5-(PDE-5) (Chen 2009).  Epimedium has also been 
tested and found to have ability to mimic a male-hormone-like effect. Wang et al. found 
that, in rats, after 14 days of taking an Epimedium decoction dose of 2.0 mg/kg body weight, 
there was improved sexual function and an increased content of plasma testosterone (Wang 
et al. 2001).  Luo and She et al. also showed that guinea pigs fed with 5g/kg of Epimedium 
plants for 8 weeks and rats fed with 150mg/kg for 7 days, showed significant growth of their 
testicles, epididymis, adenohypophysis, seminal vesicles, anterior pituitary gland and their 
whole body weight (Hou et al. 2004).  As well, consumption of Epimedium plants protects 
the structure and functions of sperm membranes by improving their superoxide dismutase 
activity and intervening in lipid peroxidation.  It also stimulates the sensory nerves causing 
an increase in the amount of testosterone secretion and signs of sexual arousal (Guo et al. 
2005, Wang et al. 2007d).  Like Viagra and Cialis®, the chemical compounds in Epimedium 
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can increase libido and improve erectile function.  Many different inhibitors of 
phosphodiesterases are known and one of the most popular is Viagra®.  Viagra® is a drug 
used for erectile dysfunction and it is made of the citrate salt of sildenafil, which enhances 
the effect and local release of nitric oxide by selectively inhibiting cyclic guanosine 
monophosphate (cGMP)-specific phosphodiesterase type V (PDE-5).  Inhibition of PDE-5 by 
sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth 
muscular relaxation and inflow of blood to the corpus cavernosum (Zoma et al. 2004). 
The traditional Chinese medicine use of Epimedium species in the treatment of 
osteoporosis was confirmed by Ji et al by oral administration of 50-200 mg/kg/day for one 
month of an Epimedium plant which improved the content of both calcium and phosphorus 
in the bones of rats suffering from osteoporosis (Gao 1992a). Furthermore, the main 
compound in these species, icariin has been shown to reduce erythrocyte aggregation and 
whole-blood viscosity, inhibit vascular smooth-muscle extra cellular Ca2+ influx and 
peripheral vascular expansion, increase blood flow and improve the structure and function 
of bone tissue (Ma et al. 2011a). 0.1 µmol/L of icariin will also improve the proliferation of 
goat bone marrow-derived stroma cells by increasing the proportion of cells in the S and 
G2/M phases (Gao 1992b).  In general, Epimedium species are able to prevent osteoporosis 
by promoting osteoblast proliferation and increase bone formation, inhibit osteoclast-
raising activities and decrease bone absorption level and promote collagen synthesis and 
matrix mineralization in bone stroma cells (Ma et al. 2011a). 
 
Icariin expands the coronary blood vessels, the femoral artery and cerebral blood 
vessels.  It has a direct effect on relaxing vascular smooth muscle in a non-competitive 
inhibition manner, significantly reduces noradrenaline-promoting extracellular Ca2+ influx, 
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and reduces the contraction of the basilar artery.  Studies have shown that icariin increases 
the cerebral blood flow through the expansion of vascular smooth muscle and lowers 
cerebral vascular resistance to protect the brain from ischemic injury and improves cerebral 
ischemia and cerebral hypoxia in laboratory animals (Hou et al. 2004) 
 
Studies on rats have also shown that intake of 0.25 to 0.50 mg/ml of Epimedium 
species or doses of 17 and 34 mg/kg of total flavones has significant reduction in their heart 
rate and reduced myocardial contract to prevent myocardial ischemia as well as improve 
circulation through the coronary artery (Guo et al. 2005, Wang et al. 2007d).  Epimedium 
also reduces platelet aggregation, therefore, lowering blood viscosity and inhibiting 
thrombosis and promoting angiogenesis activity (Wang et al. 2004, Gao 1992a, Gao 1992b) 
 
Zhao et al. showed that icariin at concentrations of 62.5, 125 or 250 mg/L provides 
inhibitory effects on the human promyelocytic leukemia cell line HL-60 after 12 hours 
incubation. With 100 mg/L the nitro blue tetrazolium chloride was reduced after 48 hours of 
incubation, resulting in rod-shaped nuclei with decreased nuclear volume and inhibition of 
proliferation of the HL-60 cells (Zhao  et al. 1996a, Zhao  et al. 1996b, Zhao et al. 1997, Zhao  
et al. 1995).  
 
1.3.1 Chemical Constituents of Epimedium species 
More than 260 compounds have been identified from the fifty-six species of 
Epimedium. Natural products such as flavonoids, lignans, ionones, phenol glycosides, 
phenylethanoid glycosides, sesquiterpenes and some secondary metabolite classes have 
also been identified.  Lignans, such as Icariside E1, E2, E3, E4, E5, E6, E7, (+)syringaresinol-O-β-
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D-glucoside, (-)olivil-4”-O-β-Dglycopyranoside, dihydrodehydrodiconiferyl alcohol-
4’glucoside,(+)-lyoniresinol-3-O-xyloside, (-)-lyoniresinol-3-O-xyloside, icariol A1, A2, 3,5-
demetholxy-syringaresinol-glucoside, (-)-olivil, (+)-dihydro-dehydrodiconiferyl alcohol-4-O-β-
D-glucopyranoside, (+)-cycloolivil, EL1, EL2,  EL3, EL4, EL5, EL6, EL7, EL8, EL9  have been 
isolated from Epimedium grandiflorum Morr., E. diphyllum Graham, E. sagittatum (Sieb. et 
Zucc.) Maxim., E. koreanum Nakai, E brevicornum Maxim..  They are a class of secondary 
metabolites that consists of two-phenyl-propanoid molecues connected by 8-8’ carbon 
atoms.  (Zheng et al. 2002, Miyaes et al. 1987a, Miyaes et al. 1988, Miyaes et al. 1991, 
Matsushita et al. 1991, Wang et al. 2007a, Yang et al. 2009b).   
Ionones such as, Icariside B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, blumenol C glucoside, 
roseside which are found in Epimedium species, such as, E. grandiflorum, E. diphyllum, E. 
sagittatum (Miyaes et al. 1987a, Miyaes et al.1988, Miyaes et al. 1991, Matsushita et al. 
1991, Miyaes et al. 1987b).  Phenol glycosides such as ikarisoside A1, A2, A3, A4, A5, A6, 
epimedoicarisoside A and icariside A7 were isolated and identified from E. grandiflorum and 
E. koreanum (Miyaes et al. 1988, Miyaes et al. 1991, Miyaes et al. 1987b, Sum et al. 1995b, 
Li et al. 1995b).  Up to date, five phenethyl alcohol glycosides have be isolated and identified, 
ikarisoside D1, D2, D3, salidroside and thalictoside from Epimedium grandiflorum, E. 
sagittatum, E. diphyllum and some other plants (Miyaes et al. 1988, Miyaes et al. 1991, 
Matsushita et al. 1991).  Five sesquiterpenoids have been isolated from E. grandiflorum, 
namely, icarisoside C1, C2, C3. C4 and icariside F (Miyaes et al. 1987b).  They are a class of 
terpenes with a molecular formula of C15H24, composed of 15-carbons derived from the 
assembly of three isoprenoid units (Miyaes et al. 1987b).   
Of the many chemical constituents that are known to occur in Epimedium species, 
flavonoids are the most recorded and characterised, there are more than 141 different 
 36 
types of flavonoids found to occur in 17 species of Epimedium.  Among this group, only the 
prenyl-flavonoids, characteristic of the Berberidaceae family, have been reported as the 
major constituents (Wu et al. 2003a).  Some of the species of Epimedium that contain 
prenyl-flavonoids and the regional locations where they are grown are presented in Table 
1.3.  Flavonol glycosides with a prenyl group substituted at C-8 position are the main type of 
chemical constituents in Epimedium species.  Four of these, namely epimedins A, B, C and 
icariin, are used as quality control markers for standardizing Epimedium species (Baroon et 
al. 1996, Harborne 1994, Liu et al. 2006a, Lin et al. 1987).  5-Prenyl-flavonoids such as Icariin, 
icaritin, desmethylicaritin, des-methylanhydroicaritin, icariside II, ikarisoside A, baohuoside I, 
baohuoside II, epimedokoreanin B, breviflavone B, luteolin, hyperoside, epimedin B and C 
have been tested and reported to possess the “Yang” effect by increasing libido, as well, as 
exhibiting anti-tumour, antioxidant, antiradiation, antiinflammatory, antimicrobial, 
antihepatotoxic, cardiovascular, neutroprotective, anti-aging, antidepressant, anxiolytic 
oestrogenic effects and many other activities (Ma et al. 2011a). 
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Table 1.3:  Distribution of Epimedium species in parts of Asia and the different types of 
prenyl-flavonoids occurring in the various species 
Species  Location  Prenyl-Flavonoids 
E. brevicornum      Shanxi, Sichuang China Icariin (Liao et al. 1994), anhydroicaritin (Guo et 
al. 1996a), Icariside I (Liao et al. 1994), icariside 
II (Liao et al. 1994), 2”-O-rhamnosyl icarisid II 
(Guo et al. 1996), epimedin A (Wang  et al. 
2005), B (Guo et al. 1996a), C (Guo et al. 1996b), 
sagittatoside B (Guo  et al. 1996a), diphylloside 
C (Ikarisoside C) (Guo et al. 1996a), ikarisoside A 
(Baohuoside II) (Guo et al. 1996a), ikarisoside F 
(Guo et al. 1996a), baohuoside VI (Yan et al. 
1998), breviflavone A (Yap et al. 2005), B 
(Mizuno et al. 1987), hexandraside E (Yan et al. 
1998) , wushanicariin (Yan et al. 1998) 
 
E. sagittatum      China Icariin (Mizuno et al. 1987), desmo-O-
methylicariine (Zhao 2001), icariside I (Mizuno 
et al. 1987), icariside II (Baohuoside I) (Mizuno 
et al. 1987), epimedin A (Wang et al. 2005), B 
(Wang et al. 2005), C (Wang et al. 2005), 
sagittatoside A (Mizuno et al. 1988), B (Mizuno 
et al. 1988), C (Mizuno et al. 1988), sagittasine 
A (Mizuno et al. 1988), B (Mizuno et al. 1988), C 
(Mizuno et al. 1988), hexandraside F (Wang et 
al. 2005) 
 
E. koreanum Korea, China, Japan Icariin (Li et al.1995a), icariin I (Wang et al. 
2010a, Wang et al. 2010b), icariin II (Wang et al. 
2010a, Wang et al. 2010b), anhydroicaritin (Sun 
et al. 1998a), anhydroicaritin 3-O-
rhamnosylrhamnoside (Li et al. 1996b), 
demethylanhydroicaritin (Zheng et al. 2002), 
Icariside I (Li et al. 1995a), 2”-O-
rhamnopyranosyl icariside I (Sun et al. 1995a), 
icariside II (Baohuoside I) (Sun et al. 1995a), 2”-
O-rhamnosyl icariside II (Kang et al. 1991), 3”’-
carbonyl-2”-β-L-quinovosyl Icariside II (Zhang et 
al. 2007), epimedin A (Oshima et al. 1987), B 
(Oshima et al. 1987), C (Oshima et al. 1987), I 
(Sun et al. 1998b), K (Sun et al. 1996a), 
epimedoside (Sun et al. 1995b), epimedoside A 
(Sun et al. 1995a), B (Ou et al. 1997), C (Li et 
al.1995b), D (Ou et al.1997), E (Ou et al. 1997), 
epimedikoreanin A (Li et al. 1995c), B (Li et al. 
1996e), C (Li et al. 1996e), D (Li et al.1996e), 
epimeokoreanoside I (Pachaly et al.1990), II 
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(Pachaly et al. 1990), sagittatoside A (Li et al. 
1994a), B (Li et al. 1994a), dephylloside A (Li et 
al.1994a), icarisoside A (Baohuoside II) (Li et al. 
1994b), 2”-O-rhamnosy-likarisoside A (Kang et 
al. 1991), ikarisoside F (Li et al. 1994a), 
baohuosu (Li et al. 1988b), baohuoside IV (Zhao 
2001), VII (Li  et al. 1988b), 8-
isoprenylkaempferol (Sun et al. 1998a), sun et 
al. 1998b), korepimedoside A (Sun et al. 1995a), 
B (Sun et al. 1996b), C (Sun et al. 1998a), 
caohuoside A (Epimedin L) (Li et al. 1996f), B (Li 
et al. 1995d), C (Li 1995), E (Li et al. 1995e), 
hexandraside E (Zheng et al. 2002), 3,5,7-
trihydroxyl-4 methoxyl-8-prenylflavone-3-O-α-
L-rhamnopyranosyl-(1-2)- α-L-
rhamnopyranoside (Li et al.  1994a) 
 
E. wushanense Sichuang, China Icariin (Zhou iet al. 2005), icariside I (Zhou et al. 
2005), epimedoside A (Takemoto et al. 1975), 8-
Prenylkaempferol-4-methylether-3-[xylpsyl(1-
4)rhamnoside]-7-glucoside (Zhou et al. 2005), 
rouhuoside (Zhou et al. 2005),  
 
E. acuminatum Sichuang, China Icariin (Dong et al. 1994), 2”-O-rhamnosyl 
icarisid II (Jia et al. 1998), epimedin C (Jia et al. 
1998), epimedoside A (Dong et al. 1994), 
diphylloside B (Jia et al. 1998), C (Ikarisosids C) 
(Jia et al. 1998), ikarisoside A (Baohuoside II) 
(Dong et al. 1994), 2”-O-rhamnosy-likarisoside 
A (Jia et al. 1998), ikarisoside B (Jia et al. 1998), 
cuhuoside  (Liang et al. 1993), acuminatoside 
(Hu et al. 1992a) 
 
E. platyetalum Sichuang, China Icariin (Zhu et al. 1993), icariside II (Baohuoside 
I) (Liang et al. 1997), maohuosides A (Wang et 
al. 2002a, Wang et al. 2002b), B (Wang et al. 
2002a, Wang et al. 2002b), platypetaloside A 
(Zhu et al. 1993). 
 
E. grandiflorum Japan, China Icariin (Tokuoka et al. 1975a), epimedoside A 
(Takemoto et al. 1975), B (Tokuoka et al. 1975b), 
C (Tokuoka et al. 1975b), D (Tokuoka et al. 
1975c), E (Tokuoka et al. 1975c), diphylloside C 
(Ikarisoside C) (Fukai et al. 1988), ikarisoside A 
(Baohuoside II) (Fukai et al. 1988), ikarisoside B 
(Fukai et al. 1988, D (Fukai et al. 1988, E (Fukai 
et al. 1988, F (Fukai et al. 1988) 
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E. fargesii Sichuang, China Icariin (Guo et al. 1996c) , epimedin B (Guo et al. 
1996c), epimedin C (Guo et al. 1996c), 
epimedoside A (Guo et al. 1996c), diphylloside 
C (Ikarisoside C) (Guo et al. 1996c) 
 
E. leptorrhizum Guizhou, Hunan,  Icariin (Han et al. 2002a), icariside I (Han et al. 
2002a), 2”-O-rhamnosyl icarisid II (Han et al. 
2002b, Jia et al. 1999), epimedin C (Jia et al. 
1999), sagittatoside A (Jia et al. 1999), 
ikarisoside B (Jia et al. 1999) 
 
E.  hunanense Hunan, China Icariin I (Liang et al. 1997), icariside II 
(Baohuoside I) (Liang et al. 1997), epimedin B 
(Liang et al. 1997), C (Liang et al. 1997) 
 
E. sempervirens Japan Icariside II (Baohuoside I) (Jia et al.1999), 
diphylloside C (Ikarisosids C) (Jia et al. 1999), 
ikarososide E (Jia et al. 1999), sempervirenoside 
A (Mizuno et al. 1988c), B (Mizuno et al. 1990) 
 
E. davidii Sichung, China Icariside II (Li et al. 1988b), baohuoside III (Li et 
al. 1988a), V (Li et al. 1988a), VI (Li et al. 1988b) 
 
E. truncatum Hubei Epimedoside A (Xu et al. 2005), C (Xu et al. 
2005), baohuoside III (Xu et al. 2005), V (Xu et al. 
2005) 
 
E. diphyllum  Diphylloside B (Mizuno et al. 1988b), C 
(Ikarisosids C) (Mizuno et al. 1989) 
 
E. pubescens Sichung, Hubei,  Baojuoside VII (Li 1992), rouhuoside  (Li et al. 
1990b) 
 Shanxi, Guizhou,  
 China 
 
E. wanshanense  Anhydroicaritin (Li et al. 1996a), 
anhydroicaritin-3-O-α-L-rhamnopyranosyl-(1-
>2)-α-L-rhamnopyranoside (Li et al. 1996c), 
demethylanhydroicaritin (Li et al. 1996a, Li et al. 
1997a), desmethylanhydroicaritin-3-O-α-L-
rhamnopyranosyl-(1->2)-α-L-rhamnopyranoside 
(Li et al. 1996a), icariside II (Baohuoside I) (Fukai 
et al. 1988), 2”-O-rhamnosyl icarisid II (Li et al. 
1996d), epimedin B (Li et al. 1996a), C (Li et al. 
1996a), epimedoside C (Li et al. 1997a, Li et al. 
1997b), sagittatoside A (Li et al. 1996c), B (Li et 
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al. 1996c), diphylloside A (Li et al. 1996a),  B (Li 
et al. 1996a),  ikarisoside A (Baohuoside II) (Li et 
al. 1996d), 2”-O-rhamnosy-ikarisoside A (Li et al. 
1996d), ikaisoside B (Li et al. 1996d) 
 
 
 
Originally, it was necessary to isolate a compound prior to the application of 
spectroscopic methods for the identification and isolation of flavonol glycoside structures.  
This involved a combination of selective extraction, partitioning and preparative 
chromatography in order to obtain sufficient pure compound for the study of its structures 
by means of mass spectrometry. This technique is able to determine the mass spectra of 
compounds, including those found in Epimedium species.  The mass spectral breakdown 
data of flavonol glycosides; icarlin, epimedin A, B, and C is provided in Table 1.4. 
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                    (1)                (2) 
  
  (3)                (4) 
 
  (5) 
Figure 1.11: Example of flavonol glycoside with isoprenyl group on carbon 8 (1), R 
representing different sugar substituents; Structures of the 4 major flavonol glycosides 
occurring in Epimedium species:  epimedin A (2), epimedin B (3), epimedin C (4), icariin (5) 
(Lin et al. 1987) 
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Table 1.4:  Mass spectral data of epimedin A, epimedin B, epimedin C and Icariin (Dong et al. 
1994, Guo et al. 1996c) 
Compound  M/Z 
Epimedin A  838 (M+) 
   677 (M+-162), 531 (M+-162-146), 369 (M+-162-162-146) 
 
Epimedin B  809 (M++H) 
   677 (M -132+H), 531 (M+-132-146+H), 369 (M+-132-146-162+H) 
 
Epimedin C  823 (M++H) 
   677 ((M+-146+H), 532 ((M+-146-146+H), 369 ((M+-146-146-162+H) 
 
Icariin   677 (M++H) 
   531 (M+-146+H), 369 (M+-146-162+H) 
 
 
1.3.2 Methods used for the analysis of active compounds found in Epimedium species 
Table 1.5 presents a variety of techniques have been used to analyse Epimedium 
species, for example, HPLC, MS, GC, MEKC and CZE. 
 
The 2000 edition of the Chinese Pharmacopeia Commission gives details of an 
isocratic HPLC elution procedure which relies on quantification of icariin and total flavonoids 
for the purpose of standardization.  This does not take into consideration the amounts of 
epimedins A, B, and C, and hence provides limited evaluation information (Chinese 
Pharmacopoeia Commission 2000).  Liu et al. (2005) used preparative high – speed counter 
– current chromatography method for the isolation and purification of flavonoids from E. 
koreanum.  The 2010 edition of the Chinese Pharmacopeia gives details to an HPLC method 
for the determination of icariin from Epimedium species (Hu 1997).  Ito et al. measured 1H 
and 13C NMR spectra with JEOL JNM – GX400 in CD3OD, the chemical shifts given in δ values 
with TMS as the internal standard and HPLC was carried out on a CIG column system with 
ODS – silica (30 µm) as the stationary phase (Ito et al. 1988a).  An Agilent 1100 HPLC system 
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with DAD was used by Xie et al. for the chromatographic fingerprint evaluation of 
Epimedium species (Xie et al. 2010).  Shen et al. developed and validated a LC – MS method 
for the quantification of compounds found in Epimedium species in a single injection by 
using the Agilent 1200 LC system with a Phenomenex Synergi 4 µMax – RP column and an 
API3200 Triple – Quadrupole mass spectrometer (Shen et al. 2009).  Zhao et al. established 
a new method for the analysis of phenolic compounds found in Epimedium species by using 
an Agilent 1100 HPLC equipped with a quaternary pump and a diode – array detector (Zhao 
et al. 2008).  An on – line high – performance liquid chromatography – diode array detection 
– electrospray ionization – mass spectrometry – chemiluminescence was used by Ding et al. 
for the evaluation of 1,1 – diphenyl – 2 – picrylhydrazyl radical and 2,2’ – azinobis – (3 – 
ethylbenzothiazoline – 6 – xulfonic acid) that is found in Epimedium species (Ding et al. 249).  
Hong et al. used liquid chromatography – tandem mass spectrometry for the determination 
of breviflavone A and B from E. brevicornum (Hong et al. 2009).  A liquid chromatography 
tandem mass spectrometry was used by Gong et al. for the determination of levels of icariin 
in human serum after oral administration of Epimedium species by derivatisation with 
dansyl chloride (Gong et al. 2007).  Chen et al. used pressurized liquid extraction and high – 
performance liquid chromatography simultaneously determine 15 flavonoids, namely,  
hexandraside E, kaempferol – e – O – rhamnoside, hexandraside F, epimedin A, epimedin B, 
epimedin C, icariin, epimedoside C, baohuoside II, caohuoside C, baohuoside VII, 
sagittatoside A, sagittatoside B, 2” – O – rhamnosyl icariside II, baohuoside I from different 
species of Epimedium herbs (Chen et al. 2007).  An Ultra – performance liquid 
chromatography – tandem mass spectrometry was used by Wu et al. for the identification 
and determination of 6 flavonoids in dog plasma after oral administration of Epimedium 
extract solutions, namely, epimedin A, B, C, icariin, sagittatoside B, 2” – O – rhamnosyl 
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icariside II, baohuoside I (Wu et al. 2011).  Liang et al. performed the separation of 16 
flavonoids and 1 phenylethanoid glucoside found in Epimedium species by using a Waters 
quanta 4000 capillary electrophoresis system (micellar electrokinetic capillary 
chromatography) (Liang et al. 1996).  Wang et al. developed a MEKC method by using a 
Waters uanta 4000 capillary electrophoresis system for the determination of five flavonoids, 
namely, 2” – O – rhamnosylicariside I, ikarisoside A, icariin, epimedin B, kaempferol – 3 – O – 
Rhamnoide from E. brevicornum (Wang et al. 2003).  Capillary zone electrophoresis was 
used by Liu et al. for the simultaneous determination of four flavonoids including icariin, 
epimedin A, B and C from Epimedium species (Liu et al. 2006a).  Shen et al. used Agilent 
6890N gas chromatography – 5975 inert XL mass spectrometry for the quantification of 
icaritin and desmethylicaritin in human sera after consumption of Epimedium. (Shen et al. 
2007). 
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Table 1.5:  Comparison of different techniques and methods used for the identification and analysis of Epimedium species 
Article Method Apparatus Used Mobile Phase Parameters 
2000 Chinese 
Pharmacopeia (Chinese 
Pharmacopoeia 
Commission 2000) 
Isocratic HPLC HPLC with C18 reverse 
phase column 
acetonitrile: water (30:70) 270nm, 
Liu et al. (Liu et al. 2005) High – speed counter 
– current 
chromatography 
HPLC with C18 reverse 
phase column 
chloroform: methanol: water 
(4:3.5:2) 
254 nm, 25 °C, 2.0 mL/min 
2010 Chinese 
Pharmacopeia (Hu et al. 
1997) 
HPLC HPLC with C18 reverse 
phase column 
acetonitrile (A) and water (B) at 
a gradient of 0 – 29 mins, 25% 
A, 29 – 30 mins, 25 – 41% A, 30 
– 55 mins, 41% A 
270 nm 
Xie et al. (Xie et al. 2010) HPLC with DAD Agilent 1100 HPLC with 
diode array detector and 
Zorbax Eclipse Plus – C18 
(250 x 4.6 mm, 5 µm) 
methanol (A)-acetonitrile (B)-
0.5% acetic acid (C) at a 
gradient of 0 min, 0 (A)-12 % 
(B)-88 % (C), 30 min, 0 (A)- 25 % 
(B)- 75 % (C), 45 min, 0 (A)- 
25 % (B)- 75 % (C), 45.01 min, 
11 % (A)- 23.5 % (B)- 65.5 % (C), 
60 min, 11 % (A)- 23.5 % (B)- 
65.5 % (C), 65 min, 4 % (A)- 
35 % (B)- 61 % (C), 85 min, 4 % 
(A)- 35 % (B)- 61 % (C), 90 min, 
0 (A)- 50 % (B)- 50 % (C), 100 
min, 0 (A)- 50 % (B)- 50 % (C) 
20 µL, 20 °C, 270 nm. 1.0 mL/min 
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Shen et al. (Shen et al. 
2009) 
LC – MS Agilent 1200 LC with 
Phenomenex Synergi 4 
µMax-RP (150 mm x 2.0 
mm I.D.) column and 
API3200 Triple-
Quadrupole Mass 
spectromenter 
water containing 0.5 mM 
ammonium formate at pH 3 (A) 
and acetonitrile with 0.1 % 
formic acid (B) gradient of 
solvent B was programmed to 
increase from 45 % to 90 % 
within 5 mins and maintain at 
90% for 3 mins to complete the 
separation 
35 °C, 0.4 mL/min, 10 µL for HPLC, 
temperature 550 °C, ion – spray 
voltage – 4500 V for MS 
Zhao et al. (Zhao et al. 
2008) 
HPLC – ESI – MS/MS Agilent 1100 HPLC with 
Zorbax SB – 18 column 
(250 x 4.6 mm, 5 µm), 
Finnigan LCQ advantage 
ion trap mass 
spectrometer 
Acetonitrile (A) and water with 
0.1 % formic acid (B) was used 
at a gradient of 0 – 15 mins, 12 
– 25% A, 15 – 30 mins, 25% A 
30 – 55 mins, 25 – 35% A, 55 – 
70 mins, 35 – 60% A, 70 – 80 
mins, 60 – 90% A 
270 nm, 30 °C for HPLC, ion spray 
voltage 4.5 kV, sheath gas 
(nitrogen) 50 arbitrary unis, 
auxiliary gas (nitrogen) 10 units, 
capillary temperature and voltage 
are  320 °C and – 14V and 16 V, 
tube lens offset voltage -20 V and 
10 V, m/z 300 - 1500  
Ding et al. (Ding et al.  
2011) 
On – line high – 
performance liquid 
chromtography – 
diode array detection 
– electrospray 
ionization – mass 
spectrometry – 
chemiluminescence 
Agilent 1100 HPLC with 
LiChrospher C18 Column 
(250 x 4.6 mm, 4 µm) and 
MSD Trap XCT ESI 
Aqueous 0.1% formic acid (A) 
and acetonitrile (B) at a 
gradient of 0 – 20 mins 15 – 
25% B 20 – 30 mins 25 – 27% B 
30 – 40 mins 27% B 40 – 55 
mins 27 – 40% B 55 – 65 mins 
40 – 50% B 65 – 80 mins 50 – 
60% B 80 – 85 mins 60 – 100% 
B 
1.0 mL/min, 30 °C, 270 nm for 
HPLC; m/z 100 – 900, capillary 
voltage 3200 V, drying gas 
temperature 350 °C, flow rate 9.0 
L/min, nebulising pressure 40 psi 
for MS 
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Hong et al. (Hong et al. 
2009) 
HPLC – MS Agilent 1100 HPLC with 
Cadenza CD – C18 (150 x 
2 mm, 3 µm) with Agilent 
G2445A ion – trap mass 
spectrometer 
950 mL/L acetonitrile – 50 mL/L 
water containing 1 mL/L formic 
acid (A) and 50 mL/L 
acetonitrile – 950 mL/L water 
containing 1 mL/L formic acid  
(B) at a gradient of 0 – 12 mins, 
20 – 25% A, 12 – 25 mins, 25 – 
70% A 
0.25 mL/min for HPLC; capillary 
voltage 3.5 kV, end plate offset 
voltage – 500 V, nebulizer gas 
(nitrogen) pressure 30 psi, drying gas 
(nitrogen) flow rate 9L/min, 
temperature 350 °C, m/z 197 for MS 
Gong et al. (Gong et al. 
2007) 
HPLC – MS Agilent 1100 HPLC with 
Phenomenex Synergi 4 
µm Max – RP 80A (150 x 
2 mm) and API 4000 
triple quadrupole mass 
spectrometer 
950 mL/L acetonitrile – 50 mL/L 
water containing 1 mL/L formic 
acid (A) and 50 mL/L 
acetonitrile – 950 mL/L water 
containing 1 mL/L formic acid 
(B) 35 – 90% A from 0 – 6 mins, 
90% A from 6 – 10 mins 
0.25 mL/min for HPLC; gas regulator 
maintained at 552 kPa, electrospray 
voltage, ion spray interface 
temperature, SRM transitions were  at 
5000 V, 350 °C and m/z 910 – 764 for 
dansyl – icariin, 5500 V,  400 °C and 
m/z 511 – 171 for dansyl – d5 – E2, 
respectively 
Chen et al. (Chen et al. 
2007) 
HPLC – MS Agilent 1100 HPLC and 
Zorbax SB – C18 column 
(250 x 4.6 mm, 5 µm) 
with MSD trap MS 
water (A) and acetonitrile (B) at 
a gradients condition of 0 – 15 
mins, 22 – 28% B, 15 – 20 mins, 
28 – 35% B, 20 – 40 mins, 35 – 
39% B, 40 – 50 mins, 39 – 100% 
B 
1 mL/min, 10 µL, 25 °C and 270 nm for 
HPLC; m/z 100 – 1000 u, source 
voltage of 4.5 kV, dry gas (nitrogen) 
flow rate 10L/min, pressure of 
nebulizer 35 psi, temperature kept at 
350 °C 
Wu et al. (Wu et al. 2011) UPLC – MS Agilent 6410B triple 
quadrupole LC – MS 
system including Agilent 
1200 HPLC and an Agilent 
Zorbax SB – C18 column 
(50 x 2.1 mm, 1.8 µm) 
0.3% acetic acid (A) and 
acetonitrile with 0.3% acetic 
acid (B) at a gradient of 23 – 
30% B from 0 – 1 mins 30 – 
38% B from 1 – 3 mins 38 – 
50% B from 3 – 6 mins 50 – 
60% B from 3 – 6.5 mins 
30 °C, 0.4 mL/min, 3 µL for HPLC; 
nebuliser pressure 45 psi, dry gas at 
10L/min, dry temperature at 325 °C, 
capillary voltage 4000 V, delta EMV at 
350 V for MS 
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Liang et al. (Liang et al. 
1996) 
MEKC Waters quanta 4000 
capillary electrophoresis 
system with 0.050 x 360 
mm fused silica capillary 
N/A pH for AMPSO, CAPS, phosphate and 
borate was at 10.5, for borate with 
SDS was 8.5, capillary tubes were 
purged with 0.1 M NaOH, water and 
buffer successively, voltage 16 – 25 kV 
and detection wavelength was 254 
nm 
Wang et al. (Wang et al. 
2003) 
MEKC Waters quanta 4000 
capillary electrophoresis 
system with 70 x 62.4 
cm, 75 µm fused silica 
capillary 
N/A Detection wavelength 254 nm, 
27.5 °C, separation voltage 15 kV, 
buffer adjusted with 0.2 M NaOH 
Liu et al. (Liu et al. 2006a) CZE Agilent capillary zone 
electrophoresis with 56 x 
48 cm, 75 µm fused silica 
capillary 
N/A Buffers are 50 mM borate and 22% 
acetonitrile adjusted to pH 10, 
capillary rinsed with 1 M sodium 
hydroxide, pressure was 50 mbar for 5 
seconds, detection wavelength 270 at 
25 °C 
Shen et al. (Shen et al. 
2007) 
GC – MS Agilent 6890N GC 
coupled with 5975 inert 
XL mass selective 
detector with HP – SMS 
capillary column with 5% 
phenylmethyl – siloxane 
(30m x 0.25 mm x 0.25 
µm)  
N/A Carrier gas (helium) flow rate 3 
mL/min, 4.0 µL injection volume, 
initial oven temperature at 150 °C and 
ramped up to 300 °C at 30 °C/min, 
m/z 50 - 700 
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1.4 Panax species 
Ginseng is a short plant, classed under the family Araliaceous that grows naturally on 
the slopes of ravines and shady, well drained mountainous hardwood forests common in 
eastern China.   In the wild, this plant usually grows to about 7 to 21 inches in height. The 
root is a creamy yellow looking parsnip with rootlets that branch off, sometimes taking the 
shape of a human body.  The name ginseng came from two words meaning "Man Plant" due 
to its take on the human form. Later, ginseng was given the botanical name Panax derived 
from Greek for “All Healing” or “Cure All” and related to the word Panacea (Ito et al. 1988).  
Panax was discovered approximately 5000 years ago in the mountains of Manchuria, China 
(Ito et al. 1988).  It was first used as a source of food, later its human shaped root was 
associated with strength-giving and rejuvenating powers, and quickly became a powerful 
symbol of divine harmony on earth (Ito et al. 1988).   
(1)  
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(2) (3)  
Figure 1.12: Photographs showing (1) P. ginseng plant (2) P. notoginseng roots (3) P. 
quinquefolius roots 
 
Panax species have a long and rich history in Traditional Chinese Medicine, since the 
Han dynasty. For more than two thousand years, practitioners of Chinese medicine have 
been using ginseng effectively on their patients.  The most important part of the plant used 
has been the roots.  In the late 17th century, through travellers and writings of missionaries 
such as Father Jartoux of the French Jesuit Mission to China, the medicinal properties of 
ginseng became well known in Europe (Jumppanen et al. 1993, Evans 1994).  Year 1713 in 
Canada, Father Lafitau started a search for ginseng plants in a shady forest in Montreal and 
discovered wild ginseng, its roots were harvested for trading with China.  France and Britain 
at first and then Britain alone dominated the trading of North American ginseng with China. 
By 1784, the transportation to China and harvesting of North American ginseng had soared 
exponentially. In this same year, an American ship named “Empress of China” is said to have 
conveyed 63,000 pounds across to China (Jumppanen et al. 1993, Evans 1994). Due to 
increased demand for the North American ginseng, the number of ginseng farmers 
increased more than tenfold.  By the early 19th century, Americans were the main carriers of 
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North American ginseng, and was exporting to a value of US $ 42,000,000 (Evans 1994).    
Since then, Ontario, Canada began cultivating North American ginseng in the 1960’s, and in 
1980’s cultivation started in British Columbia as well (Oliver 1994).  In 1975, due to the high 
demand of North American ginseng, business opportunities led to China’s own experimental 
cultivation of North American ginseng, its successfulness led to 100,000 m2 of land 
cultivating North American ginseng in 1994 (Ito et al. 1988, Xin 1994).   
Panax species in general are very slow growing; this artificially keeps the demand 
high on the international market. Ginseng roots are harvested at the age of three to four 
years old and dried to make into a medicinal herb.  Ginseng roots consist of the main root, 
secondary roots and small fibre roots but, during the drying process, some secondary roots 
and most small fibre roots will fall off (Ito et al. 1988).  These secondary roots and small 
fibre roots are kept and usually sold in traditional medicine shops at a lower price than the 
main root, as people believe that the main root has higher ginsenoside content (Ito et al. 
1988).  When manufacturing standardized ginseng products the main roots are usually used 
to ensure control for a reliable, good quality product, but when secondary and small fibre 
roots are included then both the analytical data on ginsenoside content and compound 
profile should be provided (Ito et al. 1988).   
Many types of Panax species exist, but only three of these are given herbal medicinal 
use consideration, namely Panax quinquefolius L. (North American ginseng), Panax ginseng 
C.A. Meyer (Asian ginseng) and Panax notoginseng Burkill (Sanqi). P. ginseng and P. 
notoginseng are easily distinguished. P. ginseng is a yellow - brown, elongated dried root, 
whereas P. notoginseng, grown mainly in Southern China, is a brown – black, rounded dried 
root (Figure 1.12) (Ito et al. 1988).  However, the roots of P. ginseng and P. quinquefolius L. 
 52 
look very similar, both are yellow – brown in colour and elongated (Ito et al. 1988).  
According to Traditional Chinese Medicine the origin of the herb is very important. Hence, 
since P. ginseng is not native to North America, it is referred to as Asian Ginseng and P. 
quinquefolius is named North American Ginseng (Ito et al. 1988).  Analytical results have 
shown that some ginseng that claimed to be North American ginseng used in China was not 
actual North American ginseng but rather P. ginseng, due to high popular demand for North 
American ginseng, substitutes of P. ginseng have been used in the name of North American 
ginseng (Ma et al. 2011a).  
Only botanical experts are able to determine the difference between the roots of P. 
quinquefolius and P. ginseng from their visual aspects. Which of these species is used is 
extremely important since they possess different medicinal properties. They have opposite 
effects in that P. ginseng is a stimulating tonic, whereas, P. quinquefolius exerts a calming 
effect (Ito et al. 1988).  P. notoginseng has been found to exert various effects on the body: 
for example, cardiocerebral vascular system, central nervous system, endocrine system, 
inflammation, hypoglycaemic, hypolipidemic, immunostimulatory, antitumour, anti-
inflammatory, analgesic, antioxidant, hemostatic, antithrombotic, antiatherosclerotic, 
fibrinolytic, antiarrhythmic, hemoptysis, hemostatic, hematoma, hypotention, oestrogen-
like and sperm motility-enhancing effects (Ng 2006, Wang et al. 2006, Wan et al. 2008, 
Cicero et al. 2000). 
Panax ginseng has also been discovered to possess anti-tumour properties.  Kim et al. 
(1998) and Lee et al. (1997) reported that it inhibited lung tumours caused by 
benzo[α]pyrene-induced autochthonous in the immune system of mice (Kim et al. 1998, Lee 
et al. 1997).  As well, Park et al. isolated an acidic polysaccharide (MB40) from P. ginseng 
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which, when combined in use with paclitaxel or cisplatin was able to increase overall 
therapeutic effect on human prostate cancer and decrease haematopoietic complications 
caused by chemotherapy or radiation therapy (Park et al. 2004).  In 2004, Shin et al. also 
reported that Red Ginseng Acid Polysaccharide (RGAP), another acidic polysaccharide, also 
isolated from P. ginseng possesses immunomodulatory and anti-tumour activities.  Tests 
were performed on mice bearing S 180 tumour cells, with the combined treatment of 25 
mg/kg of RGAP and 15 mg/kg paclitaxel and this resulted in an increase life span of 42.8%, 
as well, when paciltaxel and RGAP were used on mice with B16 melanoma, the tumour 
weight decreased by 76.3% (Shin et al. 2004).   
In 1982, Wang et al. reported a polysaccharide from P. ginseng to have the ability to 
promote phagocytosis of the reticuloendothelial system and antibody production (Wang et 
al. 1982).  In 2004, Lim et al. reported of a water-soluble ginseng marc polysaccharide that is 
able to increase the lysosomal phosphatase activity, as well increased the viability of 
peritoneal macrophages. This shows that the ginseng marc polysaccharide is a nonspecific 
immunomodulatory agent (Lim et al. 2004). 
 
1.4.1. Chemical Constituents of Panax species 
The chemical constituents in ginseng are triterpene saponins, also known as 
ginsenosides.  They are found in the roots, stem, leaf and flower of the Panax plant, but in 
Traditional Chinese Medicine and the pharmaceutical industry, ginseng roots are mainly 
used due to the presence of relatively higher content of these chemical constituents (Sticher 
1998, Ma et al. 1995, Lang et al. 1993, Li et al. 1996).   Thin Layer Chromatography was the 
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first method used to separate the ginsenosides in ginseng and therefore these ginsenosides 
are given the name R with a subscript letter depending on its decreasing polarity and 
increasing mobility in thin layer chromatographic analysis, for example, Ra (Ma et al. 1995, 
Lang et al. 1993, Li et al. 1996).  Before ginseng roots are dried the compounds are a 
malonyl derivative, but after the drying process, the malonyl becomes unstable and 
becomes detached (Shibata et al. 1985, Yamaguchi et al. 1988).  Therefore, malonyl 
ginsenosides are not found in dried roots.  However, for naming of malonyl – ginsenosides a 
preceding lower case letter ‘m’ is given, for example, Ra and mRa.  The terminal glucose at 
position 3 is replaced by arabinose in some ginsenosides. When this occurs the naming of 
Rb1 and Rb2 is used to distinguish between di-glucoside and arabinyl glucoside respectively.  
Ginsenosides have two dammarane skeletons, 20R compounds (panaxadiol and panaxatriol) 
from acid hydrolysis yielding two aglycones and 20S compounds (protopanaxadiol and 
protopanaxatriol), the genuine aglycones (Shibata et al. 1985) [see figure 1.13].  Major 
ginsenosides from Panax ginseng (Asian ginseng) and Panax quinquefolius (North American 
ginseng) are 20S derivatives.  Steaming the roots of Panax ginseng will produce Red Ginseng 
and then heating it will produce 20R derivatives. Since North American ginseng are usually 
never steamed, 20R derivatives are usually absent from North American ginseng (Shibata et 
al. 1985). 
Eight major ginsenosides present in ginseng dried roots are:  R1, Rg1, Re, Rf, Rb1, Rc, Rb2, 
and Rd(Shibata et al. 1985, Yamaguchi et al. 1988, Court et al.1996).  These ginsenosides and 
some other common ginsenosides are listed in figure 1.6. 
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Ginsenoside               R1                 R2  R3  R4 
Rb1              Glc-Glc-      Glc-Glc- -  - 
Rb2             Glc-Glc-     Ara(p)-Glc- -  - 
Rc             Glc-Glc-     Ara(f)-Glc- -  - 
Rd             Glc-Glc-           Glc-  -  - 
Rg3             Glc-Glc-            H-  -  - 
Rh2               Glc-                H-       -  - 
Re                  -                   -                  Rha-Glc-       Glc- 
Rg1                  -  -                 Glc-           Glc- 
Rf                           -  -               Glc-Glc-       H- 
R1                    -  -            Glc-Xyl-        Glc-   
Figure 1.13: Structures of ginsenosides found in Panax species (protopanaxadiol-type) 
(20S) (Left), (protopanaxatriol-type) (20S) (Right), Glc, glucose; Ara(p), arabinose in pyranose 
form; Ara(f), arabinose in furanose form; Rha, rhamnose; H, hydrogen; Xyl, Xylose (Shibata 
et al. 1985) 
 
Many of the useful biologically-related properties of the main gensenosides occurring in 
Panax species are detailed below: 
1. Rb1 
 This exerts an anti-oxidative effect to protect neuronal cells from overproduction of 
nitric acid, as well as decrease the level of free radicals induced by xanthine/xanthine 
oxidase.  They have also been shown to modulate methamphetamine-induced behaviour in 
pre and post-synaptic dopaminergic receptors and inhibit calcium current and cell 
membrane capacitance in rat adrenal chromaffin cells, therefore, regenerate catecholamine 
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secretion in adrenal chromaffin cells (Kim et al. 1998b, Kim et al. 1998c, Kim et al. 1998d, 
Guogan et al. 1997) 
2.  Rg3 
 Rg3 protects neuronal cells from the overproduction of nitric acid and inhibits the 
secretion of catecholamine from acetylcholine-stimulated cells (Kim et al. 1998d, Tachikawa 
et al. 1997). 
3. Rg1 
 Rg1 modulates methamphetamine-induced behaviour in pre and post-synaptic 
dopaminergic receptors, increases the incidence of copulatory behaviour in mice, inhibits 
calcium current and cell membrane capacitance in rat adrenal chromaffin cells, inhibits 
catecholamine secretion at pre-synaptic sites to treat adverse effects from morphine and 
decreases the level of free radicals caused by xanthine/xanthine oxidase (Kim et al. 1998b, 
Kim et al. 1998c, Guogan et al. 1997, Yoshimura et al. 1998, Kim et al. 1998a). 
4. Rd 
 Rd prevents free-oxygen radicals from attacking cell membranes, therefore 
possessing anti-oxidative effects (Yokozawa et al. 1998). 
5. Rf 
 Rf inhibits tonic effect in mice as well as calcium current and cell membrane 
capacitance in rat adrenal chromaffin cells, therefore; regenerate catecholamine secretion 
in adrenal chromaffin cells (Kim et al.1998c, Mogil et al. 1998). 
6. Rh2 
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 Rh2 inhibits growth of human ovarian cancer cells the best results were found when it 
was used in collaboration with cis-diaminedichloroplatinum (II) and cisplatin (CDDP), where 
it promoted apoptosis in human hepatoma SK – HEP – 1 cells (Nakata et al.1998, Park et al. 
1997). 
7. Rc 
 Rc decreases the level of free radicals induced by xanthine/xanthine oxidase and 
inhibits calcium current and cell membrane capacitance in rat adrenal chromaffin cells (Kim 
et al. 1998c, Guogan et al. 1997) 
8. Re 
 Re decreases the level of free radicals induced by xanthine/xanthine oxidase and 
inhibits calcium current and cell membrane capacitance in rat adrenal chromaffin cells (Kim 
et al. 1998c, Guogan et al. 1997) 
9. Rg2 and Rh1 
 These have been shown to decreases the level of free radicals induced by 
xanthine/xanthine oxidase (Guogan et al. 1997) 
 
1.4.2 Distinction between the Panax species based on their ginsenosides  
The ginsenoside content contributes to the pharmacological effects of Panax species 
and, therefore, the relative concentration of the different ginsenosides will influence the 
overall effect. The USP HPLC method for the identification of P. quinquefolius and P. ginseng 
recommends a ratio comparison of the 7 major ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1 and Rf 
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(Members of the USP Dietary Supplements and Food Ingredients Expert Committees 2009).  
Ma et al. also claimed that using these 7 major ginsenosides and R1, it is sufficient enough 
for the identification of the two species mentioned above as well as discriminate P. 
notoginseng (Ma et al. 1996).  To distinguish between these three Panax species, P. ginseng 
and P. notoginseng contain low levels of ginsenoside Rf and Rg2, which are not found in P. 
quinquefolius (Li et al. 1996).  P. quinquefolius contains higher amounts of ginsenosides Re 
and Rb1, whereas, P. ginseng contains higher concentration of Rb2 (Ma et al. 1996).  P. 
notoginseng contains ginsenoside R1, which is absent in both P. quinquefolius and P. ginseng.  
The USP indicates that, for P. ginseng the ratio of peak area of the ginsenosides Rb2 and Rb1 
is less than 0.4 and the ratio of Rg1 (protopanaxatriol group) to Rb1 (protopanaxadiol group) 
in P. quinquefolius should be less than 0.3 (Members of the USP Dietary Supplements and 
Food Ingredients Expert Committees 2009, Ma et al. 1996). 
 
A new type of P. quinquefolius from Maryland, USA, has been identified and contains 
high Rg1/Low Re, in comparison to the previously reported and extensively investigated P. 
quinquefolius, which contains low Rg1/ High Re content (Members of the USP Dietary 
Supplements and Food Ingredients Expert Committees 2009, Schlag et al. 2006).  This was 
the result of Schlag and McIntosh investigating wild roots of P. quinquefolius grown in 
Maryland and they consistently found the concentration of Rg1 to be significantly higher 
than that of Re (Schlag et al. 2006). 
 
Ginsenosides occur in the roots, stem, leaf and flower (Ma et al. 1995). Hence, the 
ginsenoside profiles can effectively identify the different ginseng species and the different 
plant parts of these species. The main roots of P. quinquefolius provide the Rc/Rb1 ratio 
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which is < 0.3, while the leaves of this plant have a large concentration of ginsenoside Rb3 
(Ma et al. 1996, Qu et al. 2009).   
 
The roots and leaves of Panax species contain the same ginsenosides but the 
difference between them is the relative amounts and ratio of the ginsenosides as illustrated 
with that of P. quinquefolius.  Table 1.6 shows that the major differences found between 
root and leaf was their content of ginsenosides Rb1 and Rb2. In the roots, Rb1 is relatively high 
compared to the concentration of Rb2, whereas, in the leave Rb2 was high compared to Rb1, 
therefore, the ratio of Rb1/Rb2 is higher in the roots than in the leaf of this Panax species (Ma 
et al. 1995, Lang et al. 1993, Ma et al. 1996). 
 
Table 1.6: Ginsenoside content in the dried root and leaves of cultivated Panax 
quinquefolius (Ma et al. 1995, Lang et al. 1993) 
Plant Part  Ginsenoside Content [% w/w] 
   Rb1 Rb2 Rb3 Rc Rd Rg1 + Re  Ro total 
Roots   2.9 0.1 0.08 0.5 0.4 0.9  0.4 5.3 
Roots   2.6 trace 0.04 0.4 0.2 1.0  0.2 4.4 
Roots   1.6 0.06 0.07 0.4 0.2 0.9  0.2 3.4 
Leaf   0.2 1.6 4.9 0.6 3.0 1.3  trace 11.6 
 
 Studies have shown that the total ginsenoside content in the roots of P. ginseng 
increases with age, which includes the ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, Rg1 and Rg2. Based 
on their data on the rate of root growth and ginsenoside content, it has been suggested that 
roots should be harvest after 5 – 6 years of cultivation to obtain the maximum yield of 
ginsenosides (Li et al. 1996, Ma et al. 1994). Examination of the total ginsenoside content of 
1,2,3, and 4 year old roots of P. quinquefolius has shown that this increases over 1-3 years. 
This analysis was carried out using fresh roots so the malonyl glycosides were also present 
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and measured.  Table 1.7 focuses only on the ginsenosides founds in dried roots and mature 
leaves, hence omitting the data for malonyl glycosides. For the 4 year old ginseng root, 
three of the ginsenosides show a significant increase compared to the ginseng of a younger 
age, namely, Rb1 by 4.8 times, Re by 1.9 times and Ro by 2.7 times, whereas, the other four 
ginsenosides Rb2, Rc, Rd and Rg1 showed either little or no increase (Table 1.8).  The use of 3 
to 4 year old P. quinquefolius roots in both Traditional Chinese Medicine and the natural 
health product markets is appropriate and these would have a relatively high content of Rb1 
and a large ratio of Rb1/Rb2. 
 
Table 1.7: Ginsenoside content in dried root and leaf of cultivated P. quinquefolius (Li et 
al. 1996) 
Plant Part  Ginsenoside Content [% w/w] 
   Rb1 Rb2 Rc Rd Rg1 Re  total 
4 years old root 1.2 0.02 0.2 0.3 0.2 1.1 3.0 
Mature leaf  0.2 0.6 0.3 1.7 0.3 1.6 4.7 
 
Table 1.8: Influence of plant age on root weight and ginsenoside content of P. 
quinquefolius (Court et al. 1996) 
Root age (years) Ginsenoside contect (mg/g dry weight) 
   1  2  3  4 
Weight (g)  0.3  2.1  4.3  11.8 
Rb1   4.3  9.8  8.8  20.7 
Rb2   0.4  0.4  0.3  0.4 
Rc   22.4  2.1  2.0  2.4 
Rd   2.7  3.5  2.8  4.1 
Re   7.9  9.7  10.4  14.9 
Rg1   1.5  1.7  1.7  1.5 
Ro   1.8  2.3  3.2  4.8 
Total   21.3  31.6  33.5  60.6 
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1.4.3 Methods used for the analysis of active compounds occurring in Panax species 
Table 1.9 shows a variety of techniques have been used to analyse Panax species.  In 
the 2009 edition of USP, the active compounds of P. ginseng were separated using a thin – 
layer chromatography (TLC) and as well as HPLC analysis (Members of the USP Dietary 
Supplements and Food Ingredients Expert Committees 2009).  Corthout et al. have 
illustrated the use of TLC – densitometric assay for the identification of ginsenosides from P. 
ginseng roots (Corthout et al. 1999).  Vanhaelen – Fastre et al. used a high – performance 
TLC densitometric determination of six of the major ginsenosides from P. ginseng, namely; 
Rb1, Rb2, Rc, Rd, Re and Rg1 (Vanhaelen et al. 2000).  HPLC – MS was used by Zhao et al. for the 
determination of ginsenosides Rg3 due to its accurate, sensitive, specific and high 
throughput (Zhao et al. 2010).  Cheng et al. developed a two – step counter – current 
chromatography method, as well as a counter – current chromatography method with 
isocratic elution for the preparation and determination of ginsenoside Re, Rb, Rc and Rb2 
from ginseng (Cheng et al. 2011).  Li et al. illustrated the use of a liquid chromatography – 
electrospray ionisation - mass spectrometry method to identify and analyze the saponins 
from P. notoginseng (Li et al. 2005).  Wan et al. used a pressurized liquid extraction and high 
performance liquid chromatography coupled with evaporative light scattering detection 
method for the chemical characteristics from different plant parts, such as, root, fibre root, 
rhizome, stem, leaf, flower and seed of P. notoginseng (Wan et al. 2006a).  A HPLC and 
pressurized liquid extraction method was used by Wan et al. to determine simultaneously 
the nine saponins from P. notoginseng including notoginsenoside R1, ginsenoside Rg1, Re, Rf, 
Rb1, Rc, Rb2, Rb3 and Rd (Wan et al. 2006b).  Toh et al. used an ultra – high performance liquid 
chromatography/time – of – flight mass spectrometry for time – dependent profiling of raw 
and steamed P. notoginseng (Toh et al. 2010).  Liquid chromatography – electrospray mass 
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spectrometry was used by Fuzzati et al. for the identification of ginsenosides in P. ginseng 
roots (Fuzzati et al. 1999).  Lau et al. used a high – performance liquid chromatography with 
diode array detection for the analysis of six of the saponins of P. notoginseng, namely, 
notoginsenoside R1, ginsenoside Rg1, Re, Rb1, c and Rd (Lau et al. 2003).  A UPLC – UV (Ultra 
Performance Liquid Chromatography) method was developed by Chen et al. to quantify and 
compare simultaneously the concentration of seven major ginsenosides in a crude extract 
derived from root of P. quinquefolium (Chen et al. 2007).  Li et al. developed a high – 
performance liquid chromatography – UV method for the determination of six of the major 
active saponins of P. notoginseng, namely, notoginsenoside R1, ginsenoside Rg1, Rb1, Rg2, Rh1 
and Rd (Li et al. 2005).  A HPLC method was developed by Lau et al. for the quantification of 
the saponins of P. notoginseng (Lau et al. 2004).  Dan et al. used a UPLC – ESI – MS method 
for the metabolite profiling of P. notoginseng (Dan et al. 2008).  An ultrahigh pressure 
technology was used by Zhang et al. for the identification of ginsenosides from extract P. 
quinquefolium (Zhang et al. 2006).  Wang et al. chose MEKC (micellar electrokinetic 
chromatography) for the analysis of P. notoginseng in his study since it requires relatively 
short analysis time, high efficiency, technical simplicity and applicability to most analytes  
(Wang et al. 2006).  In 1993, Cui et al. analyzed a few of the important ginsenosides by using 
gas chromatography equipped with a flame ionization detector (Cui et al. 1993).  Xie et al. 
developed a gas chromatography – mass spectrometry method for the quantification of 
dencichine and ethyl chloroformate derivatised compounds in complex plant matrices of P. 
notoginseng (Xie et al. 2007).  In 2000, Chen and Sorensen used near – infrared 
spectroscopy for the determination of ginsenosides in P. notoginseng (Chen et al. 2000).  Liu 
et al. used Fourier transform infrared spectroscopy for the study on the interaction of total 
saponins of P. notoginseng with human serum albumin (Liu et al. 2003). 
 Table 1.9:  Comparison of different techniques and methods used for the identification and analysis of Panax species 
Article Method Apparatus Used Mobile Phase Parameters 
2009 United States 
Pharmacopoeia (Members 
of the USP dietary 
supplements and food 
ingredients expert 
committees 2009) 
Thin – 
Layer 
Chromatog
raphy and 
HPLC 
TLC with silica gel layers and HPLC 
with 4.6 mm x 2.0 cm guard column 
with 4.6 mm x 15 cm analytical 
column 
Lower phase: chloroform: 
methanol: water (13:7:2) 
Upper phase:  water: butyl 
alcohol: ethyl acetate (5:4:1) 
for TLC and water (A) and 
acetonitrile and water (8:2) at a 
gradient of 0 – 12 mins, 24% 
(B), 12 – 28 mins, 24 – 35% (B), 
28 – 51.5 mins, 35 – 43.5% (B), 
51.5 – 52.5, 43.5 – 100% (B), 
52.5 – 64.5 mins, 100 – 24% 
(B), 64.5 – 77 mins, 24% (B) 
Develop TLC plate in lower phase 
solvent till 10.5 cm mark is reached, 
then turn plate 90° and develop in 
upper phase solvent until 10.5 cm is 
reached.  Spray with 0.5 mL 
anisaldehyde, 10 mL glacial acetic 
acid, 85 mL methanol, 5 mL sulphuric 
acid spray reagent and oven at 105° - 
110° for 10 mins. For HPLC:  203 nm, 
1.5 mL/min, 25 °C and 20 µL. 
Corthout et al. (Lang et al. 
1993) 
TLC – 
densitomet
ric assay 
TLC plates with Desaga TLC 
applicator AS – 30 and scanned with 
Desaga densitometer CD60 
chloroform: ethyl acetate: 
methanol: water (15:40:22:9) 
Develop TLC plates in mobile phase 
and heat for 120 °C for 5 mins. 535 
nm, spray agent consist of 0.5 mL 
anisaldehyde, 10 mL glacial acetic 
acid, 85 mL methanol, 5 mL sulphuric 
acid. 
Vanhaelen – Fastre et al. 
(Vanhaelen et al. 2000) 
HPTLC HPTLC silica gel plates at 12 mm 
with automatic TLC sampler II 
apparatus as bands of 10 mm length 
and densitometer with deuterium 
lamp and optical slit of 5 x 0.10 mm. 
1, 2 – dichloroethane – 100% 
ethanol – methanol – water 
(56:8:19.2:19.2:4:80, v/v) 
Developed at 4 °C for 70 – 75 mins 
and then heated at 50 °C for 20 mins 
and exposed to vapors of thionyl 
chloride at room temperature for 30 
mins. Ginsenosides were quantified at 
275 nm at a scanning speed of 5 
mm/sec. 
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Zhao et al. (Zhao et al. 
2010) 
HPLC – MS Shimadzu DGU – 20A pump, 
autosampler and a Waters 
SymmetryShield RP18 column (4.6 
mm x 100 mm, 3.5 µm) and AB API – 
4000 triple quadrupole mass 
spectrometer equipped with 
turboionspray (ESI) interface 
Methanol: 10 mM ammonium 
acetate (95:5 v/v) 
HPLC:  1.0 mL/min, 10 µL.  MS:  
nebulizer at 500 °C, needle voltage at 
– 4500.00V, nebulizer gas, nitrogen 
gas, curtain gas and collision gas were 
set at 11, 12, 10 and 10 units, 
respectively.  MRM mode at m/z 
783.5 to m/z 637.4.  Nitrogen was 
used as collision gas, electron 
multiplier set at 2000V. 
Cheng et al. (Cheng et al. 
2011) 
Two – step 
– counter – 
current 
chromatog
raphy and 
HPLC 
High performance counter – current 
chromatography with a stainless 
steel tubing had a volume of 33 mL 
and one with polyfluoroalkoxy 
tubing with a volume of 903 mL; 
Shimadzu LC – 20AT HPLC with SPD 
– M20A photodiode array detector 
and an alltima C18 column (250 x 
4.6 mm, 5 µm) 
Methylene chloride: methanol: 
water: isopropanol (6:2:4:3) 
and n – hexane: n – butanol: 
0.1% formic acid (0.7:3:4) for 
the two – step CCC separation; 
Acetonitrile (A) and Water (B) 0 
– 10 mins, 20 – 24% A, 10 – 25 
mins, 24 – 37% A, 25 – 35 mins, 
37 – 46.5% A 
upper phase was the stationary phase, 
lower phase (mobile phase) was 
pumped into the column at a flow 
rate of 20 mL/min, and centrifuge 
rotation speed of 1250 rpm in the first 
separation step and 40 mL/min with a 
speed of 1400 rpm in the second 
separation step both at 25 – 30 °C, 
samples went through column at 20 
mL/min from 0 – 66 mins, 50 mL/min 
from 67 – 110 mins and 100 mL/min 
from 110 min till the end for first 
separation step, for second step the 
rate was not changed; 1 mL/min for 
HPLC, 203 nm, capillary voltage 3500 
V, nebulizer pressure 35 psi, drying 
gas flow 9L/min, gas temp. 350 °C, 
mass scanning range of 100 – 2200 
m/z. 
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Li et al. (Li et al. 2005) Liquid 
chromatog
raphy – 
electrospra
y ionisation 
– mass 
spectromet
ry 
Waters 600 pump equipped with an 
ELSD and used in conjugation with 
Capcell Pak C18 column (250 x 4.6 
mm, 5 µm) and a Finngan LCQ ion – 
trap mass spectrometer with an 
electrospray ion source 
0.2% acetic acid in water (A) 
and Acetonitrile (B) were used 
at a gradient of 0 – 2 mins, 25% 
B, 2 – 50 mins, 25 – 50% B 
35 °C, 10 µL for HPLC parameters; 
nebulizer temperature at 80 °C, 
nebulising gas (Nitrogen) at a flow 
rate of 2.0 L/min for ELSD parameters, 
sheath gas flow rate at 60 bar, 
auxiliary gas flow rate at 10 bar, 
electrospray voltage of the ion source 
at 5 kV, capillary voltage at 10 V, 
capillary temperature at 280 °C and 
full scan of ions ranged from 400 to 
2000 molecular weights in the 
negative ion mode for MS 
parameters. 
Wan et al. (Wan et al. 
2006) 
Pressurized 
liquid 
extraction 
and HPLC 
coupled 
with 
evaporativ
e light 
scattering 
detection 
method 
Agilent 1100 series HPLC with 
Zorbax ODS C18 column (250 x 4.6 
mm, 5 µm) and a Zorbax ODS C18 
guard column (12.5 x 4.6 mm, 5 
µm); Alltech ELSD 
Water (A) and Acetonitrile (B) 
had a gradient elution of the 
following:  0 – 30 mins, 8 – 19% 
B, 30 – 40 mins, 19 – 31% B, 40 
– 60 mins, 31 – 56% B 
40 °C, 1.5 mL/min, 10 µL for HPLC 
parameter; ELSD was set with tube 
temperature of 60 °C and nebulizer 
nitrogen gas flow at 1.4 L/min. 
Wan et al. (Wan et al. 
2006) 
Pressurized 
liquid 
extraction 
method 
and HPLC 
with DAD 
Dionex ASE 200; Agilent 1100 liquid 
chromatography with Zorbax ODS 
C18 column (4.6 x 250 mm, 5 µm) 
and a Zorbax ODS C18 guard column 
(4.6 x 250 mm, 5 µm) 
water (A) and Acetonitrile (B) 
at a gradient of 0 – 30 mins, 18 
– 19% B, 30 – 35 mins, 19 – 
35% B, 35 – 60 mins, 35 – 55% 
B 
Extraction was done with a particle 
size of 0.3 – 0.45 mm with methanol 
at 150 °C for 15 mins at a pressure of 
6.895 x 103 MPa; for HPLC, the flow 
rate was 1.5 mL/min, at a 
temperature of 40 °C and 203 nm. 
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Toh et al. (Toh et al. 2010) UPLC/Time 
– of – flight 
mass 
spectromet
ry 
Acquity UPLC system with a 
quadrupole orthogonal acceleration 
time – of – flight tandem mass 
spectrometer used in conjugation 
with Acquity BEH C18 (100 x 2.1 
mm, 1.7 µm) equipped with the 
TOFMS ESI 
0.1% formic acid in water (A) 
and 0.1% formic acid in 
Acetonitrile (B) with a gradient 
of 0 – 0.2 mins, 2% B, 0.2 – 2.0 
mins, 2 – 30% B, 2.0 – 4.7 mins, 
30 – 60% B, 4.7 – 6.5 mins, 60 – 
80% B, 6.5 – 8.3 mins, 80 – 90% 
B, 8.3 – 9.5 mins, 98% B, 9.5 – 
10.0 mins, 2% B 
0.5 mL/min, 45 °C for UPLC; capillary 
voltage at 3.1 kV, sampling cone 
voltage at 45 V, extraction cone 
voltage 4.5 V, ion guide 3.0 V, 
desolvation temperature at 350 °C, 
source temperature at 120 °C, 
desolvation gas flow rate at 700 L/h, 
collision energy at 5 eV, MCP detector 
voltage 1800 V, pusher voltage 938 V, 
pusher voltage offset at 2.00V and 
puller voltage at 670 V, the mass 
range was at 400 – 1500 Da. 
Fuzzati et al. (Fuzzati et al. 
1999) 
Liquid 
chromatog
raphy – 
electrospra
y mass 
spectromet
ry 
Waters 600 pump with Hypersil BDS 
C18 (250 x 4.6 mm, 5 µm); Sedex 
Model 55 from S.E.D.E.R.E  ELSD; 
Finnigan MAT LCQ ion – trap mass 
spectrometer 
8 mM ammounium acetate, pH 
7 with ammounium hydroxide 
(A) and MeCN (B) at a gradient 
of 0 – 15 mins, 20 – 28% B, 15 – 
35 mins, 28 – 32% B, 35 – 55 
mins, 32 – 40% B, 55 – 60 mins, 
40% B 
0.7 mL/min and 25 °C for HPLC, 
nebulizer temperature at 70 °C, 
nebulising gas (Nitrogen) at a pressure 
of 2.5 bar for ELSD, source voltage 
4.78 kV, sheath gas flow – rate 5.3 
bar, auxiliary gas flow 1.2 bar, 
capillary voltage – 31 V and capillary 
temperature 290 °C for MS. 
Lau et al. (Lau et al. 2003) HPLC with 
diode array 
detection 
Agilent 1100 liquid chromatography 
with reverse phase column C18 (250 
x 4.6 mm, 5 µm) 
Water (A) and Acetonitrile (B) 
separating active constituents 
at the following gradient:  0 – 
30 mins, 20% B, 30 – 60 mins, 
20 – 45% B, 60 – 78 mins, 45 – 
75% B, 78 – 80 mins, 75 – 100% 
B 
35 °C, 1 mL/min, 5 µL, 203 nm. 
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Chen et al. (Chen et al. 
2007) 
HPLC – UV Waters HPLC system with an Alltima 
C18 reverse – phase column (250 x 
4.6 mm) 
0.05% phosphoric acid in water 
(A) and Acetonitrile (B) and the 
gradient was set to as follows:  
0 – 35 mins, 20% B, 35 – 65 
mins, 20 – 35% B, 65 – 75 mins, 
35 – 45% B, 75 – 80 mins, 45 – 
20% B 
1.2 mL/min, 35 °C, 203 nm, 20 µL. 
Li et al. (Li et al. 2005) HPLC – UV Agilent 1100 liquid chromatography 
with a Zorbax SB – C18 reverse – 
phase column (250 x 4.6 mm, 5 µm) 
and a Zorbax SB – C18 guard column 
(20 x 4 mm, 5 µm) 
Acetonitrile (A) and 0.001% 
aqueous formic acid (B) at a 
gradient of 0 – 8 mins, 25 – 
26% A, 8 – 10 mins, 26 – 33% A, 
10 – 30 mins, 33 – 45% A 
0.8 mL/min, 203 nm, 5 µL. 
Lau  et al. (Lau et al. 2004) HPLC with 
photodiod
e array 
detector 
Waters Alliance liquid 
chromatography with photodiode 
array detector 2996 used in 
conjugation with Waters Symmetry 
C18 reverse - phase (250 x 4.6 mm, 
5 µm) 
Water (A) and Acetonitrile (B) 
flowing at a speed of 1 mL/min 
and at a gradient of 0 – 30 
mnins, 20% B, 30 – 60 mins, 20 
– 45% B, 60 – 78 mins, 45 – 
75% B, 78 – 80 mins, 75 – 100% 
B 
5 µL, 203 nm, 1 mL/min. 
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Dan et al. (Dan et al. 2008) UPLC – ESI 
– MS 
Acquity UPLC systems with a Acquity 
UPLC BEH C18 column (50 x 2.1 mm, 
1.7 µm) 
0.01% HCO2H in water (A) and 
CH3CN (B), flowing at a rate of 
0.35 mL/min and at a gradient 
as follows:  0 – 3 mins, 9 – 75% 
A, 3 – 10 mins, 75 – 70% A, 10 – 
16 mins, 70 – 65% A, 16 – 18 
mins, 65 – 50% A, 18 – 21 mins, 
50 – 35% A 
5 µL, 0.35 mL/min for UPLC, positive 
ion electrospray ionization mode by 
scanning over m/z range 400 – 1400, 
ESI capillary voltage at 3.0 kV, temper 
for electrospray source and 
desolvation gas were 100 and 300 °C 
respectively, nitrogen gas (nebulising 
gas), desolvation gas, cone gas at a 
flow rate of 60, 600 and 50L/h 
respectively and the voltage varied 
over 25 – 90 V for ESI. 
Li et al. (Li et al. 2004) Solid phase 
extract and 
HPLC – UV  
Agilent 1100 liquid chromatography 
systems with a agilent Zorbax SB – 
C18 reversed – phase column (250 x 
4.6 mm, 5 µm) 
Water (A) and Acetonitrile (B) 
at a gradient of 0 – 20 mins, 20 
– 25% B, 20 – 25 mins, 25 – 
31% B, 25 – 55 mins, 31 – 40% 
B 
5 µL, 35 °C, 0.8 mL/min. 
Zhang et al. (Zhang et al. 
2006) 
Ultrahigh 
pressure 
extraction 
and HPLC 
DL700 Ultrahigh pressure machine; 
SCL – 10A VP system with SPC – 
M10A VP UV photodiode array 
detector in conjugation with 
Diamonsil C18 (250 x 4.6 mm, 5 µm) 
Acetonitrile (A) and 0.05% 
phosphoric acid aqueous 
solution (B) and the gradient 
used was 0 – 20 mins, volume 
fraction 80 – 78%, 20 – 45 
mins, VF 72 – 55%, 45 – 55 
mins, VF 55 – 45%, 55 – 60 
mins, 45 – 0%, 60 – 65 mins, VF 
0 – 80% 
10 mL methanol used for extraction, 
35 °C, 1.0 mL/min, 20 µL, 203 nm for 
HPLC. 
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Liu et al. (Liu et al. 2003) HPLC with 
infrared 
spectrosco
py 
Waters 510 system with a Waters 
490E multiwavelength Detector in 
conjugation with Phenomenex C18 
(250 x 4 mm, 5 µm); Nicolet Nexus 
670 FT – IR spectrometer 
CH3CN (A) and H2O (B) flowing 
at a gradient of 0 – 2 mins, 25 – 
50% (A) at a flow rate 1.0 
mL/min, 2 – 4 mins, 50 – 40% A 
at a flow rate of 1.8 mL/min, 4 
– 20 mins, 40 – 100% A at a 
flow rate of 1.0 mL/min 
15 µL, 203 nm for HPLC; for each 
spectrum a 512 – scan interferogram 
was collected at a resolution of 4 cm -
1, baseline was carried out passing 
trough 1700 – 1600 cm -1 amide I band 
and 1330 – 1220 cm -1 for amide III 
band. 
Wang et al. (Wang et al. 
2006) 
MEKC HP3D capillary electrophoresis 
system with diode – array detector 
9190 – 600 mm) with a 70 cm x 75 
µm fused silica capillary 
N/A 25 °C, 195 nm and separation voltage 
of – 20 kV, at a current of – 28 µA, a 
water plug was injected into the 
capillary by 30 mbar for 2 secs from 
cathode end and voltage was applied 
at negative polarity. 
Cui et al. (Cui et al. 1993) GC HP 5890A gas chromatography and 
a DB – 5 column (15 m x 0.32 mm x 
0.25 µm) 
N/A 220 °C was set for 1 min, then 
increase at 10 °C/min until 300 °C is 
reached and then kept constant for 11 
mins, column (helium) flow rate was 
2.0 mL/min, injector temperature of 
275 °C and detector temperature of 
290 °C. 
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Xie et al. (Xie et al. 2007) GC Perkin – Elmer GC and Model 
TURBOMASS MS with Agilent J&W 
DB – 5MS (30 m x 0.25 mm x 0.25 
µm fused – silica capillary column) 
N/A Initial temperature was 80 °C and held 
for 2 mins, increased to 140 °C at a 
rate of 10 °C/min, then to 240 °C at a 
rate of 4 °C/min and followed by 
10 °C/min until 280 °C and held for 3 
mins.  The electron energy was set to 
70 eV, ion source temperature at 
200 °C, injector temperature to 260 °C 
and carrier gas, helium, was set to a 
column flow rate of 1.0 mL/min.  MS 
data were collected in the full scan 
mode of 30 – 550 m/z and the dwell 
time for each scan was set at 100 ms 
and solvent delay was at 2.5 mins. 
Chen and Sorensen (Chen 
et al  2000) 
NIR NIRSystems 6500 N/A Scans in the region of 400 – 2500 nm 
and obtained data are processed by 
Unscrambler 7.01 and ISI 3.00, 
samples were contained at 20 – 26 °C. 
 
 
 
 
 
 1.5 Aims and objectives for the research programme 
- To develop RRLC analytical methods and conditions for the analysis of 
phenylethanoids (salidroside, tyrosol), phenylpropanoid glycosides (rosarin, rosavin, 
rosin) and monoterpene (rosiridin) from Rhodiola rosea 
- To develop RRLC analytical methods and conditions for the analysis of flavonoids 
(epimedin A, B, C and icariin) in Epimedium species 
- To develop RRLC analytical methods and conditions for the analysis of saponins (R1, 
Rg1, Re, Rf, Rb1, Rc, Rb2, Rd) from Panax quinquefolius, Panax ginseng and Panax 
notoginseng 
- To develop RRLC analytical methods and conditions for the analysis of eleutherosides 
B and E from E. senticosus 
- To develop RRLC analytical methods and conditions for the analysis of the all the 
chemical constituents  from R. rosea and E. senticosus  in a single run 
- To develop RRLC analytical methods and conditions for the analysis of all the active 
chemical constituents from Epimedium species and the three major Panax species, 
namely, P. quinquefolius, P. ginseng and P. notoginseng in a simultaneous run. 
- To develop RRLC analytical methods and conditions for the analysis of all the active 
chemical constituents from the four herbs, namely, R. rosea, Epimedium species, P. 
quinquefolius and E. senticosus 
- To simultaneously evaluate the stability of more than 20 active compounds from the 
“Energy formula” by using the developed RRLC method 
- To evaluate raw materials and commercial products containing the four herbs and 
determine if the proposed developed methods are practical for use, furthermore, 
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with respect to the commercial products to clarify that their content matches the 
claim on their label 
Achievement of these aims would allow simultaneous control of qualitative and 
quantitative identification of the four herbs in commercially formulated products.  In 
addition, the analysis by using RRLC will contribute significantly to the botanical industry to 
prevent spiking in order to meet the expected concentration for the species from raw 
materials to semi – finished and then to the finished products.  The challenges faced today 
are mainly aimed at identification and quantification of the compounds in formulated 
products, as the developed conventional analytical methods cannot be used for the analysis 
of multiple chemical constituents due to interference. Therefore, these newly developed 
RRLC methods can contribute fully to overcome this difficulty and, moreover, allow 
consistency of formulated herbal products containing these herbs to a high quality. 
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Chapter 2 Materials and Methods 
2.1 Materials 
HPLC grade acetonitrile CH3CN and methanol MeOH were purchased from Fisher 
Scientific (Ottawa, Canada).  Deionized Water was prepared by a Nanopure Ultrapure water 
system (Barnstead, USA) for preparing samples and mobile solutions.  All solvents and 
reagents were analytical reagent grade. 
Ginsenoside standards Rg1, Re, Rb1, Rc, Rb2, Rd and Rf were purchased from Sigma 
(USA), ginsenoside R1 was purchased from the National Institute of Drug Control and 
Biological Products (China).  
Icariin standard was purchased from Sigma (USA) and epimedins A, B, C were from 
Biopurify (Chengdu, China). 
The reference standards of salidroside (purity: 98.3%), tyrosol (purity: 98.1%), 
rosarin (purity: 98.6%), rosavin (purity: 99.2%), and rosin (purity: 98.1%) were purchased 
from ChromaDex (Irvine, CA, USA); and rosiridin was purchased from Biopurify (Chengdu, 
China). 
Eleutheroside B (purity: 99.6%), eleutheroside E (purity: 99.1%) references samples 
were purchased from Biopurify (Chengdu, China).  
Analysis was carried out using an Agilent series 1200 RRLC instrument (Santa Clara, 
CA, USA) equipped with a binary pump, a micro vacuum degasser, a multi-wavelength (MW) 
detector, an autosampler, and a thermostated column. Optimum resolution and peak shape 
were obtained on a Luna C18-HST (High Speed Technology) column (2.5 μm, 100 × 3.0 mm) 
from Phenomenex (Torrance, CA, USA). 
A VWR Sonicator and 0.20 µm syringe filter were purchased from VWR International 
(Mississauga, Canada). 
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Ginseng samples:  P. quinquefolius, fresh and dried root samples, were mostly from 
plants grown in North America. P. ginseng roots were collected from ginseng growers in 
Korea and China.  P. notoginseng samples were from Kunming Institute of Botany in China.  
Panax quinquefolius roots were processed by Canadian Phytopharmaceuticals Corp., Canada 
to produce a powder extract containing 10% (w/w) major ginsenosides.   
Epimedium plants were collected from local growers. (British Columbia, Canada). 
Four samples of dried R. rosea roots (H1, H2, H3 and H4) were provided by Alberta 
Agriculture and Rural Development (Edmonton, AB, Canada) and a supplier in China (Shanxi, 
China); one fresh R. rosea root sample (H5) was provided by a Canadian supplier (Calgary, 
AB, Canada). Nineteen commercial Rhodiola extracts samples were collected from suppliers 
in China and as well as Canada (Vancouver, BC). 
Five commercial E. senticosus powder extracts samples were collected from 8 
suppliers in China (Shanxi and Kunming). 
Six commercial polyherbal formulated capsules containing R. rosea and E. senticosus 
ingredients were purchased from a local drug store (Vancouver, BC, Canada).  
Six commericial polyherbal formulated capsules containing P. quinquefolius and 
Epimedium ingredients were purchased from a local drug store (Vancouver, BC, Canada). 
4 in 1 polyherbal formulated capsules containing P. quinquefolius, Epimedium, R. 
rosea and E. senticosus were manufactured by Canadian Phytopharmaceuticals Corp. using 
the P. quinquefolius, Epimedium, R. rosea and E. senticosus powder extracts collected from 
different suppliers as indicated above. 
 All these samples are verified using references and stored in the refrigerator at 4oC. 
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2.2 Methods 
Stock reference standard solutions of ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, 
epimedins A, B, C, icariin, salidroside, tyrosol, rosarin, rosavin, rosin, rosiridin, eleutheroside 
B and E with concentration of 1 mg/mL were prepared in methanol.  Rosiridin is for 
identification purposes only.  All stock solutions were refrigerated at 4°C until used.  
Working solutions were prepared by diluting the stock solution with methanol.  Each 
compound was diluted to a different concentration to try to imitate the peak height in the 
actual herb HPLC profile.   All RRLC data acquisition and processing were performed by 
ChemStation revision B.01.01 software.   
Recovery testing for all the active compounds found in R. rosea, E. senticosus, P. 
quinquefolius and Epimedium plants were conducted by taking a known quantity of the each 
of the active compounds, namely, salidroside, tyrosol, eleutheroside B, eleutheroside E, 
rosarin, rosavin, rosin, R1, Rg1, Re, epimedin A, B, C, icariin, Rf, Rb1, Rc, Rb2 and Rd.   These 
active compounds were spiked with 0.1 g of its correlated authentic plant.  These fortified 
samples were then extracted and analyzed in triplicate.  All experiments were run with 
water (A) and acetonitrile (B) as solvents in different ratios. 
 
2.2.1    Rhodiola rosea method development 
2.2.1.1  Extraction of powdered R. rosea roots with 75% aqueous methanol 
About 5 g of dried R. rosea roots was ground into fine powder and accurately 
weighed into a 10 mL volumetric flask, then ultrasonic extracted at 37oC with 75% MeOH aq. 
solution for 15 min, and made up to volume. Prior to RRLC analysis, the sample was filtered 
through a 0.20 μm syringe filter.  Each sample was injected five times, 1µL each, and the 
RSD was calculated for all the samples.   
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2.2.1.2  Extraction of R. rosea powder extract with methanol 
About 50 mg of R. rosea powder extract was accurately weighed into a 10 mL 
volumetric flask, ultrasonic extracted at 37oC with 100% pure MeOH for 15 min, and then 
made up to volume. Prior to RRLC analysis, sample was filtered through a 0.20 μm syringe 
filter. Every sample was injected five times of 1µL each and the RSD was calculated for all 
the samples.   
 
2.2.1.3  Establishment of a calibration curve for R. rosea 
The stock reference standard solutions of salidroside, tyrosol, rosarin, rosavin and 
rosin were each prepared at a concentration of 1.0 mg/mL in MeOH.  Further calibration 
levels for each compound were prepared by diluting the above reference standard solution 
to 0.03, 0.005, 0.01, 0.015 and 0.01 µg/µl. All solutions were stored in a refrigerator at 4oC.  
Rosiridin is for identification purposes only, therefore, no calibration curve was established 
for this compound. 
 
2.2.1.4  Recovery of R. rosea active compounds 
 A recovery test was performed to determine the accuracy of our proposed method.  
A known quality of the five references were spiked into 0.1 g of authentic R. rosea root 
extract, this fortified sample was then extracted and analyzed in triplicate.   
 
2.2.1.5  Analysis of R. rosea root powder and powder extract 
The active compounds found in R. rosea, namely, salidroside, tyrosol, rosarin, rosavin, 
rosin and rosiridin were separated by RRLC using solvents water (A) and acetonitrile (B) with 
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the following gradient elution with a sample injection of 1 µL:  0-6 min, 6-17% B, 6-7 min, 
17-19.7% B, 7-9 min, 19.7-19.7% B, 9-10 min, 19.7-100% B at a flow rate of 1.0 mL/min. The 
column temperature was 40oC, and detection wavelengths were set at 205 and 254 nm. 
Each chromatographic run was followed by a 2 min post run and an equilibration period of 5 
min. 
 
2.2.2    Epimedium method development 
2.2.2.1  Extraction of Epimedium powder extract with methanol 
About 50 mg of Epimedium powder extract was accurately weighed into a 10 mL 
volumetric flask, ultrasonic extracted at 37oC with 100% pure MeOH for 15 min, and then 
made up to volume. Prior to RRLC analysis, the sample was filtered through a 0.20 μm 
syringe filter. Every sample was injected five times, 1µL each time, and the RSD was 
calculated for all the samples.   
 
2.2.2.2  Establishment of a calibration curve for Epimedium  
The stock reference standard solutions of Epimedins A, B, C and icariin were 
prepared at a concentration of 1.0 mg/mL in MeOH. Further calibration levels were 
prepared by diluting the above reference standard solutions to 23.98, 39.58, 60.18 and 
90.00 µg/mL, respectively.  All solutions were stored in a refrigerator at 4oC.   
 
2.2.2.3  Recovery of Epimedium active compounds 
 A recovery test was performed to determine the accuracy of our proposed method.  
A known quality of the five references were spiked into 0.1 g of authentic Epimedium leave 
extract, this fortified sample was then extracted and analyzed in triplicate.   
78 
2.2.2.4 Analysis of Epimedium powder extract using the Phenomenex Luna column 
The active compounds found in Epimedium in methanol, namely, Epimedins A, B, C 
and icariin were separated by RRLC using solvents water (A) and acetonitrile (B) with the 
following gradient elution with a sample injection of 1 µL:    19.7% - 19.7% B at 0 – 9 min; 
19.7% - 30% B at 9 – 10 min; 30 – 30% B at 10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 
100% B at 16 – 18 min. The column temperature was 40oC, detection wavelength 203 nm. 
Each chromatographic run was followed by a 2 min post run and an equilibration period of 5 
min. 
 
2.2.2.5  Analysis of Epimedium powder extract using the Zorbax eclipse XDB column 
The active compounds found in Epimedium in methanol, namely, Epimedins A, B, C 
and icariin were separated by RRLC using solvents water (A) and acetonitrile (B) with the 
following gradient elution with sample injection of 1 µL:  22 – 22% B at 0 – 1.6 min; 22 – 40% 
B at 1.6 – 3.5 min; 40 – 50% B at 3.5 – 5 min; 50 – 100% B at 5 – 6 min. The column 
temperature was 40oC and detection wavelength 203 nm. Each chromatographic run was 
followed by a 2 min post run and an equilibration period of 5 min. 
 
2.2.3    Panax method development 
2.2.3.1  Extraction of Panax powder extract 
About 50 mg of Panax powder extract was accurately weighed into a 10 mL 
volumetric flask, ultrasonic extracted at 37oC with 100% pure MeOH for 15 min, and then 
made up to volume. Prior to RRLC analysis, the sample was filtered through a 0.20 μm 
syringe filter. Every sample was injected five times, 1µL each time, and the RSD was 
calculated for all the samples.   
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2.2.3.2 Extraction of three different Panax root powder with 75% aqueous 
methanol 
 
About 100 mg each of the three different Panax species root powder samples was 
accurately weighed into a 10 mL volumetric flask, ultrasonic extracted at 37oC with 75% 
MeOH aq. solution for 15 min, and then made up to volume. Prior to RRLC analysis, the 
sample was filtered through a 0.20 μm syringe filter. Each sample was injected five times, 
1µL each time, and the RSD was calculated for all the samples.   
 
2.2.3.3  Establishment of calibration curve for three different Panax species 
The stock reference standard solutions of ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, and 
Rd were prepared at a concentration of 1.0 mg/mL in MeOH. Further calibration levels were 
prepared by diluting the above reference standard solution to 179.00, 29.55, 89.10, 37.37, 
223.58, 37.42, 30.45 and 45.00 µg/mL, respectively.  All solutions were stored in a 
refrigerator at 4oC.   
 
2.2.3.4  Recovery of Panax species active compounds 
 A recovery test was performed to determine the accuracy of our proposed method.  
A known quality of the five references were spiked into 0.1 g of authentic Panax root extract, 
this fortified sample was then extracted and analyzed in triplicate.   
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2.2.3.5 Analysis of all three species of Panax root powder and its powder extract 
using the Phenomenex Luna column 
 
The active compounds found P. quinquefolius, P. ginseng and P. notoginseng root 
powder and powder extracts, namely, ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, and Rd were 
separated by RRLC using solvents water (A) and acetonitrile (B) with the following gradient 
elution with sample injections of 1 µL:  19.7% - 19.7% B at 0 – 9 min, 19.7% - 30% B at 9 – 10 
min, 30 – 30% B at 10 – 11 min, 30 – 50% B at 11 – 16 min, 50 – 100% B at 16 – 18 min. The 
column temperature was 40oC, and detection wavelength 203 nm.  Each chromatographic 
run was followed by a 2 min post run and an equilibration period of 5 min. 
 
2.2.3.6 Analysis of Panax root powder and powder extract using the Zorbax eclipse 
XDB column 
The active compounds found P. quinquefolius, P. ginseng and P. notoginseng root 
powder and powder extracts, namely, ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, and Rd were 
separated by RRLC using solvents water (A) and acetonitrile (B)  with the following gradient 
elution with sample injections of 1 µL:  22 – 22% B at 0 – 1.6 min; 22 – 40% B at 1.6 – 3.5 
min; 40 – 50% B at 3.5 – 5 min; 50 – 100% B at 5 – 6 min. The column temperature was 40oC, 
and detection wavelength set at 203 nm.  Each chromatographic run was followed by a 2 
min post run and an equilibration period of 5 min. 
 
2.2.4    Eleutherococcus senticosus method development 
2.2.4.1  Extraction of E. senticosus powder extract with methanol 
About 50 mg of E. senticosus powder extract was accurately weighed into a 10 mL 
volumetric flask, ultrasonic extracted at 37oC with 100% pure MeOH for 15 min, and then 
made up to volume. Prior to RRLC analysis, the sample was filtered through a 0.20 μm 
81 
syringe filter. Every sample was injected in triplicate, 1µL each time, and the RSD was 
calculated for all the samples.   
 
2.2.4.2  Establishment of a calibration curve for E. senticosus 
The stock reference standard solutions of eleutheroside B and E were prepared at a 
concentration of 1.0 mg/mL in MeOH. Further calibration levels were prepared by diluting 
the above reference standard solution to 0.0102 and 0.01735 µg/µL. All solutions were 
stored in a refrigerator at 4oC.   
 
2.2.4.3  Recovery of E. senticosus active compounds 
 A recovery test was performed to determine the accuracy of our proposed method.  
A known quality of the five references were spiked into 0.1 g of authentic E. senticosus 
extract, this fortified sample was then extracted and analyzed in triplicate.   
 
2.2.4.3  Analysis of E. senticosus powder and powder extract 
The active compounds found in E. senticosus in methanol, namely, eleutheroside B 
and E were separated by RRLC using solvents water (A) and acetonitrile (B) with the 
following gradient elution with sample injection of 1 with the following gradient elution with 
sample injections of 1 µL:  0-6 min, 6-17% B; 6-7 min, 17-19.7% B; 7-9 min, 19.7-19.7% B, 9-
10 min, 19.7-100% B at a flow rate of 1.0 mL/min. The column temperature was 40oC, the 
detection wavelength set at 220 nm. Each chromatographic run was followed by a 2 min 
post run and an equilibration period of 5 min. 
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2.2.5    Rhodiola rosea and Eleutherococcus senticosus formula analysis 
 
2.2.5.1 Establishment of a calibration curve for R. rosea and E. senticosus formula 
product 
 
The stock reference standard solutions of salidroside, tyrosol, rosarin, rosavin, rosin, 
eleutheroside B and E were prepared at a concentration of 1.0 mg/mL in MeOH. Further 
calibration levels were prepared by diluting the above reference standard solutions to 0.028, 
0.004525, 0.0118, 0.0168, 0.009575, 0.0051 and 0.008675 µg/µL. All solutions were stored 
in a refrigerator at 4oC.  Rosiridin is for identification purposes only, therefore, no calibration 
curve was established. 
 
2.2.5.2 Analysis of formulated products containing extracts of R. rosea and E. 
senticosus  
 
The active compounds found in R. rosea and E. senticosus in methanol, namely, 
salidroside, tyrosol, rosarin, rosavin, rosin eleutheroside B and E were separated by RRLC 
using solvents water (A) and acetonitrile (B) with the following gradient elution with sample 
injections of 1 µL:  0-6 min, 6-17% B; 6-7 min, 17-19.7% B; 7-9 min, 19.7-19.7% B, 9-10 min, 
19.7-100% B. The detection wavelength varied as follows: 0-3.5 min, 205 nm; 3.5-6.5 min, 
220 nm; 6.5-8 min, 205 nm at a flow rate of 1.0 mL/min. The column temperature was 40oC. 
Each chromatographic run was followed by a 2 min post run and an equilibration period of 5 
min. 
 
2.2.6    Panax and Epimedium formula analysis 
 
2.2.6.1  Calibration curve establishment for Panax  and Epimedium formula product 
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The stock reference standard solutions of ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, 
epimedins A, B, C and icariin were prepared at a concentration of 1.0 mg/mL in MeOH. 
Further calibration levels were prepared by diluting the above reference standard solutions 
to 0.089, 0.019, 0.015, 0.044, 0.112, 0.0187, 0.0152, 0.0225, 0.0025, 0.005, 0.0075 and 
0.0090  µg/µL, respectively. All solutions were stored in a refrigerator at 4oC.   
 
2.2.6.2 Analysis of Panax and Epimedium formulated products using the 
Phenomenex luna column 
 
The active compounds found in Panax and Epimedium  in methanol, namely, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, epimedins A, B, C and icariin were separated by 
RRLC using solvents water (A) and acetonitrile (B) with the following gradient elution with 
sample injection of 1 µL:  19.7% - 19.7% B at 0 – 9 min; 19.7% - 30% B at 9 – 10 min; 30 – 
30% B at 10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 16 – 18 min with a flow 
rate of 1.0 mL/min. The column temperature was 40oC, the detection wavelength set at 203 
nm. Each chromatographic run was followed by a 2 min post run and an equilibration period 
of 5 min. 
 
2.2.6.3 Analysis of Panax and Epimedium formulated products using the Zorbax 
Eclipse XDB column 
 
The active compounds found in Panax and Epimedium in methanol, namely, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, epimedins A, B, C and icariin were separated by 
RRLC using solvents water (A) and acetonitrile (B)  with the following gradient elution with 
sample injection of 1 µL:  22 – 22% B at 0 – 1.6 min; 22 – 40% B at 1.6 – 3.5 min; 40 – 50% B 
at 3.5 – 5 min; 50 – 100% B at 5 – 6 min with a flow rate of 1.0 mL/min. The column 
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temperature was 40oC, the detection wavelength set at 203 nm. Each chromatographic run 
was followed by a 2 min post run and an equilibration period of 5 min. 
 
2.2.7  R. rosea, Epimedium and Panax species formula method development 
2.2.7.1 Establishment of a calibration curve for R. rosea, Epimedium and Panax 
species formula product 
  
 The stock reference standard solution of salidroside, tyrosol, rosarin, rosavin, rosin, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd were prepared at a concentration of 1.0 
mg/mL in MeOH.  Further calibration levels were prepared by diluting the above reference 
standard solutions 0.015, 0.0025, 0.005, 0.0075, 0.005, 0.0025, 0.005, 0.0075, 0.009, 0.045, 
0.0093, 0.0074, 0.022, 0.056, 0.019, 0.0076 and 0.0112 µg/µL, respectively.  All solutions 
were stored in a refrigerator at 4°C. 
 
2.2.7.2 Analysis of R. rosea, Epimedium and Panax species formula product using 
the Phenomenex Luna column 
 
 The active compounds found in R. rosea, Epimedium and Panax species in methanol, 
namely; salidroside, tyrosol, rosarin, rosavin, rosin, ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 
and Rd were separated by RRLC with the following gradient elution with sample injection of 
1 µL:  0 mins at 6% B, 6 mins at 17% B, 7 mins at 19.7% B, 15 mins at 19.7% B, 16 mins at 
30% B, 22 mins at 50% B, 24 mins at 100% B and 26 mins at 6% B with a Phenomenex Luna 
column, at a temperature of 40 °C using water (A) and Acetonitrile (B) under the wavelength 
of 205 nm from 0 – 3 mins, 220 nm from3 – 6.5 mins, 205 nm from 6.5 – 18 mins.  Each 
chromatographic run was followed by a 2 min post run and an equilibration period of 5 mins. 
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2.2.8 R. rosea, E. senticosus and Epimedium species formulated product method 
development 
 
2.2.8.1 Establishment of calibration curve for R. rosea, E. senticosus and Epimedium 
species formula product 
 
 The stock reference standard solution of salidroside, tyrosol, rosarin, rosavin, rosin, 
eleutheroside B, E, epimedin A, B, C and icariin were prepared at a concentration of 1.0 
mg/mL in MeOH.  Further calibration levels were prepared by diluting the above reference 
standard solutions to 0.015, 0.0025, 0.005, 0.0075, 0.005, 0.0026, 0.0047, 0.0025, 0.005, 
0.0075 and 0.009 µg/µL, respectively.  All solutions were stored in a refrigerator at 4°C. 
 
2.2.8.2 Analysis of R. rosea, E. senticosus and Epimedium species formulated 
products using the Phenomenex Luna column 
 
 The active compounds found in R. rosea, E. senticosus and Epimedium species, 
namely, salidroside, tyrosol, rosarin, rosavin, rosin, eleutheroside B, E, epimedin A, B, C and 
icariin were separated by RRLC with the following gradient elution with sample injection of 1 
µL:  0 mins at 6% B, 6 mins at 17% B, 7 mins at 19.7% B, 10 mins at 19.7% B, 11 mins at 30% 
B, 17 mins at 50% B, 19 mins at 100% B and 20 mins at 6% B with a Phenomenex Luna 
column at a flow rate of 1.0 mL/min.  The column temperature was 40 °C using water (A) 
and Acetonitrile (B) at wavelength of 205 nm from 0 – 3 mins, 220 nm from3 – 6.5 mins, 205 
nm from 6.5 – 8 mins and 203 nm from 8 – 20 mins.  Each chromatographic run was 
followed by a 2 min post run and an equilibration period of 5 min. 
 
2.2.9  R. rosea, E. senticosus and Panax species formula method development 
2.2.9.1 Establishment of calibration curve for R. rosea, E. senticosus and Panax 
species formulated product 
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 The stock reference standard solution of salidroside, tyrosol, rosarin, rosavin, rosin, 
eleutheroside B, E, ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd were prepared at a 
concentration of 1.0 mg/mL in MeOH.  Further calibration levels were prepared by diluting 
the above reference standard solutions 0.015, 0.0025, 0.005, 0.0075, 0.005, 0.0026, 0.0047, 
0.045, 0.0093, 0.0074, 0.022, 0.056, 0.019, 0.0076 and 0.0112 µg/µL, respectively.  All 
solutions were stored in a refrigerator at 4°C. 
 
2.2.9.2 Analysis of R. rosea, E. senticosus and Panax species formulated product 
using the Phenomenex Luna column 
  
The active compounds found in R. rosea, E. senticosus and Panax species, namely, 
salidroside, tyrosol, rosarin, rosavin, rosin, eleutheroside B, E, ginsenosides R1, Rg1, Re, Rf, Rb1, 
Rc, Rb2 and Rd were separated by RRLC with the following gradient elution with sample 
injection of 1 µL:  0 mins at 6% B, 6 mins at 17% B, 7 mins at 19.7% B, 15 mins at 19.7% B, 16 
mins at 30% B, 22 mins at 50% B, 24 mins at 100% B and 26 mins at 6% B with a 
Phenomenex Luna column at a flow rate of 1.0 mL/min.  The column temperature was 40 °C 
using water (A) and Acetonitrile (B) at wavelengths of 205 nm from 0 – 3 mins, 220 nm 
from3 – 6.5 mins, 205 nm from 6.5 – 8 mins, 203 nm from 8 – 26 mins.  Each 
chromatographic run was followed by a 2 min post run and an equilibration period of 5 min. 
2.2.10  E. senticosus, Epimedium and Panax species formula method development 
2.2.10.1 Establishment of a calibration curve for E. senticosus, Epimedium and Panax 
species formulated products 
 
 The stock reference standard solution of eleutheroside B, E, epimedin A, B, C, icariin, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd were prepared at a concentration of 1.0 
mg/mL in MeOH.  Further calibration levels were prepared by diluting the above reference 
87 
standard solutions to 0.0026, 0.0047, 0.0025, 0.005, 0.0075, 0.009, 0.045, 0.0093, 0.0074, 
0.022, 0.056, 0.019, 0.0076 and 0.0112 µg/µL, respectively.  All solutions were stored in a 
refrigerator at 4°C. 
2.2.10.2 Analysis of E. senticosus, Epimedium and Panax species formulated 
products using the Phenomenex Luna column 
 
 The active compounds found in E. senticosus, Epimedium and Panax species in 
methanol, namely, eleutheroside B, E, epimedin A, B, C, icariin, ginsenosides R1, Rg1, Re, Rf, 
Rb1, Rc, Rb2 and Rd were separate by RRLC with the following gradient elution with sample 
injection of 1 µL:  0 mins at 6% B, 6 mins at 17% B, 7 mins at 19.7% B, 15 mins at 19.7% B, 16 
mins at 30% B, 22 mins at 50% B, 24 mins at 100% B and 26 mins at 6% B with a 
Phenomenex Luna column at a flow rate of 1.0 mL/min.  The column temperature was 40 °C 
using water (A) and Acetonitrile (B) at a wavelength of 220 nm from 0 – 6.5 mins, 203 nm 
from 6.5 – 26 mins.  Each chromatographic run was followed by a 2 min post run and an 
equilibration period of 5 min. 
 
2.2.11  R. rosea + Epimedium + Panax + E. senticoccus formulated analysis 
2.2.11.1 Establishment of a calibration curve for 4 in 1 formula 
The stock reference standard solution of salidroside, tyrosol, rosarin, rosavin, rosin, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, epimedins A, B, C, icariin, eleutheroside B and E 
were prepared at a concentration of 1.0 mg/mL in MeOH. Further calibration levels were 
prepared by diluting the above reference standard solution to 0.0112, 0.00181, 0.00472, 
0.00672, 0.00383, 0.0358, 0.00747, 0.00591, 0.01782, 0.0447, 0.0075, 0.0061, 0.009, 
0.00181, 0.00472, 0.00672, 0.0072, 0.00204 and 0.00347 µg/µL, respectively. All solutions 
were stored in a refrigerator at 4oC.   
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2.2.11.2 Analysis of 4 in 1 formulated products 
The active compounds found in Panax and Epimedium, namely, salidroside, tyrosol, 
rosarin, rosavin, rosin, ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, epimedins A, B, C, icariin, 
eleutheroside B and E were separated by RRLC with the following gradient elution with 
sample injection of 1 µL:  6-17% B at 0-6 min, 17-19.7% B at 6-7 min, 19.7% B at 7-15 min, 
19.7-30% B at 15-16 min, 30% B at 16-17 min, 30-50% B at 17-22 min, 50-100% at 22-24 min 
with a flow rate of 1.0 mL/min. The column temperature was 40oC, and detection 
wavelengths varied as follows: 0 – 3 mins HPLC chromatograph was analyzed at 203 nm, 3-
6.5 mins at 220 nm, 6.5-22 mins at 203 nm.  Each chromatographic run was followed by a 2 
min post run and an equilibration period of 5 min. 
 
2.2.12   Stability testing 
 
2.2.12.1 Stability testing for Panax powder extracts 
Six bottles of P. quinquefolius capsules were placed in the stability chamber for stability 
testing.  Each bottle was placed there for a different time period of up to six months.  RRLC 
testing was conducted at the end of each month to see the changes that occurred.  The 
Phenomenex luna column was used for the RRLC testing and separation was obtained by 
gradient elution using water (A) and acetonitrile (B) as the mobile phase according to the 
following profile:  19.7% - 19.7% B at 0 – 9 min; 19.7% - 30% B at 9 – 10 min; 30 – 30% B at 
10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 16 – 18 min. The column 
temperature was 40oC, the detection wavelength 203 nm, and injection volume, 1 µL. Each 
run was followed by a 2 min post run and an equilibration period of 5 min. 
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2.2.12.2 Stability testing for Panax and Epimedium powder extracts 
Six bottles of P. quinquefolius and Epimedium formulated capsules were placed in 
the stability chamber for stability testing.  Each bottle was placed in there for a different 
time period of up to six months.  RRLC testing was conducted at the end of each month to 
see the changes that occurred.  The Phenomenex luna column was used for the RRLC testing 
and separation was obtained by gradient elution using water (A) and acetonitrile (B) as the 
mobile phase according to the following profile:  19.7% - 19.7% B at 0 – 9 min; 19.7% - 30% 
B at 9 – 10 min; 30 – 30% B at 10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 16 – 
18 min. The column temperature was 40oC, the detection wavelength 203 nm, and injection 
volume, 1 µL. Each run was followed by a 2 min post run and an equilibration period of 5 
min. 
 
2.2.12.3 Stability testing for Panax and Vitamin C powder extracts 
Six bottles of P. quinquefolius and Vitamin C formulated capsules were placed in the 
stability chamber for stability testing.  Each bottle was placed there for a different time 
period of up to six months.  RRLC testing was conducted at the end of each month to see 
the changes that occurred.  The Phenomenex luna column was used for the RRLC testing 
and separation was obtained by gradient elution using water (A) and acetonitrile (B) as the 
mobile phase according to the following profile:  19.7% - 19.7% B at 0 – 9 min; 19.7% - 30% 
B at 9 – 10 min; 30 – 30% B at 10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 16 – 
18 min. The column temperature was 40oC, the detection wavelength 203 nm, and injection 
volume, 1 µL. Each run was followed by a 2 min post run and an equilibration period of 5 
min. 
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2.2.12.4 Stability testing for Panax and Citric Acid powder extracts 
Six bottles of P. quinquefolius and Citric Acid formulated capsules were placed in the 
stability chamber for stability testing.  Each bottle was placed there for a different time 
period of up to six months.  RRLC testing was conducted at the end of each month to see 
the changes that occurred.  The Phenomenex luna column was used for the RRLC testing 
and separation was obtained by gradient elution using water (A) and acetonitrile (B) as the 
mobile phase according to the following profile:  19.7% - 19.7% B at 0 – 9 min; 19.7% - 30% 
B at 9 – 10 min; 30 – 30% B at 10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 16 – 
18 min. The column temperature was 40oC, the detection wavelength 203 nm, and injection 
volume, 1 µL. Each run was followed by a 2 min post run and an equilibration period of 5 
min. 
 
2.2.12.5 Stability testing for P. quinquefolius liquid extracts 
Six bottles of P. quinquefolius liquid extract were placed in the stability chamber for 
stability testing.  Each bottle was placed there for a different time period of up to six months.  
RRLC testing was conducted at the end of each month to see the changes that occurred.  
The Phenomenex luna column was used for the RRLC testing and separation was obtained 
by gradient elution using water (A) and acetonitrile (B)  as the mobile phase according to the 
following profile:  19.7% - 19.7% B at 0 – 9 min; 19.7% - 30% B at 9 – 10 min; 30 – 30% B at 
10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 16 – 18 min. The column 
temperature was 40oC, the detection wavelength 203 nm, and injection volume, 1 µL. Each 
run was followed by a 2 min post run and an equilibration period of 5 min. 
 
2.2.12.6 Stability testing for P. quinquefolius and Vitamin C liquid extracts 
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Six bottles of P. quinquefolius and Vitamin C liquid extract were prepared to reach a 
pH of 4 and were placed in the stability chamber for stability testing.  Each bottle was placed 
there for a different time period of up to six months.  RRLC testing was conducted at the 
end of each month to see the changes that occurred.  The Phenomenex luna column was 
used for the RRLC testing and separation was obtained by gradient elution using water (A) 
and acetonitrile (B)  as the mobile phase according to the following profile:  19.7% - 19.7% B 
at 0 – 9 min; 19.7% - 30% B at 9 – 10 min; 30 – 30% B at 10 – 11 min; 30 – 50% B at 11 – 16 
min; 50 – 100% B at 16 – 18 min. The column temperature was 40oC, the detection 
wavelength 203 nm, and injection volume, 1 µL. Each run was followed by a 2 min post run 
and an equilibration period of 5 min. 
 
2.2.12.7 Stability testing for P. quinquefolius and Citric Acid liquid extracts 
Six bottles of P. quinquefolius and Citric Acid liquid extract were prepared to reach a 
pH of 3 and were placed in the stability chamber for stability testing.  Each bottle was placed 
in there for a different time period of up to six months.  RRLC testing was conducted at the 
end of each month to see the changes that occurred.  The Phenomenex luna column was 
used for the RRLC testing and separation was obtained by gradient elution using water (A) 
and acetonitrile (B)  as the mobile phase according to the following profile:  19.7% - 19.7% B 
at 0 – 9 min; 19.7% - 30% B at 9 – 10 min; 30 – 30% B at 10 – 11 min; 30 – 50% B at 11 – 16 
min; 50 – 100% B at 16 – 18 min. The column temperature was 40oC, the detection 
wavelength 203 nm, and injection volume, 1 µL. Each run was followed by a 2 min post run 
and an equilibration period of 5 min. 
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2.2.12.8 Stability testing for R. rosea + Epimedium + P. quinquefolius + E. senticoccus 
powder extracts 
 
Six bottles of 4 in 1 formulated powder extract were prepared and placed in the 
stability chamber for stability testing.  Each bottle was placed there for a different time 
period of up to six months.  RRLC testing was conducted at the end of each month to see 
the changes that occurred.  The Phenomenex luna column was used for the RRLC testing 
and separation was obtained by gradient elution using water (A) and acetonitrile (B) as the 
mobile phase according to the following profile:  0 mins at 6% B, 6 mins at 17% B, 7 mins at 
19.7% B, 15 mins at 19.7% B, 16 mins at 30% B, 22 mins at 50% B, 24 mins at 100% B and 26 
mins at 6% B with a Phenomenex Luna column, at a temperature of 40 °C, the detection 
wavelengths of 205 nm from 0 – 3 mins, 220 nm from3 – 6.5 mins, 205 nm from 6.5 – 18 
mins and injection volume, 1 µL.  Each run was followed by a 2 min post run and an 
equilibration period of 5 min. 
 
2.2.12.9 Stability testing for R. rosea + Epimedium + P. quinquefolius + E. senticoccus 
liquid extracts 
 
Six bottles of 4 in 1 formulated powder extract were prepared and placed in the 
stability chamber for stability testing.  Each bottle was placed in there for a different time 
period of up to six months.  RRLC testing was conducted at the end of each month to see 
the changes that occurred.  The Phenomenex luna column is used for the RRLC testing and 
separation was obtained by gradient elution using water (A) and acetonitrile (B) as the 
mobile phase according to the following profile:  0 mins at 6% B, 6 mins at 17% B, 7 mins at 
19.7% B, 15 mins at 19.7% B, 16 mins at 30% B, 22 mins at 50% B, 24 mins at 100% B and 26 
mins at 6% B with a Phenomenex Luna column, at a temperature of 40 °C, the wavelengths 
205 nm from 0 – 3 mins, 220 nm from3 – 6.5 mins, 205 nm from 6.5 – 18 mins and injection 
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volume, 1 µL.  Each run was followed by a 2 min post run and an equilibration period of 5 
min. 
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Chapter 3  RESULTS 
The results chapter is divided up into four sections. The first section describes the 
process for the high performance liquid chromatographic method development to establish 
suitable separation conditions for the main compounds that occur in R. rosea, E. senticosus, 
Epimedium and Panax species, using references to confirm compounds from each of the 
herbs. Thereafter, the second section then focuses on the quantitative and qualitative 
determination of the main compounds in these herbs by means of calibration curves. 
Section three discusses the validation of the developed methods by applying these to 
examples of commercial products.  Section four describes accelerated stability testing of the 
extracts from the herbs by means of a controlled environment in a stability chamber unit. 
3.1  Development of analytical methods 
3.1.1  Development of analytical methods for selected single herbs 
3.1.1.1  Rhodiola rosea 
A gradient elution for an extract of R. rosea with water (A) and acetonitrile (B) with 
setting of 0-8 mins 12% (B), 8-10 mins 25% B, 10 mins 100% B, 11 mins 12% B and 18 mins 
6% B was used as a trial run, using the Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 
a temperature of 40 °C and wavelength settings of 205 nm from 0 to 5.6 mins, 254 nm from 
5.6 to 6 mins and 205 nm from 6 to 18 mins (Fig 3.1). 
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Figure 3.1:  Chromatograph for extract of R. rosea produced by RRLC with conditions of 0 
mins 12% acetonitrile (B), 8 mins 25% B, 10 mins 100% B, 11 mins 12% B and 18 mins 6% B 
using a Phenomenex luna column (2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings 
of 205 nm from 0 to 5.6 mins, 254 nm from 5.6 to 6 mins, 205 nm from 6 to 18 mins. 
 
 
 
Both salidroside and tyrosol were not observed on the chromatograph since the 
concentration of acetonitrile is too high and it was concluded that these two compounds 
had been eluted with the solvent peaks.  Furthermore, there is poor resolution with the 
rosarin peak and the peak in front of it at 4.8 min.  A new revised gradient elution was then 
proposed as follows:  0 mins at 8% B, 3 mins at 20% B, 5 mins at 20% B, 8 mins at 100% B 
and 9 mins at 8% B with a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at a 
temperature of 40 °C using water (A) and Acetonitrile (B) at a wavelength of 205 nm from 0 
mins to 3.7 mins, 254 nm from 3.7 mins to 4 mins, and 205 nm from 4 mins to 9 mins (Figure 
3.2). 
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Figure 3.2:  Chromatograph for extract of R. rosea produced by RRLC with the solvents as 
before and conditions of 0 mins 8% B, 3 mins 20% B, 5 mins 20% B, 8 mins 100% B and 9 
mins 8% B using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C using 
wavelength settings of 205 nm from 0 to 3.7 mins, 254 nm from 3.7 to 4 mins, and 205 nm 
from 4 to 9 mins. 
 
In Figure 3.2, the entire run was shortened to 4 minutes, and the salidroside peak 
eluted at 1.3 minutes, which is acceptable with this sample.  Though, when there are more 
impurities existing in the sample, it can become difficult to accurately determine the 
amount of salidroside (Wei and Ma 1991).  However, there is poor resolution between 
rosarin and the peak in front of it.  Therefore the acetonitrile content was decreased at the 
start of the analysis from 8% to 6% to slow down the elution of salidroside and gradient 
elution time from 6 to 7 mins to separate rosarin from the compound eluting just in front of 
it.  The revised gradient was as follows:  0 mins 6% B, 6 mins 17% B, 7 mins 20% B, 9 mins 
20% B, 10 mins 100% B and 11 mins 6% B with a Phenomenex Luna column(2.5 µm, 100 x 
3.0 mm), temperature of 40 °C with wavelength settings of 205 nm from 0 to 7.3 mins, 254 
nm from 7.3 to 8 mins and 205 nm from 8 to 10 mins (Fig 3.3). 
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Figure 3.3:  Chromatograph for extract of R. rosea produced by RRLC with conditions of 0 
mins 6% B, 6 mins 17% B, 7 mins 20% B, 9 mins 20% B, 10 mins 100% B and 11 mins 6% B 
using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings 
of 205 nm from 0 to 7.3 mins, 254 nm from 7.3 to 8 mins, and 205 nm from 8 to 10 mins. 
 
The chromatograph shows that salidroside was eluted at approx. 2.2 mins, and the 
elution of rosarin and rosin are distanced from any interfering compounds with the whole 
separation completed within 7.5 mins. 
 
3.1.1.2  Panax species   
3.1.1.2.1 Chromatographic Separations Using the Zorbax Eclipse Column (1.8 µm, 4.6 
x 50 mm) 
 
The analytical method development for extracts from Panax species was conducted 
with a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm).  Elution was with water (A) and 
acetonitrile (B) with the following gradient of 0 mins 30% B, 1.6 mins 30% B, 3.5 mins 40% B, 
5 mins 50% B, 6 mins 100% B and 6.5 mins 30% B, at 40 °C with a single wavelength setting 
of 203 nm.  The results obtained are shown in Fig. 3.4. 
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Figure 3.4:  Chromatographic separation of Rg1, Re, Rb1, Rc, Rb2 and Rd references produced 
by RRLC with conditions of 0 mins 30% B, 1.6 mins 30% B, 3.5 mins 40% B, 5 mins 50% B, 6 
mins 100% B and 6.5 mins 30% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm) at 
40 °C with a wavelength setting of 203 nm. 
 
The chromatograph shows that Rg1 and Re are eluted within 30 secs and they are not 
resolved into individual peaks.  The downside of an active compound eluting so early is that 
it is too close to the solvent peaks.  Therefore the concentration of acetonitrile is required to 
be decreased at the start of the separation run.  The revised gradient elution was:  0 mins 
29% B, 1.6 mins 29% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 100% B and 6.5 mins 29% B 
with the same column, at 40 °C and a single wavelength setting of 203 nm.  The results 
obtained are shown in Fig. 3.5. 
 
Figure 3.5:  Chromatographic separation of Rg1, Re, Rb1, Rc, Rb2 and Rd references produced 
by RRLC with conditions of 0 mins 29% B, 1.6 mins 29% B, 3.5 mins 40% B, 5 mins 50% B, 6 
mins 100% B and 6.5 mins 29% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 
40 °C and a wavelength setting of 203 nm. 
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The modification to the eluting gradient did not have a significant effect on the 
separation of Rg1 and Re.  Hence, the acetonitrile was adjusted from 29% (Fig. 3.6) to 22%, 
and with the same conditions except for the gradient, as follows:  0 mins 22% B, 1.6 mins 
22% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 100% B and 6.5 mins 29% B (Fig 3.6). 
 
Figure 3.6:  Chromatographic separation of Rg1, Re, Rb1, Rc, Rb2 and Rd references produced 
by RRLC with conditions of 0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 50% B, 6 
mins 100% B and 6.5 mins 22% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 
40 °C and a single wavelength setting of 203 nm. 
 
The changes to the gradient elution did move Rg1 and Re further along to about 1.5 
mins, but as it can be seen in Fig 3.6, they are now merged.  This could be an option for the 
fast analysis of ginseng products, but optimisation was continued in an  attempt to separate 
these compounds.  Therefore, a further change in the gradient was proposed which 
included just Rg1 and Re reference standards to confirm their position on the chromatograph. 
The gradient used was  0 mins 20% B, 2 mins 22% B, 2.3 mins 25% B, 3.5 mins 40% B, 6 mins 
100% B and 6.5 mins 20% B with the same column, temperature and wavelength setting (Fig 
3.6). 
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Figure 3.6:  Chromatographic separation of ginsenosides Rg1 and Re references produced by 
RRLC with conditions of 0 mins 20% B, 2 mins 22% B, 2.3 mins 25% B, 3.5 mins 40% B, 6 mins 
100% B and 6.5 mins 20% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 40 °C 
and a single wavelength setting of 203 nm. 
 
From this chromatograph (Fig 3.6), it seems as Rg1 and Re are starting to separate.  
Hence, it was considered appropriate to see the effect of further reducing the content of 
acetonitrile.  The gradient elution then used was;  0 mins 20% B, 2 mins 20% B, 3 mins 40% B, 
6 mins 100% B and 6.5 mins 20% B.(Fig 3.7) 
 
Figure 3.7:  Chromatographic separation of Rg1 and Re references produced by RRLC with 
conditions of 0 mins 20% B, 2 mins 20% B, 3 mins 40% B, 6 mins 100% B and 6.5 mins 20% B 
using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 40 °C and a single wavelength 
setting of 203 nm. 
 
The chromatograph in Fig 3.7 shows some improvement with regard to the 
separation of Rg1 and Re, hence the concentration of acetonitrile was reduced even further.  
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The revised gradient elution was as follows: 0 mins 19% B, 1.6 mins 19% B, 3.5 mins 40% B, 
5 mins 50% B, 6 mins 100% B, 6.5 mins 19% B (Fig 3.8). 
 
Figure 3.8:  Chromatographic separation of extract of Panax ginseng produced by RRLC with 
conditions of 0 mins 19% B, 1.6 mins 19% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 100% B, 
6.5 mins 19% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 50 °C and a single 
wavelength setting of 203 nm. 
 
The modified conditions successfully separated Rg1 and Re as evidenced on the above 
chromatograph (Fig. 3.8), but this was only after the temperature was also adjusted from 
40°C to 50°C and under the following gradient conditions: 0 mins 22% B, 1.6 mins 22% B, 3.5 
mins 40% B, 5 mins 50% B, 6 mins 100% B and 6.5 mins 29% B with a Zorbax Eclipse column 
(1.8 µm, 4.6 x 50 mm) at 50 °C and a wavelength setting of 203 nm.  However, there was 
one significant difference compared to the expected conventional sequence of elution with 
the ginsenosides, that Re is eluted ahead of Rg1.  This shows a different profile compared to 
the conventional HPLC sequence, therefore, this method was abandoned and the 
Phenomenex column was used for the qualitative and quantitative determination of Panax 
species.  
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3.1.1.2.2 Chromatographic Separation Using the Phenomenex Luna Column (2.5 µm, 
100 x 3.0 mm) 
 
The analytical method development with a Phenomenex Luna column (2.5 µm, 100 x 
3.0 mm) at 40 °C for extracts of all Panax species was started with the following gradient 
with mixtures of water (A) and acetonitrile (B):  0 mins 19% B, 12 mins 19% B, 14 mins 31% B, 
22 mins 43% B, 25 mins 55% B, 27 mins 100% B and 30 mins 19% B with a wavelength 
setting of 203 nm. (Fig 3.9) 
 
Figure 3.9:  Chromatographic separation of the extract of Panax species produced by RRLC 
with  conditions of 0 mins 19% acetonitrile (B), 12 mins 19% B, 14 mins 31% B. 22 mins 43% 
B, 25 mins 55% B, 27 mins 100% B and 30 mins 19% B using a Phenomenex Luna column (2.5 
µm, 100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm 
 
This gradient elution gave a chromatogram (Fig 3.9) where all the major active 
compounds in P. quinquefolius are suitably separated, but the problem is that the 
chromatographic run is too long (20 mins); and there is very little scope of making 
improvements with these conditions. Therefore, the gradient elution conditions were 
modified with an initial acetonitrile concentration of 21% as follows:  0 mins 21% B, 10 mins 
21% B, 12 mins 30% B, 15 mins 30% B, 20 mins 45% B, 22 mins 100% B and 24 mins 20% B, 
with a wavelength setting of 203 nm (Fig 3.10). 
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Figure 3.10:  Chromatographic separation of extract of Panax quinquefolius produced by 
RRLC with conditions of 0 mins 21% B, 12 mins 21% B, 14 mins 31% B. 22 mins 43% B, 25 
mins 55% B, 27 mins 100% B and 30 mins 21% B using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm. 
 
The changes in the conditions to the chromatographic run decreased the total time 
to about 19 mins, but the ginsenosides Rg1 and Re did not separate, probably resulting from 
the initial high acetonitrile concentration where Rg1 and Re elute too fast.  Their coincidence 
of elution stems from both compounds having a similar structure and hence also their 
respective polarities.  Consequently, the content of acetonitrile was reduced to 20% to 
attempt to separate two compounds.  The following gradient was therefore applied with the 
same column and wavelength setting:  0 mins 20% B, 10 mins 20% B, 12 mins 30% B, 15 
mins 32% B, 19 mins 46% B, 22 mins 11% B and 23 mins 19.5% B (Fig 3.11). 
 
Figure 3.11:  Chromatograph for the extract of Panax quinquefolius produced by RRLC with 
conditions of 0 mins 20% B, 12 mins 20% B, 14 mins 31% B, 22 mins 43% B, 25 mins 55% B, 
27 mins 100% B and 30 mins 20% B using a Phenomenex Luna column (2.5 µm, 100 x 3.0 
mm), at 40 °C and a wavelength setting of 203 nm. 
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 The chromatograph (Fig. 3.11) still shows Rg1 and Re superimposed as a single peak, 
therefore the acetonitrile concentration was decreased further with the following gradient 
applied:  0 mins 19.5% B, 10 mins 19.5% B, 12 mins 30% B, 15 mins 32% B, 19 mins 46% B, 
22 mins 11% B and 23 mins 19.5% B (Fig. 3.12). 
 
 
Figure 3.12:  Chromatographic separation of extract of Panax quinquefolius produced by 
RRLC with conditions of 0 mins 19.5% B, 10 mins 19.5% B, 12 mins 30% B, 15 mins 32% B, 19 
mins 46% B, 22 mins 11% B and 23 mins 19.5% B using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm. 
 
 The chromatograph (Fig. 3.12) shows that Rg1 and Re were successfully separated, 
with two baseline separation peaks, and all active compounds are distanced from interfering 
compounds with the whole separation completed within 18 mins.  
 
3.1.1.3  Epimedium species 
3.1.1.3.1 Chromatographic Separation Using the Zorbax Eclipse Column (1.8 µm, 4.6 x 
50 mm) 
 The four active compounds, namely, epimedin A, B, C and icariin references were 
separated using the Zorbax Eclipse Column (1.8 µm, 4.6 x 50 mm) with water (A) and 
acetonitrile (B) for the development of the profile for the extracts of the herb.   A gradient 
elution of 0 mins 19% B, 1.6 mins 19% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 100% B, 6.5 
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mins 19% B, at atemperature of 40 °C and a wavelength setting of 203 nm was used (Fig. 
3.13). 
 
Figure 3.13:  Chromatographic separation of epimedin A, B, C and icariin references 
produced by RRLC with conditions of 0 mins 19% B, 1.6 mins 19% B, 3.5 mins 40% B, 5 mins 
50% B, 6 mins 100% B, 6.5 mins 19% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), 
at 40 °C and a wavelength setting of 203 nm. 
 
The resulting chromatograph shows (Fig 3.13) the four active compounds epimedin 
A, B, C and icariin could be eluted apart, but consideration needs to be given to reducing the 
elution time of these compounds.  Hence, minor change to the gradient elution was made 
with same column, temperature and wavelength setting of 0 mins at 20% B, 1.6 mins at 20% 
B, 3.5 mins at 40% B, 5 mins at 50% B, 6 mins at 100% B, 6.5 mins at 20% B (Fig. 3.14). 
 
Figure 3.14:  Chromatographic separation of epimedin A, B, C and icariin references 
produced by RRLC with conditions of 0 mins 20% B, 1.6 mins 20% B, 3.5 mins 40% B, 5 mins 
50% B, 6 mins 100% B, 6.5 mins 20% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), 
at 40 °C and a wavelength setting of 203 nm. 
 
 
 From the chromatograph, obtained (Fig. 3.14), it was encouraging to note that the 
retention time for the four compounds was further reduced, and therefore a decision was 
106 
taken to reduce further the retention time with the same column, temperature and 
wavelength setting.  To achieve this, the following gradient was used:  0 mins 22% B, 1.6 
mins 22% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 100% B, 6.5 mins 22% (Fig. 3.15). 
 
 
Figure 3.15:  Chromatographic separation of epimedin A, B, C and icariin references 
produced by RRLC with conditions of 0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 
50% B, 6 mins 100% B, 6.5 mins 22% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), 
at 40 °C and a wavelength setting of 203 nm. 
 
 The modification to the gradient provided a reasonable separation (Fig. 3.15).  It was 
considered that some elution time is necessary for these compounds to separate and hence, 
this gradient was regarded as acceptable.  
 
3.1.1.3.2 Chromatographic Separation Using the Phenomenex Luna Column (2.5 µm, 
100 x 3.0 mm) 
 
 The four main compounds, (epimedin A, B, C and icariin) from Epimedium species 
were then separated using the Phenomenex Luna Column (2.5 µm, 100 x 3.0 mm) for the 
development of its profile.  The main purpose of this was for the future analysis of 
formulated compounds containing Epimedium species.  The solvents (water (A) and 
acetonitrile (B)), temperature and wavelength setting were kept the same as for the Zorbax 
Eclipse column.  The gradient elution was 0 mins 19% B, 12 mins 19% B, 14 mins 31% B, 22 
mins 43% B, 25 mins 55% B, 27 mins 100% B and 30 mins 19% B (Fig. 3.16). 
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Figure 3.16:  Chromatographic separation of extracts of Epimedium species produced by 
RRLC with conditions of 0 mins 19% Acetonitrile (B), 12 mins 19% B, 14 mins 31% B, 22 mins 
43% B, 25 mins 55% B, 27 mins 100% B and 30 mins 19% B using a Phenomenex Luna 
column (2.5 µm, 100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm. 
 
From the chromatograph, it can be concluded that the acetonitrile concentration can 
be increased to reduce the retention time of the four main compounds found in Epimedium 
species which will shorten the analysis time.  Therefore the newly revised gradient elution is 
as follows:  0 mins 20% B, 10 mins 20% B, 12 mins 30% B, 15 mins 30% B and 20 mins 45% B, 
22 mins 100% B and 24 mins 20% B (Fig. 3.17).  
 
Figure 3.17:   Chromatographic separation of extracts of Epimedium species produced by 
RRLC with conditions of 0 mins 20% B, 10 mins 20% B, 12 mins 30% B, 15 mins 30% B and 20 
mins 45% B, 22 mins 100% B and 24 mins 20% B using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm. 
 
This change to the gradient elution did have the desired separation that is 
acceptable for further development.  The elution time was considered acceptable due to the 
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position it is eluted, which will be compatible with the methods used for the Panax species 
that was previously developed. 
 
3.1.1.4  Eleuthercoccus senticosus 
 Eleutherococcus senticosus’s two main active compounds, namely eleutheroside B 
and E were analyzed by HPLC using water (A) and acetonitrile (B), at 40°C and a wavelength 
setting of 220 nm and gradient elution of 0 min 5% B, 6 mins 15% B, 7 min 20% B, 9 min 20% 
B, 10 min 100% B and 2 mins 6% B, with a flow rate of 1.0 mL/min using a Phenomenex Luna 
column (2.5 µm, 100 x 3.0 mm) (Fig. 3.18). 
 
Figure 3.18:  Chromatographic separation of eleutheroside B and E references produced by 
RRLC with conditions of 0 min 5% B, 6 mins 15% B, 7 min 20% B, 9 min 20% B, 10 min 100% 
B and 2 mins 6% B at a flow rate of 1.0 mL/min using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C and a wavelength setting of 220 nm. 
 
 The chromatograph above (Fig. 3.18) shows that the eleutheroside B and E can be 
eluted earlier, and therefore, the gradient elution was modified as follows:  0 min 6% B, 6 
mins 17% B, 7 min 19.7% B, 9 min 19.7% B, 10 min 100% B and 2 mins 6% B (Fig. 3.19). 
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Figure 3.19:  Chromatographic separation of eleutheroside B and E references produced by 
RRLC with conditions of 0 min 6% B, 6 mins 17% B, 7 min 19.7% B, 9 min 19.7% B, 10 min 
100% B and 2 mins 6% B at a flow rate of 1.0 mL/min using a Phenomenex Luna column (2.5 
µm, 100 x 3.0 mm), at 40 °C and a wavelength setting of 220 nm. 
 
 The chromatograph above (Fig. 3.19) shows excellent separation between 
eleutheroside B and E with an acceptable retention time of 3.18 and 6.20 mins, respectively. 
 
3.1.2  Development of analytical methods for the mixture of extracts from two 
herbs 
3.1.2.1 Panax and Epimedium species using the Zorbax Eclipse Column (1.8 µm, 4.6 
x 50 mm) 
 
 Since gradient separation of the methanol prepared individual herb extracts was 
successful with water (A) and acetonitrile (B), it was natural to continue this trend for 
method development for a mixture of extracts from Panax quinquefolius and Epimedium 
species.  The proposed gradient elution provided very good separation of the main 
compounds:  0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 100% B 
and 6.5 mins 29% B with a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 40 °C with a 
wavelength setting of 203 (Fig. 3.20). 
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Figure 3.20:  Chromatograph for the extracts of Panax quinquefolius and Epimedium species 
produced by RRLC with conditions of 0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 
50% B, 6 mins 100% B and 6.5 mins 29% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 
mm), at 40 °C with a wavelength setting of 203 nm. 
 
 
 Hence, with the separation between the compounds of these two species, this 
method, using the Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm) was concluded to be 
suitable for analysis of extracts of Panax and Epimedium species.  
 
3.1.2.2 Panax quinquefolius and Epimedium species using the Phenomenex Luna 
Column (2.5 µm, 100 x 3.0 mm) 
 
For the method development for the mixture of methanol extracts of P. 
quinquefolius and Epimedium species, consideration was given to the best conditions 
achieved for both the Panax species and as well as the method for Epimedium.  Many 
different gradients were tried, but some of the main adjustments are as follows: 0 mins 19% 
B, 12 mins 19% B, 14 mins 31% B, 22 mins 43% B, 25 mins 55% B, 27 mins 100% B and 30 
mins 19% B using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C with a 
wavelength setting of 203 nm.  
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Figure 3.21:  Chromatograph for extracts of Panax quinquefolius and Epimedium species 
produced by RRLC with conditions of 0 mins 19% Acetonitrile (B), 12 mins 19% B, 14 mins 
31% B, 22 mins 43% B, 25 mins 55% B, 27 mins 100% B and 30 mins 19% B using a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C with a wavelength setting of 203 
nm. 
 
Fig. 3.21 shows that all of the major compounds of P. quinquefolius and Epimedium 
species are well separated, but the run is too long (19 mins).  Therefore, this was modified 
for a more rapid separation:  0 mins 20% B, 10 mins 20% B, 12 mins 30% B, 15 mins 30% B 
and 20 mins 45% B, 22 mins 100% B and 24 mins 20% B (Fig. 3.22).  
 
Figure 3.22:   Chromatograph for extracts of Panax quinquefolius and Epimedium species 
produced by RRLC with conditions of 0 mins 20% B, 10 mins 20% B, 12 mins 30% B, 15 mins 
30% B and 20 mins 45% B, 22 mins 100% B and 24 mins 20% B using a Phenomenex Luna 
column (2.5 µm, 100 x 3.0 mm), at 40 °C with a wavelength setting of 203 nm. 
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The entire run time for this gradient was shortened to 20 mins, but the ginsenosides 
Rg1 and Re could not be separated, resulting in a single peak.  This is the effect of  the  initial 
high acetonitrile concentration causing Rg1 and Re to elute together.  Consideration was then 
given to reduce marginally the initial acetonitrile concentration to 19.5% to try to separate 
these two compounds:  0 mins 19.5% B, 10 mins 19.5% B, 12 mins 30% B, 15 mins 32% B, 19 
mins 46% B, 22 mins 11% B and 23 mins 19.5% B (Fig. 3.23).  
 
Figure 3.23:  Chromatograph for extracts of Panax and Epimedium species produced by 
RRLC with conditions of 0 mins 19.5% B, 10 mins 19.5% B, 12 mins 30% B, 15 mins 32% B, 19 
mins 46% B, 22 mins 11% B and 23 mins 19.5% B using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C with a wavelength setting of 203 nm 
 
The resulting chromatograph (Fig. 3.23) did separate Rg1 and Re, but their peaks 
appear to be relatively wider.  Furthermore, the separation of Rd is not as good and could be 
improved.  In addition, the 20 mins chromatograph run time could be shortened.  Therefore, 
a chromatograph run with slight increase of acetonitrile from 19.5% to 19.7% was 
attempted:     0 mins 19.7% B, 10 mins 19.7% B, 10.5 mins 30% B, 17 mins 45% B, 18 mins 
100% B, 19 mins 19.7% B (Fig. 3.24). 
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Figure 3.24:  Chromatograph for extracts of Panax quinquefolius and Epimedium species 
produced by RRLC with conditions of 0 mins 19.7% B, 10 mins 19.7% B, 10.5 mins 30% B, 17 
mins 45% B, 18 mins 100% B, 19 mins 19.7% B using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm. 
 
The chromatograph obtained is reasonable, but there is a lot of wasted time, for 
example, the separation of Rg1 and Re starts after 9 mins.  It is possible to shorten the 
isocratic condition from 9 mins (as above) to 8.5 mins, the updated gradient then being:  0 
mins 19.7% B, 9 mins 19.7% B, 10 mins 30% B, 11 mins 30% B, 16 mins 50% B, 18 mins 100% 
B and 19 mins 19.7% B (Fig. 3.25).  
 
Figure 3.25:  Chromatograph for extracts of Panax quinquefolius and Epimedium species 
produced by RRLC with conditions of 0 mins 19.7% B, 9 mins 19.7% B, 10 mins 30% B, 11 
mins 30% B, 16 mins 50% B, 18 mins 100% B and 19 mins 19.7% B using a Phenomenex Luna 
column (2.5 µm, 100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm. 
 
The chromatograph (Fig. 3.25) shows an acceptable separation of all the major active 
ingredients found in P. quinquefolius and Epimedium species.  There is a better separation of 
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Rg1 and Re and the other compounds from Epimedium species achieve baseline separation 
and the analysis run is completed in 16 mins, showing the advantage of RRLC. 
 
3.1.2.3 R. rosea and E. senticosus using the Phenomenex Luna Column (2.5 µm, 100 
x 3.0 mm) 
 
 R. rosea and E. senticosus require different wavelengths for the determination of 
their main active compounds, but with the new RRLC, the ability of selective wavelength 
allows us to monitor the active ingredients under two different wavelengths simultaneously.  
Therefore with consideration of the conditions based on the single herb chromatograph 
runs with water (A) and acetonitrile (B) the following were used: from 0 – 3 mins, the 
wavelength detection  205 nm, 3 – 6.5 mins 220 nm and 6.5 – 22 mins 205 nm with a 
gradient elution of 0 mins 6% B, 6 mins 17% B, 7 mins 20% B, 9 mins 20% B, 10 mins 100% B 
and 10.5 mins 6% B with a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at a 
temperature of 40 °C (Fig. 3.26). 
 
Figure 3.26:  Chromatograph for reference compounds of R. rosea and E. senticosus, namely, 
salidroside, tyrosol, eleutheroside B, E, rosavrin, rosavin, rosin and rosiridin produced by 
RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 20% B, 9 mins 20% B, 10 mins 
100% B and 10.5 mins 6% B using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 
40 °C and a wavelength setting of 205 nm from 0 – 3 mins, 220 nm from 3 – 6.5 mins, 205 
nm from 6.5 – 10.5 mins. 
 
 The chromatograph above (Fig. 3.26) shows good separation between all the peaks 
of the active compounds from R. rosea and E. senticosus. 
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3.1.3 Development of analytical methods for mixture of extracts from three herbs 
3.1.3.1 R. rosea, Epimedium and Panax species 
Since gradient separation of the two herb mixture was successful with water (A) and 
acetonitrile (B), it was natural to continue this trend for method development for mixture of 
extracts containing R. rosea, Epimedium and P. quinquefolius. The following gradient was 
determined for the first trial run:  0 mins 6% B, 4 mins 19.7% B, 8 mins 19.7% B, 9 mins 30% 
B, 10 mins 30% B, 15 mins 50% B, 17  mins 100% B and 18 mins 6% B with a Phenomenex 
Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C with the wavelength settings of 205 nm from 
0 – 6.5 mins, 203 nm from 6.5 – 18 mins. 
 
Figure 3.27:  Chromatograph separation of extract of R. rosea, Epimedium species and P. 
quinquefolius  produced by RRLC with conditions of 0 mins 6% B, 4 mins 19.7% B, 8 mins 
19.7% B, 9 mins 30% B, 10 mins 30% B, 15 mins 50% B, 17  mins 100% B and 18 mins 6% B 
using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), temperature at 40 °C and a 
wavelength setting of 205 nm from 0 – 6.5 mins, 203 nm from 6.5 – 18 mins. 
 
 
The resulting chromatograph (Fig. 3.27) for rosarin, rosavin and rosin do not show 
adequate separation, as well, the five peaks corresponding to compounds of Epimedium do 
not have baseline separation.  Therefore the acetonitrile concentration was adjusted.  The 
method for the two herb extracts used acetonitrile increasing from 6% to 19.7% in 4 mins.  
This required adjustment and hence was revised to from 6% to 17% in 6 mins.  It was 
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anticipated that this may improve the separation of the rosavins.  As well, with the 30% 
acetonitrile concentration for the elution of the compounds of Epimedium species where a 
longer time period setting was required, a reduction for this would need to be considered.  
Hence, the new revised gradient is as follows with other settings unaltered:  0 mins 6% B, 6 
mins 17% B, 7 mins 19.7% B, 15 mins 19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% 
B and 26 mins 6% B (fig. 3.28).  
 
Figure 3.28:  Chromatograph for extracts of R. rosea, Epimedium and P. quinquefolius 
species produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 
mins 19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), 40 °C with wavelength settings of 205 
nm from 0 – 8 mins, 203 nm from 8 – 18 mins. 
 
 
The separation of rosarin, rosavin and rosin, showed baseline separation, and 
consequently this gradient was considered acceptable for further method development. 
 
3.1.3.2 R. rosea, E. senticosus and Epimedium species 
 It was natural to continue this trend of using water (A) and acetonitrile (B) for 
method development for mixtures of extracts contining R. rosea, E. senticosus and 
Epimedium species.  The following gradient was determined for the first trial run:  0 mins 6% 
B, 6 mins 17% B, 7 mins 19.7% B, 10 mins 19.7% B, 11 mins 30% B, 17 mins 50% B, 19 mins 
100% B and 20 mins 6% B using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm),  at 
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40 °C using wavelength settings of 205 nm from 0 – 3 mins, 220 nm from 3 – 6.5 mins, 205 
nm from 6.5 – 8 mins and 203 nm from 8 – 20 mins. 
 
 
Figure 3.29:  Chromatograph for extracts of R. rosea, E. senticosus and Epimedium species 
produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 10 mins 
19.7% B, 11 mins 30% B, 17 mins 50% B, 19 mins 100% B and 20 mins 6% B using a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), 40 °C using wavelength settings of 205 
nm from 0 – 3 mins, 220 nm from 3 – 6.5 mins, 205 nm from 6.5 – 8 mins and 203 nm from 
8 – 20 mins. 
 
 The chromatograph above (Fig. 3.29) showed acceptable baseline separation and 
therefore, this gradient was considered acceptable for further method development. 
 
3.1.3.3 R. rosea, E. senticosus and P. quinquefolius  
Since gradient separation of the three herb mixture was successful with water (A) 
and aceontrile (B), it was natural to continue this trend for method developemtn for 
mixtures of extracts containing R. rosea, E. senticosus and P. quinquefolius.  The following 
gradient was used:  0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 19.7% B, 16 mins 
30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B with a Phenomenex Luna column 
(2.5 µm, 100 x 3.0 mm), at 40 °C with wavelength settings of 205 nm from 0 – 3 mins, 220 
nm from 3 – 6.5 mins, 205 nm from 6.5 – 8 mins, 203 nm from 8 – 26 mins (Fig. 3.30). 
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Figure 3.30:  Chromatograph for extracts of R. rosea, E. senticosus and P. quinquefolius 
produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 
19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B with a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), 40 °C with wavelength settings of 205 
nm from 0 – 3 mins, 220 nm from 3 – 6.5 mins, 205 nm from 6.5 – 8 mins, 203 nm from 8 – 
26 mins. 
 
 The chromatograph (Fig. 3.30) resulted in an acceptable baseline separation and the 
time frame and was accepted for use in future method developments. 
 
3.1.3.4 E. senticosus, Epimedium and P. quinquefolius 
 
Since gradient separation of the three herb mixture was successful with water (A) 
and acetonitrile (B), it was natural to continue this trend for method development for 
mixtures of extracts containing R. rosea, E. senticosus and P. quinquefolius.  The following 
gradient was used:   0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 19.7% B, 16 mins 
30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a Phenomenex Luna column 
(2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings of 220 nm from 0 – 6.5 mins and 
203 nm from 6.5 – 26 mins (Fig. 3.31). 
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Figure 3.31:  Chromatograph for extracts of E. senticosus Epimedium species and P. 
quinquefolius produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% 
B, 15 mins 19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using 
a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings of 
220 nm from 0 – 6.5 mins and 203 nm from 6.5 – 26 mins. 
 
 
3.1.4 Development of analytical methods for mixture of extracts from four herbs 
3.1.4.1 R. rosea, E. senticosus, Epimedium species and Panax quinquefolius  
 Since gradient separation of the three herb mixture was successful with water (A) 
and acetonitrile (B), it was natural to continue this trend for method development for 
mixtures of extracts containing R. rosea, E. senticosus and P. quinquefolius.  The following 
gradient was used:   0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 19.7% B, 16 mins 
30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a Phenomenex Luna column 
(2.5 µm, 100 x 3.0 mm), at 40 °C with wavelength settings of 205 nm from 0 – 3 mins, 220 
nm from 3 – 6.5 mins, 205 nm from 7.4 – 8 mins, 203 nm from 8 – 25 mins (Fig. 3.32). 
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Figure 3.32:  Chromatographic separation of reference standards salidroside, tyrosol, 
eleutheroside B, E, rosarin, rosavin, rosin, rosiridin, Rg1, Re, epimedin A, B, C, icariin, Rb1, Rc, 
Rb2 and Rd produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 
15 mins 19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), 40 °C with wavelength settings of 205 
nm from 0 – 3 mins, 220 nm from3 – 6.5 mins, 205 nm from 7.4 – 8 mins, 203 nm from 8 – 
25 mins. 
 
 The separation of the mixture with the extracts from the four herbs with these 
conditions (Fig. 3.32) provided discrete absorptions for all the relevant compounds and was 
considered suitable for the next stage of development.  
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3.2 Qualitative and Quantitative Analysis Method Development for 
Single Herbs 
 
3.2.1 Rhodiola rosea and its main constituents, salidroside, tyrosol, rosarin, 
rosavin, rosin and rosiridin 
 
A baseline separation using a gradient elution mobile phase with water and 
acetonitrile was established for the six main compounds of R. rosea as described in Methods 
section 2.2.1.4 and the results illustrated in Figure 3.33 below.  The order of elution of these 
compounds being salidroside, tyrosol, rosarin, rosavin, rosin and rosiridin.  The retention 
times for salidroside and tyrosol are 2.37 ± 0.012 min and 2.84 ± 0.077 min, respectively, 
whilst those of rosarin, rosavin, rosin and rosiridin are 6.79 ± 0.017, 7.01 ± 0.016, 7.37 ± 
0.014 and 7.58 ± 0.021, respectively.  There is a gap of approximately 3.5 min between the 
elution of salidroside, tyrosol and the remaining four compounds.  This was exploited later 
with the separation and analysis of compounds of R. rosea with those of E. senticosus.    
 
Figure 3.33:  Chromatograph for salidroside, tyrosol, rosarin, rosavin, rosin and rosiridin 
reference samples produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 
20% B, 9 mins 20% B, 10 mins 100% B and 11 mins 6% B using a Phenomenex Luna column 
(2.5 µm, 100 x 3.0 mm), temperature 40 °C with a wavelength setting of 205 nm 
 
 
3.2.1.1 Relationship between peak area and amount of R. rosea active compounds  
 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (R2 = 0.9997 for salidroside and 0.9999 for tyrosol, rosarin, 
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rosavin and rosin) between peak area and amount of R. rosea active compounds injected 
over the range of 50 – 800 µg/mL.  Data is presented in Fig. 3.34 and Table 3.1. 
 
 
   a       b  
 
 
   c       d 
 
 
   e 
Figure 3.34:  Relationship between peak areas and concentration of salidroside (a), tyrosol 
(b), rosarin (c), rosavin (d) and rosin (e). 
 
Table 3.1:  Regression equation, linear regression for R. rosea active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Salidroside  Y = 351.24X – 0.97   0.9997 
Tyrosol   Y = 864.60X – 0.61   0.9999 
Rosarin   Y = 725.16X + 0.87   0.9999 
Rosavin   Y = 1081.57X + 1.95   0.9999 
Rosin   Y = 953.07X + 1.10   0.9999 
 
 
3.2.1.2  Extraction of R. rosea active compounds from its roots 
Optimal extraction conditions for the biologically active compounds of R. rosea were 
compared by looking at the different ratios of MeOH with water.  Previous work by Ma et al. 
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(2011) showed that refluxing and ultrasonication using MeOH produced comparable 
extraction yields of rosavins.  In this study, ultrasonication was selected for its simplicity and 
shorter extraction time (Ma et al. 2011).  Variables in the extraction procedures, such as 
solvent concentration and extraction time were optimized on a R. rosea root sample.  Figure 
3.35 below shows the increase in extraction yield of rosavins with increase in concentration 
of MeOH in water (v/v) from 20% to 75%.  Further increases of MeOH concentration up to 
100% had a negative effect on the recovery of the rosavins.  Figure 3.35 below shows that 
both 15 and 20 minutes of ultrasonication resulted in comparable recovery of the rosavins, 
indicating that 15 mins of ultrasonication was sufficient for extraction of R. rosea root.  The 
highest efficient extraction was achieved with 75% MeOH aqueous solution with 15 mins 
ultrasonication at 37 oC. 
 
Figure 3.35: Variation in the yields of Rosavins from sample roots of R. rosea at 37oC with 
different amounts of MeOH in water ultrasonication times.  X-axis consists of 5 blocks 
representing the extraction solvent varying from 20% MeOH aq. solution to pure MeOH; y-
axis shows the rosavins contents recovered under the different extraction conditions. Each 
block has 3 bars representing different ultrasonication times varying from 10 to 20 min. 
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3.2.1.3  Recovery of R. rosea active compounds 
A recovery test was performed to determine the accuracy of our proposed method.  
A known quantity of the five references were spiked into 0.1 g of authentic R. rosea root 
extract, this fortified sample was then extracted and analyzed in triplicate.  The results of 
the recovery tests were obtained by comparing the results of the original samples with the 
fortified samples.  The mean recoveries were from 98.9% to 100.9%, with RSD less than 
1.42% (Table 3.2). 
 
 
 
Table 3.2:  Retention time, Recovery and its RSD % for the R. rosea active compounds using 
the Phenomenex luna column 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Salidroside  2.37 ± 0.012  0.29  99.6   1.12 
Tyrosol   2.84 ± 0.077  1.11  100.3   1.15 
Rosarin   6.79 ± 0.017  0.16  98.9   1.23 
Rosavin   7.01 ± 0.016  0.14  100.9   1.01 
Rosin   7.37 ± 0.014  0.12  99.5   1.42 
 
 
3.2.2  Epimedium and its main constituents, epimedin A, B, C and icariin 
3.2.2.1 Separation of epimedins A, B, C and icariin with the Phenomenex luna 
column (2.5 µm, 100 x 3.0 mm) using RRLC 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods 2.2.2.3, which yielded baseline separation of four Epimedium active 
compounds, which was shown in the chromatograph (Fig. 3.36) with elution order:  
epimedins A, B, C and icariin; their respective retentions being 11.03 ± 0.17 min, 11.17 ± 
0.15 min,  11.33 ± 0.19 min and 11.56 ± 0.18 min.   
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Figure 3.36:  Chromatograph for epimedins A, B, C and icariin reference produced using 
RRLC with conditions of 0 mins 20% B, 10 mins 20% B, 12 mins 30% B, 15 mins 30% B and 20 
mins 45% B, 22 mins 100% B and 24 mins 20% B using a Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40 °C and a wavelength setting of 203 nm 
 
3.2.2.1.1 Relationship between peak area and amount of Epimedium active 
compounds processed 
 
Calibration curves (Fig. 3.37) were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  Five different concentrations of references were 
used to obtain the data noted in Table 3.3. The regression lines are linear in the 
concentration range studied, (r2 = 0.9998 for epimedin B, 0.9999 for epimedin A, C and 
1.0000 for icariin) between peak area and amount of Epimedium active compounds injected 
over the range of 23.98 – 90.00 µg/mL (Table 3.3, Fig. 3.37). 
 
Table 3.3:  Regression equation, linear regression for Epimedium active compounds for 
Phenomenex luna column 
Compounds  Regression Equation  Linear regression (r2) 
Epimedin A  Y = 600.64X+0.63   0.9999 
Epimedin B  Y = 561.73X+1.76   0.9998 
Epimedin C  Y = 667.55X+2.22   0.9999 
Icariin   Y = 986.88X+3.34   0.9999 
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   a       b 
 
   c       d 
Figure 3.37:  Relationship between peak areas and concentration of epimedin A (a), B (b), C 
(c) and icariin (d). 
 
3.2.2.1.2 Recovery of Epimedium active compounds using the Phenomenex luna 
column 
A Recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the four reference samples were spiked into a 0.1 g of authentic 
Epimedium powder extract.  This fortified sample was then extracted and analyzed in 
triplicate.  The results of the recovery tests were obtained by comparing the results of the 
original samples with the fortified samples.  The mean recoveries were from 99.6% to 
100.7%, with RSD less than 1.13% (Table 3.4). 
Table 3.4:  Retention time, Recovery and its RSD % for the Epimedium active compounds 
using the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Epimedin A  11.03   0.17  99.7   1.06 
Epimedin B  11.17   0.15  99.6   1.09 
Epimedin C  11.33   0.19  100.2   1.13 
Icariin   11.56   0.18  100.7   0.98 
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3.2.2.2 Separation of epimedins A, B, C and icariin with the Zorbax Eclipse XDB 
column (1.8 µm, 4.6 x 50 mm) using RRLC 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient, 
described in Methods section 2.2.2.4, which yielded baseline separation of four Epimedium 
active compounds, which was shown in the chromatograph (Fig. 3.38) with elution order:  
epimedins A, B, C and icariin; their respective retentions being 11.03 ± 0.17 min, 11.17 ± 
0.15 min, 11.33 ± 0.19 min and 11.56 ± 0.18 min.   
 
Figure 3.38:  Chromatograph for extract of epimedins A, B, C and icariin produced by RRLC 
with conditions of 0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 50% B, 6 mins 
100% B, 6.5 mins 22% B with a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 40 °C and a 
wavelength setting of 203 nm. 
 
 
3.2.2.2.1 Relationship between peak area and amount of Epimedium active 
compounds  
 
Calibration curves (Fig. 3.39) were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  Five different concentrations of references were 
used to obtain the data noted in Table 3.5.  The regression lines are linear in the 
concentration range studied (r2 = 1.0000 for all Epimedium active compounds) between 
peak area and amount of Epimedium active compounds injected over the range of 23.98 -
90.00 µg/mL (Table 3.5, Fig 3.39). 
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Table 3.5:  Regression equation, linear regression for Epimedium active compounds for 
Zorbax eclipse column 
Compounds  Regression Equation  Linear regression (r2) 
Epimedin A  Y = 327.20X+0.06   1.0000 
Epimedin B  Y = 301.03X+0.10   1.0000 
Epimedin C  Y = 357.25X+0.19   1.0000 
Icariin   Y = 403.63X+0.30   1.0000 
 
 
 
   a       b 
 
   c       d  
Figure 3.39:  Relationship between peak areas and concentration of epimedin  
A (a), B (b), C (c) and icariin (d)  
 
 
3.2.2.2.2 Recovery of Epimedium active compounds using Zorbax Eclipse XDB column 
(1.8 µm, 4.6 x 50 mm) 
 
A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the four reference compounds were spiked into a 0.1 g of authentic 
Epimedium powder extract.  This fortified sample was then extracted and analyzed in 
triplicate.  The results of the recovery tests were obtained by comparing the results of the 
original samples with the fortified samples.  The mean recoveries were from 99.3% to 
102.3%, with RSD less than 1.23% (Table 3.6). 
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Table 3.6:  Retention time, Recovery and its RSD % for the Epimedium active compounds 
using the Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Epimedin A  2.42   0.16  99.8   1.14 
Epimedin B  2.52   0.20  99.3   1.23 
Epimedin C  2.60   0.17  100.4   1.16 
Icariin   2.68   0.18  102.3   0.97 
 
 
3.2.3  Panax  
3.2.3.1 Separation of ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd with the 
Phenomenex luna column (2.5 µm, 100 x 3.0 mm) using RRLC 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.3.4, which yielded baseline separation of eight P. 
quinquefolius active compounds, which is shown in the chromatograph (Fig. 3.40) with 
elution order: R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd; their respective retentions being 6.53 ± 0.017 
min, 9.67 ± 0.015 min,  10.10 ± 0.019 min, 12.64 ± 0.18 min, 13.36 ± 0.019 min, 13.63 ± 
0.014 min, 13.87 ± 0.018  min and 14.46 ± 0.016 min.  There is a gap of approximately 2.54 
min between the elution of ginsenosides R1, Rg1, Re, and Rf, Rb1, Rc, Rb2, Rd.  This will be 
exploited in later work with separation and analysis of both Panax active compounds and 
Epimedium active compounds.    
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Figure 3.40:  Chromatograph for ginsenosides R1, Rg1, Re, and Rf, Rb1, Rc, Rb2, Rd references 
produced by using RRLC with conditions of 0 mins 19.5% B, 10 mins 19.5% B, 12 mins 30% B, 
15 mins 32% B, 19 mins 46% B, 22 mins 11% B and 23 mins 19.5% B using a Phenomenex 
Luna column, at 40 °C and a wavelength setting of 203 nm. 
 
 
3.2.3.1.1 Relationship between peak area and amount of Panax active compounds 
 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (r2 = 0.9994 for ginsenoside Rc, 0.9995 for ginsenoside Rg1, 
0.9998 for ginsenoside Rb2, Rd, 0.9999 for ginsenosides Re, Rb1 and 1.0000 for ginsenosides 
R1, Rf) between peak area and amount of Panax active compounds injected over the range 
of 29.55 – 233.58 µg/mL (Table 3.7, Fig. 3.41). 
 
Table 3.7:  Regression equation, linear regression for Panax active compounds for 
Phenomenex luna column 
Compounds  Regression Equation  Linear regression (r2) 
Ginsenoside R1  Y = 83.95X+0.48  1.0000 
Ginsenoside Rg1  Y = 109.54X+0.071  0.9995 
Ginsenoside Re  Y = 93.68X+0.10  0.9999 
Ginsenoside Rf  Y = 101.64X+0.57  1.0000 
Ginsenoside Rb1  Y = 88.23X+0.06  0.9999 
Ginsenoside Rc  Y = 96.46X+0.10  0.9994 
Ginsenoside Rb2  Y = 92.54X-0.02   0.9998 
Ginsenoside Rd  Y = 110.87X-0.05  0.9998 
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Figure 3.41:  Relationship between peak areas and concentration of ginsenosides R1 (a), Rg1 
(b), Re (c), Rf (dd), Rb1 (e), Rc (f), Rb2 (g) and Rd (h)  
 
 
3.2.3.1.2 Recovery of Panax active compounds using the Phenomenex luna column 
(2.5 µm, 100 x 3.0 mm) 
 
A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the four reference compounds were spiked into a 0.1 g of authentic 
Panax powder extract.  This fortified sample was then extracted and analyzed in triplicate.  
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The results of the recovery tests were obtained by comparing the results of the original 
samples with the fortified samples.  The mean recoveries were from 98.3% to 100.6%, with 
RSD less than 1.88% (Table 3.8). 
 
Table 3.8:  Retention time, Recovery and its RSD % for the Panax active compounds using 
the Phenomenex luna column 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Ginsenoside R1  6.53   0.11  99.4   1.01 
Ginsenoside Rg1  9.67   0.42  98.3   1.88 
Ginsenoside Re  10.10   0.40  98.9   1.45 
Ginsenoside Rf  12.64   0.22  99.9   1.05 
Ginsenoside Rb1  13.36   0.19  100.6   1.15 
Ginsenoside Rc  13.63   0.16  99.9   1.20 
Ginsenoside Rb2  13.87   0.18  99.5   1.19 
Ginsenoside Rd  14.46   0.21  98.7   1.18 
 
 
3.2.3.2 Separation of ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd with the  Zorbax 
Eclipse XDB column (1.8 µm, 4.6 x 50 mm) using RRLC 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient, 
described in Methods section 2.2.3.5, which yielded baseline separation of eight Panax 
active compounds, which was shown in the chromatograph (Fig. 3.42) with elution order:  
ginsenosides R1, Rg1+Re, Rf, Rb1, Rc, Rb2 and Rd; their respective retentions being 0.97 ± 0.013 
min, 1.41 ± 0.013 min, 3.04 ± 0.018 min, 3.30 ± 0.017 min, 3.40 ± 0.019 min, 3.50 ± 0.021 
min and 3.74 ± 0.016 min.  
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Figure 3.42:  Chromatograph for ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd produced by 
using RRLC with conditions of 0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 50% B, 
6 mins 100% B and 6.5 mins 29% B with a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), at 
40 °C and a wavelength setting of 203 nm.  
 
 
3.2.3.2.1 Relationship between peak area and amount of Panax active compounds  
 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (r2 = 0.9991 for ginsenoside Rd, 0.9994 for ginsenosides R1, Rb2, 
0.9995 for ginsenoside Rg1+ Re, Rf, 0.9996 for ginsenoside Rc and 0.9999 for ginsenoside Rb1) 
between peak area and amount of Panax active compounds injected over the range of 
29.55 -179.00 µg/mL (Table 3.9, Fig. 3.43). 
 
Table 3.9:  Regression equation, linear regression for Panax active compounds for Zorbax 
Eclipse XDB column 
Compounds  Regression Equation  Linear regression (r2) 
Ginsenoside R1  Y = 21.73X-0.001  0.9994 
Ginsenoside Rg1 + Re Y = 44.34X-0.14   0.9995 
Ginsenoside Rf  Y = 6.81X-0.01   0.9995 
Ginsenoside Rb1  Y = 33.84X+0.29  0.9999 
Ginsenoside Rc  Y = 36.04X+0.18  0.9996 
Ginsenoside Rb2  Y = 36.32X+0.14  0.9994 
Ginsenoside Rd  Y = 41.85X+0.14  0.9991 
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Figure 3.43:  Relationship between peak areas and concentration of Rg1 (a), Re (b), Rb1 (c), Rc 
(d), Rb2 (e) and Rd (f) 
 
 
3.2.3.2.2 Recovery of Panax active compounds using the Zorbax Eclipse XDB column 
(1.8 µm, 4.6 x 50 mm) 
 
A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the four reference compounds were spiked into a 0.1 g of authentic 
Panax powder extract.  This fortified sample was then extracted and analyzed in triplicate.  
The results of the recovery tests were obtained by comparing the results of the original 
samples with the fortified samples.  The mean recoveries were between 96.1% to 102.9%, 
with RSD less than 2.81% (Table 3.10). 
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Table 3.10:  Retention time, Recovery and its RSD % for the Epimedium active compounds 
using the Zorbax Eclipse column  (1.8 µm, 4.6 x 50 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Ginsenoside R1  0.97   0.12  97.2   1.42 
Ginsenoside Rg1 + Re 1.41   0.38  96.1   2.81 
Ginsenoside Rf  3.04   0.14  100.4   1.19 
Ginsenoside Rb1  3.30   0.19  102.9   1.25 
Ginsenoside Rc  3.40   0.17  100.2   1.36 
Ginsenoside Rb2  3.50   0.16  99.6   1.29 
Ginsenoside Rd  3.74   0.19  98.9   1.78 
 
 
3.2.4  Eleutherococcus senticosus  
3.2.4.1  Separation of eleutheroside B and E with the Phenomenex luna column (2.5 
µm, 100 x 3.0 mm) using RRLC 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.4.3, which yielded baseline separation of eleutheroside B 
and E shown in Figure 3.44 below.  Eleutheroside B has a retention time of 3.38 ± 0.012 min 
and eleutheroside E has a retention time of 6.45 ± 0.015.   
 
Figure 3.44:  Chromatograph for eleutheroside B and E references produced by using RRLC 
with conditions of 0 min 6% B, 6 mins 17% B, 7 min 19.7% B, 9 min 19.7% B, 10 min 100% B 
and 2 mins 6% B at a flow rate of 1.0 mL/min with the Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm), at 40oC and a wavelength setting of 220 nm 
 
 
 
 
 
 
136 
3.2.4.1.1 Relationship between peak area and amount of eleutherside B and E 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (r2 = 0.9999 for both eleutheroside B and E) between peak area 
and amount of active compounds injected over the range of 29.55 – 233.58 µg/mL (Table 
3.11, Fig. 3.45). 
 
Table 3.11:  Regression equation, linear regression for eleutheroside B and E for 
Phenomenex luna column 
Compounds  Regression Equation  Linear regression (r2) 
Eleutheroside B  Y = 1400.21X + 1.10  0.9999 
Eleutheroside E  Y = 953.07X + 1.10  0.9999 
 
 
 
   a       b 
Figure 3.45:  Relationship between peak areas and concentration eleutheroside B (a) and E 
(b)  
 
3.2.4.1.2 Recovery of Eleutherococcus senticosus active compounds 
A recovery test was performed to determine the accuracy of the proposed method.  A 
known quantity of the four reference compounds were spiked into a 0.1 g of authentic E. 
senticosus powder extract.  This fortified sample was then extracted and analyzed in 
triplicate.  The results of the recovery tests were obtained by comparing the results of the 
original samples with the fortified samples.  The mean recoveries were from 99.7% to 
100.5%, with RSD less than 1.11% (Table 3.12). 
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Table 3.12:  Retention time, Recovery and its RSD % for the Panax active compounds using 
the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Eleutheroside B  3.38 ± 0.012  0.06  100.5   1.11 
Eleutheroside E  6.54 ± 0.015  0.11  99.7   0.98 
 
 
 
3.3  Qualitative and Quantitative Analysis Method Development for Two Herbs 
3.3.1 Analysis of the main compounds of R. rosea and E. senticosus using the 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm) 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.5.2, which yielded baseline separation of six R. rosea 
active compounds and two E. senticosus active compounds.  They are shown in the 
chromatograph (Fig. 3.46) with the elution order:  salidroside, tyrosol, eleutheroside B, 
eleutheroside E, rosarin, rosavin, rosin and rosiridin; their respective retentions being 2.40 ± 
0.013 min, 2.91 ± 0.035 min, 3.43 ± 0.021 min, 6.56 ± 0.014 min, 6.79 ± 0.017 min, 7.01 ± 
0.016 min, 7.37 ± 0.014 min and 7.58 ± 0.021 min. 
 
 
Figure 3.46:  Chromatograph for salidroside, tyrosol, rosarin, rosavin, rosin, rosiridin, 
eleutheroside B and E produced by using RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 
7 mins 20% B, 9 mins 20% B, 10 mins 100% B and 10.5 mins 6% B using a Phenomenex Luna 
column (2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings of 205 nm from 0 – 3 mins, 
220 nm from3 – 6.5 mins, 205 nm from 6.5 – 10.5 mins 
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3.3.1.1 Relationship between peak area and amount of R. rosea and E. senticosus 
active compound  
 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (R2 = 0.9997 for salidroside and 0.9999 for tyrosol, 
eleutheroside B, eleutheroside E, rosarin, rosavin and rosin) between peak area and amount 
of R. rosea and E. senticosus active compounds injected over the range of 50 – 800 µg/mL 
(Fig. 3.47, Table 3.13). 
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Figure 3.47:  Relationship between peak areas and concentration salidroside (a), tyrosol (b), 
eleutheroside B (c) and E (d), rosarin (e), rosavin (f) and rosin (g) 
 
Table 3.13:  Regression equation, linear regression for R. rosea and E. senticosus active 
compounds 
Compounds  Regression Equation  Linear regression (r2) 
Salidroside  Y = 351.24X – 0.97  0.9997 
Tyrosol   Y = 864.60X – 0.61  0.9999 
Eleutheroside B  Y = 1400.21X + 1.10  0.9999 
Eleutheroside E  Y = 953.07X + 1.10  0.9999 
Rosarin   Y = 725.16X + 0.87  0.9999 
Rosavin   Y = 1081.57X + 1.95  0.9999 
Rosin   Y = 953.07X + 1.10  0.9999 
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3.3.1.2  Recovery of R. rosea and E. senticosus active compounds 
A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the five reference compounds were spiked into a 0.1 g of authentic R. 
rosea and E. senticosus root extract.  This fortified sample was then extracted and analyzed 
in triplicate.  The results of the recovery tests were obtained by comparing the results of the 
original samples with the fortified samples.  The mean recoveries were from 98.9% to 
100.9%, with RSD less than 1.42% (Table 3.14). 
 
Table 3.14:  Retention time, Recovery and its RSD % for the R. rosea and E. senticosus active 
compounds using the Phenomenex luna column 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Salidroside  2.37 ± 0.012  0.29  99.6   1.12 
Tyrosol   2.84 ± 0.077  1.11  100.3   1.15 
Eleutheroside B  3.38 ± 0.012  0.06  100.5   1.11 
Eleutheroside E  6.54 ± 0.015  0.11  99.7   0.98 
Rosarin   6.79 ± 0.017  0.16  98.9   1.23 
Rosavin   7.01 ± 0.016  0.14  100.9   1.01 
Rosin   7.37 ± 0.014  0.12  99.5   1.42 
 
 
3.3.2 Analysis of the main compounds of P. quinquefolius and Epimedium using 
the Phenomenex Luna column (2.5 µm, 100 x 3.0 mm) 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.6.2, which yielded baseline separation of eight 
ginsenosides and four Epimedium active compounds.  They are shown in the chromatograph 
(Fig. 3.48) with elution order:  ginsenosides R1, Rg1, Re, epimedin A, B, C, icariin, Rf, Rb1, Rc, 
Rb2 and Rd; their respective retentions being  6.53 ± 0.021 min, 9.67 ± 0.015 min, 10.10 ± 
0.012 min, 11.03 ± 0.018 min, 11.17 ± 0.016 min, 11.33 ± 0.021 min, 11.56 ± 0.018 min, 
12.64 ± 0.021 min, 13.36 ± 0.023 min, 13.63 ± 0.019 min,  13.87 ± 0.016 min and 14.46 ± 
0.020 min. 
141 
 
Figure 3.48:  Chromatograph for extracts of P. quinquefolius and Epimedium produced by 
using RRLC with conditions of 0 mins 19.7% B, 9 mins 19.7% B, 10 mins 30% B, 11 mins 30% 
B, 16 mins 50% B, 18 mins 100% B and 19 mins 19.7% B using a Phenomenex Luna column 
(2.5 µm, 100 x 3.0 mm), at 40 °C and a wavelength setting of 205 nm 
 
 
3.3.2.1 Relationship between peak area and amount of P. quinquefolius and 
Epimedium active compound  
 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (r2 = 0.9994 for ginsenoside Rc, 0.9995 for ginsenoside Rg1, 
0.9998 for ginsenoside Rb2, Rd, epimedin B, 0.9999 for ginsenosides Re, Rb1, epimedin A, C 
and 1.0000 for ginsenosides R1, Rf, icariin) between peak area and amount of P. quinquefolius 
and Epimedium active compounds injected over the range of 29.55 – 233.58 µg/mL (Table 
3.15, Fig. 3.49). 
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Table 3.15:  Regression equation, linear regression for Panax and Epimedium species active 
compounds 
Compounds  Regression Equation  Linear regression (r2) 
Ginsenoside R1  Y = 83.84X+0.442  1.0000 
Ginsenoside Rg1  Y = 109.53X+0.090  0.9995 
Ginsenoside Re  Y = 93.75X+0.25  0.9999 
Epimedin A  Y = 600.64X + 0.63  0.9999 
Epimedin B  Y = 561.73X + 1.76  0.9998 
Epimedin C  Y = 667.55X + 2.22  0.9999 
Icariin   Y = 986.88X + 3.34  1.0000 
Ginsenoside Rf  Y = 101.64X+0.57  1.0000 
Ginsenoside Rb1  Y = 88.23X+0.06  0.9999 
Ginsenoside Rc  Y = 96.46X+0.10  0.9994 
Ginsenoside Rb2  Y = 92.54X-0.02   0.9998 
Ginsenoside Rd  Y = 110.87X-0.05  0.9998 
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   e       f 
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Figure 3.49:  Relationship between peak areas and concentration of R1 (a), Rg1 (b), Re (c), Rf 
(d), Rb1 (e), Rc (f), Rb2 (g) and Rd (h)  
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3.3.2.2  Recovery of P. quinquefolius and Epimedium active compounds 
A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the five references were spiked into a 0.1 g of authentic P. 
quinquefolius and Epimedium root extract.  This fortified sample was then extracted and 
analyzed in triplicate.  The results of the recovery tests were obtained by comparing the 
results of the original samples with the fortified samples.  The mean recoveries were from 
98.3% to 100.7%, with RSD less than 1.88% (Table 3.16). 
 
 
Table 3.16:  Retention time, Recovery and its RSD % for the R. rosea and E. senticosus active 
compounds using the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Ginsenoside R1  6.53   0.11  99.4   1.01 
Ginsenoside Rg1  9.67   0.42  98.3   1.88 
Ginsenoside Re  10.10   0.40  98.9   1.45 
Epimedin A  11.03   0.17  99.7   1.06 
Epimedin B  11.17   0.15  99.6   1.09 
Epimedin C  11.33   0.19  100.2   1.13 
Icariin   11.56   0.18  100.7   0.98 
Ginsenoside Rf  12.64   0.22  99.9   1.05 
Ginsenoside Rb1  13.36   0.19  100.6   1.15 
Ginsenoside Rc  13.63   0.16  99.9   1.20 
Ginsenoside Rb2  13.87   0.18  99.5   1.19 
Ginsenoside Rd  14.46   0.21  98.7   1.18 
 
 
3.3.3 P. quinquefolius and Epimedium active compound analysis using the Zorbax 
Eclipse XDB Column (1.8 µm, 4.6 x 50 mm) 
 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.6.3, which yielded baseline separation of eight 
ginsenosides and four Epimedium active compounds.  They are shown in the chromatograph 
(Fig. 3.50) with elution order:  ginsenosides R1, Rg1, Re, epimedin A, B, C, icariin, Rf, Rb1, Rc, 
Rb2 and Rd; their respective retentions being  0.97 ± 0.024 min, 1.41 ± 0.015 min, 2.42 ± 
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0.021 min, 2.52 ± 0.016 min, 2.60 ± 0.022 min, 2.68 ± 0.020 min, 3.04 ± 0.018 min, 3.30 ± 
0.020 min, 3.40 ± 0.017 min, 3.50 ± 0.019 min and 3.74 ± 0.022 min . 
 
Figure 3.50:  Chromatograph for extracts of P. quinquefolius and Epimedium produced by 
using RRLC with conditions of 0 mins 22% B, 1.6 mins 22% B, 3.5 mins 40% B, 5 mins 50% B, 
6 mins 100% B and 6.5 mins 29% B using a Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm), 
40 °C and a wavelength setting of 203 nm 
 
 
3.3.3.1 Relationship between peak area and amount of P. quinquefolius and 
Epimedium active compound  
 
Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes. The regression lines are linear in the 
concentration range studied (r2 = 0.9991 for Rd, 0.9994 for ginsenoside R1 and RB2, 0.9995 
for ginsenoside Rg1 + Re, Rf, 0.9996 for ginsenoside Rc, 0.9999 for ginsenosides Rb1, and 
1.0000 for epimedin A, B, C and icariin) between peak area and amount of P. quinquefolius 
and Epimedium active compounds injected over the range of 29.55 – 233.58 µg/mL (Table 
3.17, Fig. 3.51). 
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Table 3.17:  Regression equation, linear regression for P. quinquefolius and Epimedium 
active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Ginsenoside R1  Y = 21.73X – 0.001   0.9994 
Ginsenoside Rg1+Re Y = 44.34X – 0.14   0.9995 
Epimedin A  Y = 327.20X + 0.06   1.0000 
Epimedin B  Y = 301.03X+0.10   1.0000 
Epimedin C  Y = 357.25X+0.19   1.0000 
Icariin   Y = 403.63X+0.30   1.0000 
Ginsenoside Rf  Y = 6.81X – 0.01    0.9995 
Ginsenoside Rb1  Y = 33.84X + 0.29   0.9999 
Ginsenoside Rc  Y = 36.04X + 0.18   0.9996 
Ginsenoside Rb2  Y = 36.32X + 0.14   0.9994 
Ginsenoside Rd  Y = 41.85X + 0.14   0.9991 
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Figure 3.51:  Relationship between peak areas and concentration of R1 (a), Rg1+Re (b), 
epimedin A (c), epimedin B (d), epimedin C (e), icariin (f), Rf (g), Rb1 (h), Rc (i), Rb2 (j) and Rd (k) 
 
 
3.3.3.2 Recovery of P. quinquefolius and Epimedium active compounds on the 
Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm) 
 
A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the five reference compounds were spiked into a 0.1 g of authentic P. 
quinquefolius and Epimedium root extract.  This fortified sample was then extracted and 
analyzed in triplicate.  The results of the recovery tests were obtained by comparing the 
results of the original samples with the fortified samples.  The mean recoveries were from 
96.1% to 102.9%, with RSD less than 2.81% (Table 3.18). 
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Table 3.18:  Retention time, Recovery and its RSD % for the P. quinquefolius and Epimedium 
active compounds using the Zorbax Eclipse Column (1.8 µm, 4.6 x 50 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Ginsenoside R1  0.97   0.12  97.2   1.42 
Ginsenoside Rg1+Re 1.41   0.38  96.1   2.81 
Epimedin A  2.42   0.16  99.8   1.14 
Epimedin B  2.52   0.20  99.3   1.23 
Epimedin C  2.60   0.17  100.4   1.16 
Icariin   2.68   0.18  102.3   0.97 
Ginsenoside Rf  3.04   0.14  100.4   1.19 
Ginsenoside Rb1  3.30   0.19  102.9   1.25 
Ginsenoside Rc  3.40   0.17  100.2   1.36 
Ginsenoside Rb2  3.50   0.16  99.6   1.29 
Ginsenoside Rd  3.74   0.19  98.9   1.78 
 
 
3.4 Qualitative and Quantitative Analysis Method Development for Three Herbs 
3.4.1 Analysis of Main Compounds of R. rosea, Epimedium and Panax species using the 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm) 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.7.2, which yielded baseline separation of six R. rosea, four 
Epimedium and eight P. quinquefolius active compounds.  They are shown in the 
chromatograph (Fig. 3.52) in this order:  salidroside, tyrosol, rosarin, rosavin, rosin, rosiridin, 
ginsenosides R1, Rg1, Re, epimedin A, B, C, icariin,  ginsenosides Rf, Rb1, Rc, Rb2 and Rd; their 
respective retention being  2.37 ± 0.012 min, 2.84 ± 0.017 min, 6.79± 0.017 min, 7.01 ± 
0.016 min, 7.37 ± 0.014 min, 7.52 ± 0.018 min, 11.12 ± 0.015 min,  15.21 ± 0.015 min, 15.57 
± 0.014 min, 16.78 ± 0.014 min, 17.12 ± 0.021 min, 17.33 ± 0.011 min, 17.48 ± 0.017 min, 
18.32 ± 0.021, 19.41 ± 0.013 min, 19.52 ± 0.018 min, 19.81 ± 0.023 min and 20.43 ± 0.019 
min. 
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Figure 3.52:  Chromatograph for extracts of R. rosea, Epimedium and Panax species 
produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 
19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings of 205 
nm from 0 – 3 mins, 220 nm from 3 – 6.5 mins, 205 nm from 6.5 – 18 mins 
 
 
3.4.1.1  Relationship between peak area and amount of R. rosea, Epimedium and 
Panax species active compounds  
 
 Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  The regression lines are linear in the 
concentration range studied (R2 = 0.9999 for salidroside, 1.0000 for tyrosol, 0.9998 for 
epimedin A, 0.9999 for epimedin B, 1.0000 for epimedin C, 0.9998 for icariin, 0.9999 for 
rosarin, 0.9999 for rosavin, 0.9999 for rosin, 1.0000 for R1, 0.9997 for Rg1, 1.0000 for Re, 
0.9999 for Rf, 0.9999 for Rb1, 0.9994 for Rc, 0.9998 for Rb2 and 0.9999 for Rd) between peak 
area and amount of R. rosea, Epimedium and Panax species active compounds injected over 
the range of 23.98 – 800 µg/mL (Table 3.19, Fig. 3.53). 
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Table 3.19:  Regression equation, linear regression for R. rosea, Epimedium and Panax 
species active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Salidroside  Y = 362.41X – 0.89   0.9999 
Tyrosol   Y = 861.76X – 0.75   1.0000 
Rosarin   Y = 730.22X + 0.78   0.9999 
Rosavin   Y = 1079.75X + 1.83   0.9999 
Rosin   Y = 949.19X + 1.25   0.9999 
Ginsenoside R1  Y = 85.96 X+0.57   0.9999 
Ginsenoside Rg1  Y = 112.48X+0.062   0.9997 
Ginsenoside Re  Y = 95.84 X+0.29   1.0000 
Epimedin A  Y = 605.56X+0.49   0.9998 
Epimedin B  Y = 578.78X+1.81   0.9999 
Epimedin C  Y = 666.49X+2.19   1.0000 
Icariin   Y = 979.97X+3.43   0.9998 
Ginsenoside Rf  Y = 105.42X+0.47   0.9999 
Ginsenoside Rb1  Y = 87.35X+0.15   0.9999 
Ginsenoside Rc  Y = 97.52X+0.18    0.9994 
Ginsenoside Rb2  Y = 93.66X-0.18    0.9998 
Ginsenoside Rd  Y = 117.53X-0.52   0.9999 
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Figure 3.53:  Relationship between peak areas and concentration of Salidroside (a), tyrosol 
(b), rosarin (c), rosavin (d), rosin (e), epimedin A (f), epimedin B (g), epimedin C (h), icariin (i), 
R1 (j), Rg1 (k), Re (l), Rf (m), Rb1 (n), Rc (o), Rb2 (p) and Rd (q)  
 
 
3.4.1.2  Recovery of R. rosea, Epimedium and Panax species active compounds 
 A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the 17 reference compounds were spikes into a 0.1 g of authentic R. 
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rosea root extract, Epimedium species extract and Panax species root extract.  This fortified 
sample was then extracted and analyzed in triplicate.  The results of the recovery tests were 
obtained by comparing the results of the original samples with the fortified samples.  The 
mean recoveries were from 98.1% to 100.4%, with RSD less than 1.79%. 
 
Table 3.20:  Retention time, Recovery and its RSD % for the R. rosea, Epimedium and Panax 
active compounds using the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Salidroside  2.37 ± 0.012  0.27  99.8   1.11 
Tyrosol   2.84 ± 0.017  1.22  100.4   1.13 
Rosarin   6.79 ± 0.017  0.18  98.1   1.19 
Rosavin   7.01 ± 0.016  0.15  100.2   1.05 
Rosin   7.37 ± 0.014  0.14  99.9   1.41 
Ginsenoside R1  11.12 ± 0.015  0.18  99.5   1.02 
Ginsenoside Rg1  15.21 ± 0.015  0.48  99.1   1.79 
Ginsenoside Re  15.57 ± 0.014  0.39  98.7   1.48 
Epimedin A  16.78 ± 0.014  0.18  99.2   1.07 
Epimedin B  17.12 ± 0.021  0.16  99.8   1.08 
Epimedin C  17.33 ± 0.011  0.17  99.9   1.12 
Icariin   17.48 ± 0.017  0.17  100.1   0.97 
Ginsenoside Rf  18.32 ± 0.021  0.23  100.3   1.06 
Ginsenoside Rb1  19.41 ± 0.013  0.17  100.4   1.16 
Ginsenoside Rc  19.52 ± 0.018  0.14  100.1   1.19 
Ginsenoside Rb2  19.81 ± 0.023  0.19  99.1   1.20 
Ginsenoside Rd  20.43 ± 0.019  0.24  99.2   1.20 
 
 
3.4.2 Analysis of the major active compounds of R. rosea, E. senticosus and 
Epimedium species using RRLC on the Phenomenex Luna column (2.5 µm, 
100 x 3.0 mm) 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.7.2, which yielded baseline separation of six R. rosea, two 
E. senticosus and four Epimedium active compounds.  They are shown in the chromatograph 
(Fig. 3.54) with elution order:  salidroside, tyrosol, eleutheroside B, E, rosarin, rosavin, rosin, 
rosiridin, epimedin A, B, C and icariin; their respective retention being 2.39 ± 0.013 min, 2.82 
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± 0.017 min, 3.08 ± 0.012 min, 6.47 ± 0.015 min, 6.72 ± 0.017 min, 6.85± 0.016 min, 7.35 ± 
0.016 min, 6.85 ± 0.016 min, 11.54 ± 0.015 min, 11.72 ± 0.011 min and 11.89 ± 0.020 min 
(Fig. 3.54).  
 
 
Figure 3.54:  Chromatograph for extracts of R. rosea, E. senticosus and Epimedium species 
with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 10 mins 19.7% B, 11 mins 
30% B, 17 mins 50% B, 19 mins 100% B and 20 mins 6% B using a Phenomenex Luna column 
(2.5 µm, 100 x 3.0 mm), at 40 °C with wavelength settings of 205 nm from 0 – 3 mins, 220 
nm from3 – 6.5 mins, 205 nm from 6.5 – 8 mins and 203 nm from 8 – 20 mins 
 
 
3.4.2.1 Relationship between peak area and amount of R. rosea, E. senticosus and 
Epimedium species active compounds  
 
 Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  The regression lines are linear in the 
concentration range studied (R2 = 0.9999 for salidroside, 1.0000 for tyrosol, 0.9990 for 
eleutheroside B, 0.9999 for eleutheroside E, 0.9999 for rosarin, 0.9999 for rosavin, 0.9999 
for rosin, 0.9998 for epimedin A, 0.9999 for epimedin B, 1.0000 for epimedin C, 0.9998 for 
icariin) between peak area and amount of R. rosea, Epimedium and Panax species active 
compounds injected over the range of 23.98 – 800 µg/mL (Table 3.21, Fig. 3.55). 
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Table 3.21:  Regression equation, linear regression for R. rosea, Epimedium and Panax 
species active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Salidroside  Y = 362.41X – 0.89   0.9999 
Tyrosol   Y = 861.76X – 0.75   1.0000 
Eleutheroside B  Y = 1480.21X + 1.23   0.9990 
Eleutheroside E  Y = 954.58X + 1.18   0.9999 
Rosarin   Y = 730.22X + 0.78   0.9999 
Rosavin   Y = 1079.75X + 1.83   0.9999 
Rosin   Y = 949.19X + 1.25   0.9999 
Epimedin A  Y = 605.56X+0.49   0.9998 
Epimedin B  Y = 578.78X+1.81   0.9999 
Epimedin C  Y = 666.49X+2.19   1.0000 
Icariin   Y = 979.97X+3.43   0.9998 
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Figure 3.55:  Relationship between peak areas and concentration of Salidroside (a), tyrosol 
(b), eleutheroside B (c), eleutheroside E (d), rosarin (e), rosavin (f), rosin (g), epimedin A (h), 
epimedin B (i), epimedin C (j), icariin (k) 
 
 
3.4.2.2 Recovery of R. rosea, E. senticosus and Epimedium species active 
compounds 
 
 A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the five reference compounds were spikes into a 0.1 g of authentic R. 
rosea root extract, this fortified sample was then extracted and analyzed in triplicate.  The 
results of the recovery tests were obtained by comparing the results of the original samples 
with the fortified samples.  The mean recoveries were from 99.1% to 100.9%, with RSD less 
than 1.45% (Table 3.22). 
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Table 3.22:  Retention time, Recovery and its RSD % for the R. rosea, Epimedium and Panax 
active compounds using the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Salidroside  2.39 ± 0.013  0.26  99.4   1.10 
Tyrosol   2.82 ± 0.017  1.09  100.8   1.14 
Eleutheroside B  3.08 ± 0.012  0.08  100.9   1.13 
Eleutheroside E  6.47 ± 0.015  0.09  99.6   0.97 
Rosarin   6.72 ± 0.017  0.14  99.2   1.21 
Rosavin   6.85 ± 0.016  0.12  100.7   1.09 
Rosin   7.35 ± 0.016  0.14  99.9   1.45 
Epimedin A  11.39 ± 0.011  0.19  99.5   1.01 
Epimedin B  11.54 ± 0.015  0.14  99.1   1.08 
Epimedin C  11.72 ± 0.011  0.18  99.8   1.11 
Icariin   11.89 ± 0.020  0.17  100.4   0.97 
 
 
3.4.3 Analysis of the major active compounds of R. rosea, E. senticosus and Panax 
species major active compounds analysis using RRLC on the Phenomenex 
Luna column (2.5 µm, 100 x 3.0 mm) 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.7.2, which yielded baseline separation of six R. rosea, two 
E. senticosus and eight P. quinquefolius active compounds.  They are shown in the 
chromatograph (Fig. 3.56) with elution order:  salidroside, tyrosol, eleutheroside B, 
eleutheroside E, rosarin, rosavin, rosin, rosiridin, ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and 
Rd; their respective retention being  2.36 ± 0.014 min, 2.85 ± 0.018 min, 3.23 ± 0.021 min, 
6.38 ± 0.022 min, 6.82± 0.016 min, 6.92 ± 0.014 min, 7.35 ± 0.016 min, 7.48 ± 0.018 min, 
11.08 ± 0.017,  15.10 ± 0.016 min, 15.52 ± 0.015 min, 18.12 ± 0.019, 19.35 ± 0.017 min, 
19.50 ± 0.019 min, 19.76 ± 0.020 min and 20.41 ± 0.017 min. 
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Figure 3.56:  Chromatograph for extracts of R. rosea, E. senticosus and Panax species with 
conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 19.7% B, 16 mins 30% B, 
22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a Phenomenex Luna column (2.5 
µm, 100 x 3.0 mm), at 40 °C with wavelength settings of 205 nm from 0 – 3 mins, 220 nm 
from3 – 6.5 mins, 205 nm from 6.5 – 8 mins, 203 nm from 8 – 26 mins 
 
 
3.4.3.1 Relationship between peak area and amount of R. rosea, E. senticosus and 
Panax species active compounds  
 
 Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  The regression lines are linear in the 
concentration range studied (R2 = 0.9999 for salidroside, 1.0000 for tyrosol, 0.9993 for 
eleutheroside B, 1.0000 for eleutheroside E, 0.9999 for rosarin, 0.9999 for rosavin, 0.9999 
for rosin, 1.0000 for R1, 0.9997 for Rg1, 1.0000 for Re, 0.9999 for Rf, 0.9999 for Rb1, 0.9994 for 
Rc, 0.9998 for Rb2 and 0.9999 for Rd) between peak area and amount of R. rosea, E. 
senticosus and Panax species active compounds injected over the range of 29.55 – 800 
µg/mL (Table 3.23, Fig. 3.57). 
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Table 3.23:  Regression equation, linear regression for R. rosea, Epimedium and Panax 
species active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Salidroside  Y = 362.41X – 0.89   1.0000 
Tyrosol   Y = 861.76X – 0.75   0.9997 
Eleutheroside B  Y = 1479.95X + 1.05   0.9993 
Eleutheroside E  Y = 982.51X + 1.35   1.0000 
Rosarin   Y = 730.22X + 0.78   0.9999 
Rosavin   Y = 1079.75X + 1.83   1.0000 
Rosin   Y = 949.19X + 1.25   0.9999 
Ginsenoside R1  Y = 85.96 X+0.57   1.0000 
Ginsenoside Rg1  Y = 112.48X+0.062   0.9998 
Ginsenoside Re  Y = 95.84 X+0.29   1.0000 
Ginsenoside Rf  Y = 105.42X+0.47   0.9999 
Ginsenoside Rb1  Y = 87.35X+0.15   0.9999 
Ginsenoside Rc  Y = 97.52X+0.18    0.9994 
Ginsenoside Rb2  Y = 93.66X-0.18    0.9998 
Ginsenoside Rd  Y = 117.53X-0.52   1.0000 
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Figure 3.57:  Relationship between peak areas and concentration of Salidroside (a), tyrosol 
(b), eleutheroside B (c), eleutheroside E (d), rosarin (e), rosavin (f), rosin (g), R1 (h), Rg1 (i), Re 
(j), Rf (k), Rb1 (l), Rc (m), Rb2 (n) and Rd (o) processed through extraction 
 
3.4.3.2  Recovery of R. rosea, E. senticosus and Panax species active compounds 
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 A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the 17 reference compounds were spiked into a 0.1 g of authentic R. 
rosea root extract, E. senticosus extract and Panax species root extract.  This fortified 
sample was then extracted and analyzed in triplicate.  The results of the recovery tests were 
obtained by comparing the results of the original samples with the fortified samples.  The 
mean recoveries were from 98.5% to 100.5%, with RSD less than 1.77% (Table 3.24). 
 
Table 3.24:  Retention time, Recovery and its RSD % for the R. rosea, E. senticosus and 
Panax active compounds using the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Salidroside  2.36 ± 0.014  0.24  99.5   1.12 
Tyrosol   2.85 ± 0.018  1.01  100.2   1.12 
Eleutheroside B  3.23 ± 0.021  0.16  100.1   1.14 
Eleutheroside E  6.38 ± 0.022  0.10  100.3   1.03 
Rosarin   6.82 ± 0.016  0.17  98.5   1.17 
Rosavin   6.92 ± 0.014  0.16  100.5   1.06 
Rosin   7.35 ± 0.016  0.15  99.7   1.43 
Ginsenoside R1  11.08 ± 0.017  0.17  99.6   1.04 
Ginsenoside Rg1  15.10 ± 0.016  0.45  99.3   1.77 
Ginsenoside Re  15.52 ± 0.014  0.34  98.6   1.47 
Ginsenoside Rf  18.12 ± 0.019  0.22  100.5   1.07 
Ginsenoside Rb1  19.35 ± 0.017  0.13  100.5   1.17 
Ginsenoside Rc  19.50 ± 0.019  0.19  100.2   1.15 
Ginsenoside Rb2  19.76 ± 0.020  0.15  99.4   1.21 
Ginsenoside Rd  20.41 ± 0.017  0.26  99.6   1.22 
 
 
3.4.4 Analysis of main compounds of E. senticosus, Epimedium and Panax species 
using RRLC on the Phenomenex Luna column (2.5 µm, 100 x 3.0 mm) 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.7.2, which yielded baseline separation of two E. senticosus, 
four Epimedium and eight P. quinquefolius active compounds.  They are shown in the 
chromatograph (Fig. 3.58) with elution order:  eleutheroside B, eleutheroside E, 
ginsenosides R1, Rg1, Re, epimedin A, B, C, icariin, ginsenosides Rf, Rb1, Rc, Rb2 and Rd; their 
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respective retention being  3.12 ± 0.019 min, 6.42 ± 0.020 min, 11.13 ± 0.019 min,  15.28 ± 
0.014 min, 15.61 ± 0.017 min, 16.92 ± 0.012 min, 17.10 ± 0.014 min, 17.28 ± 0.009 min, 
17.40 ± 0.018 min, 18.21 ± 0.018 min, 19.28 ± 0.019 min, 19.50 ± 0.020 min, 19.82 ± 0.019 
min and 20.39 ± 0.018 min. 
 
 
Figure 3.58:  Chromatograph for extracts of E. senticosus Epimedium and Panax species 
produced by RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 
19.7% B, 16 mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B with a 
Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C and wavelength settings of 220 
nm from 0 – 6.5 mins, 203 nm from 6.5 – 26 mins 
 
 
3.4.4.1 Relationship between peak area and amount of E. senticosus, Epimedium 
and Panax species active compounds  
 
 Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  The regression lines are linear in the 
concentration range studied (R2 = 0.9993 for eleutheroside B, 1.0000 for eleutheroside E, 
0.9998 for epimedin A, 0.9999 for epimedin B, 1.0000 for epimedin C, 0.9998 for icariin, 
1.0000 for R1, 0.9997 for Rg1, 1.0000 for Re, 0.9999 for Rf, 0.9999 for Rb1, 0.9994 for Rc, 
0.9998 for Rb2 and 0.9999 for Rd) between peak area and amount of E. senticosus, 
Epimedium and Panax species active compounds injected over the range of 23.98 – 233.58 
µg/mL (Table 3.25, Fig. 3.59). 
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Table 3.25:  Regression equation, linear regression for E. senticosus, Epimedium and Panax 
species active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Eleutheroside B  Y = 1482.56X + 1.52   0.9993 
Eleutheroside E  Y = 974.48X + 1.39   1.0000 
Ginsenoside R1  Y = 85.84 X+0.68   1.0000 
Ginsenoside Rg1  Y = 112.82X+0.052   0.9998 
Ginsenoside Re  Y = 95.95 X+0.35   1.0000 
Epimedin A  Y = 605.28X+0.82   0.9998 
Epimedin B  Y = 578.16X+1.76   0.9999 
Epimedin C  Y = 666.96X+2.28   1.0000 
Icariin   Y = 979.79X+3.54   0.9998 
Ginsenoside Rf  Y = 105.63X+0.64   0.9999 
Ginsenoside Rb1  Y = 87.63X+0.24   0.9999 
Ginsenoside Rc  Y = 97.82X+0.29    0.9994 
Ginsenoside Rb2  Y = 93.76X-0.27    0.9998 
Ginsenoside Rd  Y = 117.76X-0.49   1.0000 
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Figure 3.59:  Relationship between peak areas and concentration of eleutheroside B (a), 
eleutheroside E (b), epimedin A (c), epimedin B (d), epimedin C (e), icariin (f), R1 (g), Rg1 (h), 
Re (i), Rf (j), Rb1 (k), Rc (l), Rb2 (m) and Rd (n) processed through extraction 
 
 
 
3.4.4.2  Recovery of E. senticosus, Epimedium and Panax species active compounds 
 A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the 14 reference compounds were spikes into a 0.1 g of authentic, E. 
senticosus extract, Epimedium species extract and Panax species root extract.  This fortified 
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sample was then extracted and analyzed in triplicate.  The results of the recovery tests were 
obtained by comparing the results of the original samples with the fortified samples.  The 
mean recoveries were from 98.6% to 100.5%, with RSD less than 1.76% (Table 3.26). 
 
Table 3.26:  Retention time, Recovery and its RSD % for the E. senticosus, Epimedium and 
Panax active compounds using the Phenomenex luna column (2.5 µm, 100 x 3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Eleutheroside B  3.12 ± 0.019  0.12  100.3   1.15 
Eleutheroside E  6.42 ± 0.020  0.12  100.2   1.03 
Ginsenoside R1  11.13 ± 0.019  0.16  99.4   1.05 
Ginsenoside Rg1  15.28 ± 0.014  0.41  99.3   1.76 
Ginsenoside Re  15.61 ± 0.017  0.35  98.6   1.47 
Epimedin A  16.92 ± 0.012  0.15  99.7   1.02 
Epimedin B  17.10 ± 0.014  0.12  99.6   1.05 
Epimedin C  17.28 ± 0.009  0.14  99.7   1.17 
Icariin   17.40 ± 0.018  0.13  100.5   0.96 
Ginsenoside Rf  18.21 ± 0.018  0.21  100.4   1.04 
Ginsenoside Rb1  19.28 ± 0.019  0.15  100.1   1.15 
Ginsenoside Rc  19.50 ± 0.020  0.15  100.2   1.17 
Ginsenoside Rb2  19.82 ± 0.019  0.17  99.2   1.18 
Ginsenoside Rd  20.39 ± 0.018  0.23  99.4   1.22 
 
 
3.5  Qualitative and quantitative analysis method development  for four herbs 
3.5.1 Analysis of the main compounds of R. rosea, E. senticosus, Epimedium and 
Panax species using RRLC on the Phenomenex Luna column (2.5 µm, 100 x 
3.0 mm) 
A mobile phase consisting of acetonitrile and water was delivered as the gradient 
described in Methods section 2.2.7.2, which yielded baseline separation of six R. rosea, two 
E. senticosus, four Epimedium and eight P. quinquefolius active compounds.  They are shown 
in the chromatograph (Fig. 3.60) with elution order:  salidroside, tyrosol, eleutheroside B, 
eleutheroside E, rosarin, rosavin, rosin, rosiridin, ginsenosides R1, Rg1, Re, epimedin A, B, C, 
icariin, ginsenosides Rf, Rb1, Rc, Rb2 and Rd; their respective retention being  2.22 ± 0.013 min, 
2.71 ± 0.015 min, 3.22 ± 0.016 min, 6.21 ± 0.019 min, 6.72 ± 0.017 min, 7.01 ± 0.017 min, 
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7.38 ± 0.018 min, 12.49 ± 0.018 min,  16.01 ± 0.016 min, 16.42 ± 0.015 min, 17.09 ± 0.014 
min, 17.28 ± 0.012 min, 17.47 ± 0.011 min, 17.71 ± 0.016 min, 18.94 ± 0.017 min, 19.54 ± 
0.015 min, 19.71 ± 0.017 min, 20.01 ± 0.020 min and 20.68 ± 0.019 min. 
 
 
Figure 3.60:  Chromatograph for salidroside, tyrosol, eleutheroside B, E, rosarin, rosavin, 
rosin, rosiridin, Rg1, Re, epimedin A, B, C, icariin, Rb1, Rc, Rb2 and Rd references produced by 
RRLC with conditions of 0 mins 6% B, 6 mins 17% B, 7 mins 19.7% B, 15 mins 19.7% B, 16 
mins 30% B, 22 mins 50% B, 24 mins 100% B and 26 mins 6% B using a Phenomenex Luna 
column (2.5 µm, 100 x 3.0 mm), at 40 °C with wavelength settings of 205 nm from 0 – 3 
mins, 220 nm from3 – 6.5 mins, 205 nm from 7.4 – 8 mins, 203 nm from 8 – 18 mins 
 
 
 
3.5.1.1 Relationship between peak area and amount of R. rosea, E. senticosus, 
Epimedium and Panax species active compounds  
 
 Calibration curves were prepared by plotting the peak area against the 
corresponding concentrations of analytes.  The regression lines are linear in the 
concentration range studied (R2 = 0.9993 for eleutheroside B, 1.0000 for eleutheroside E, 
0.9998 for epimedin A, 0.9999 for epimedin B, 1.0000 for epimedin C, 0.9998 for icariin, 
1.0000 for R1, 0.9997 for Rg1, 1.0000 for Re, 0.9999 for Rf, 0.9999 for Rb1, 0.9994 for Rc, 
0.9998 for Rb2 and 0.9999 for Rd) between peak area and amount of E. senticosus, 
Epimedium and Panax species active compounds injected over the range of 23.98 – 233.58 
µg/mL (Table 3.27,z Fig. 3.61). 
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Table 3.27:  Regression equation, linear regression for E. senticosus, Epimedium and Panax 
species active compounds 
Compounds  Regression Equation  Linear regression (r2) 
Eleutheroside B  Y = 1482.56X + 1.52   0.9993 
Eleutheroside E  Y = 974.48X + 1.39   1.0000 
Ginsenoside R1  Y = 85.84 X+0.68   1.0000 
Ginsenoside Rg1  Y = 112.82X+0.052   0.9998 
Ginsenoside Re  Y = 95.95 X+0.35   1.0000 
Epimedin A  Y = 605.28X+0.82   0.9998 
Epimedin B  Y = 578.16X+1.76   0.9999 
Epimedin C  Y = 666.96X+2.28   1.0000 
Icariin   Y = 979.79X+3.54   0.9998 
Ginsenoside Rf  Y = 105.63X+0.64   0.9999 
Ginsenoside Rb1  Y = 87.63X+0.24   0.9999 
Ginsenoside Rc  Y = 97.82X+0.29    0.9994 
Ginsenoside Rb2  Y = 93.76X-0.27    0.9998 
Ginsenoside Rd  Y = 117.76X-0.49   1.0000 
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Figure 3.61:  Relationship between peak areas and concentration of salidroside (a), tyrosol 
(b), eleutheroside B (c), eleutheroside E (d), rosarin (e), rosavin (f), rosin (g), epimedin A (h), 
epimedin B (i), epimedin C (j), icariin (k), R1 (l), Rg1 (m), Re (n), Rf (o), Rb1 (p), Rc (q), Rb2 (r) and 
Rd (s) processed through extraction 
 
 
 
 
 
 
 
3.5.1.2 Recovery of R. rosea, E. senticosus, Epimedium and Panax species active 
compounds 
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 A recovery test was performed to determine the accuracy of the proposed method.  
A known quantity of the 14 reference compounds were spiked into a 0.1 g of authentic, R. 
rosea root extract, E. senticosus extract, Epimedium species extract and Panax species root 
extract.  This fortified sample was then extracted and analyzed in triplicate.  The results of 
the recovery tests were obtained by comparing the results of the original samples with the 
fortified samples.  The mean recoveries were from 98.6% to 100.6%, with RSD less than 
1.75% (Table 3.28). 
 
Table 3.28:  Retention time, Recovery and its RSD % for the R. rosea, E. senticosus, 
Epimedium and Panax active compounds using the Phenomenex luna column (2.5 µm, 100 x 
3.0 mm) 
Compounds  Retention Time  RSD %  Recovery Test  RSD % 
Salidroside  2.22 ± 0.013  0.25  99.6   1.14 
Tyrosol   2.71 ± 0.015  1.05  100.3   1.12 
Eleutheroside B  3.22 ± 0.016  0.14  100.2   1.13 
Eleutheroside E  6.21 ± 0.019  0.12  100.3   1.04 
Rosarin   6.72 ± 0.017  0.14  98.6   1.15 
Rosavin   7.01 ± 0.017  0.15  100.6   1.02 
Rosin   7.38 ± 0.018  0.14  99.6   1.46  
Ginsenoside R1  12.49 ± 0.018  0.16  99.5   1.04 
Ginsenoside Rg1  16.01 ± 0.016  0.43  99.4   1.75 
Ginsenoside Re  16.42 ± 0.015  0.34  98.7   1.43 
Epimedin A  17.09 ± 0.014  0.16  99.7   1.04 
Epimedin B  17.28 ± 0.012  0.14  99.5   1.03 
Epimedin C  17.47 ± 0.011  0.12  99.2   1.14 
Icariin   17.71 ± 0.016  0.14  100.4   0.94 
Ginsenoside Rf  18.94 ± 0.017  0.22  100.3   1.02 
Ginsenoside Rb1  19.54 ± 0.015  0.15  100.3   1.15 
Ginsenoside Rc  19.71 ± 0.017  0.16  100.3   1.16 
Ginsenoside Rb2  20.01 ± 0.020  0.14  99.6   1.16 
Ginsenoside Rd  20.68 ± 0.019  0.24  99.6   1.24 
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3.6  Analysis of Commercial Products 
3.6.1 Quantitative and Qualitative analysis of single raw herb and/or formulated 
commercial products 
3.6.1.1  R. rosea 
R. rosea is the best known species of the Rhodiola genus and commercial products 
containing this herb are sold with high market value due to its rosavins content.  Often 
many companies will formulate with other Rhodiola species, but then sell their product 
labelled as R. rosea.  For the purpose of this study nine commercial samples of Rhodiola 
roots were analyzed using Method 2.2.1.4.  Figure 3.62 below shows the characteristic RRLC 
chromatogram of authentic R. rosea dried roots, fresh roots and commercial powder extract 
on the natural health product market using the Phenomenex Luna column with UV 
detection performed at 205 nm.  Figure A is the chromatograph obtained from dried R. 
rosea roots, the chromatogram shows the profile of an authentic R. rosea roots 
chromatogram but the concentration of tyrosol is very minimal, it can barely be seen.  
Figure B shows a fresh R. rosea roots chromatogram and figure C shows the commercial R. 
rosea powder extract. 
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Figure 3.62:  RRLC chromatograms of dried R. rosea roots (A), fresh R. rosea roots (B), 
commercial R. rosea powder extract (C).  The chromatographic conditions are as method 
2.2.1.4 with UV detection wavelength set at 205 nm for analysis. 
 
Method 2.2.1.4 was again used for the eighteen commercial samples of R. rosea root 
powder extracts collected from 8 suppliers to compare the determined concentration of the 
5 active compounds versus the claims on the respective labels.  Out of the eighteen 
commercial samples, six of these samples did not contain the characteristic marker 
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compounds, the rosavins (PR1-Lot1 (A), PR3-Lot1 (B), PR6-Lot1 (C), PR6-Lot2 (D), PR8-Lot1 
(E), PR8-Lot2 (F)) (Fig. 3.63).   
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Figure 3.63:  RRLC chromatographs for the six claimed commercial R. rosea samples that did 
not contain the characteristic marker compounds, the rosavins (PR1-Lot1 (A), PR3-Lot1 (B), 
PR6-Lot1 (C), PR6-Lot2 (D), PR8-Lot1 (E), PR8-Lot2 (F)) 
 
In addition to this, five out of the eighteen commercial R. rosea powder extracts did 
not meet the claimed standards of the marker compound content (PR3-Lot2, PR4-Lot1, PR5-
Lot2, PR7-Lot1, PR7-Lot2).  Figure 3.64 shows the chromatogram of all the samples that did 
not meet the claimed standards of marker compounds, either by not meeting the rosavins 
content or the salidroside content claimed on the label.  Out of these five R. rosea powder 
extracts, two of these (PR4-Lot1 and PR7-Lot2) contain less salidroside than the label claim 
and the other three samples (PR3-Lot2, PR5-Lot2, PR7-Lot1) had lower rosavin or rosavins 
content.   
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Figure 3.64:  RRLC chromatograph for one commercial R. rosea sample that did not meet its 
label claim. 
 
 
Only six out of eighteen commercial R. rosea powder extracts are actual R. rosea 
powder extracts and match their labelled claim.  That is, only 33.3% of the total products 
analysed and available on the Natural Health Product market.  Table 3.29 shows the 
concentration of each marker compound in the eighteen commercial R. rosea powder 
extracts that were analyzed.   
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Table 3.29:  Marker compound contents of eighteen claimed commercial R. rosea root 
powder extracts collected from eight suppliers 
Sample Name Claimed  Concentration (mg/g)
a
 
  (mg/g)  Salidroside       Tyrosol       Rosarin       Rosavin       Rosin       Rosavins 
PR1-Lot1 Salidroside: 10       10.1   ND
b                 ND                ND              ND              ND 
PR2-Lot1 Rosavins:  30          40.9                 4.65            7.12             19.64          5.75            32.51 
PR3-Lot1 Salidroside:  30     30.18               5.14              ND                ND              ND              ND 
PR3-Lot2 Rosavins:  30     36.5                 2.49             6.84             15.70         5.67            28.21 
PR4-Lot1 Salidroside:  10     2.97                 0.52             1.28              2.48           0.68             4.44 
PR5-Lot1 Salidroside:  30     42.9                 2.27             2.72              5.32           1.47             9.51 
PR5-Lot2 Rosavins:  30          36.55              2.64              9.39             26.20         6.32            41.91 
PR5-Lot3 Salidroside 10;     22.35               1.81             6.39             20.68         4.41            31.48 
  Rosavins:  30 
PR5-Lot4 Rosavins:  30         21.56               1.84              6.86             20.15         4.68            31.69 
PR5-Lot5  Salidroside:  10     132.00             9.35             2.33             3.22           1.86             7.41 
PR5-Lot6 Salidroside:  30     36.00               2.42              9.32             27.12         6.31            42.75 
PR6-Lot1 Salidroside:  30     31.59               2.83              ND                ND              ND              ND 
PR6-Lot2 Salidroside:  20     32.30               2.83              ND                ND              ND              ND 
PR6-Lot3 Salidroside:  20     17.4                 1.39             3.52              6.02           2.94            12.48 
PR7-Lot1 Rosavin:  30     27.73              4.16            10.86            26.10          6.59            43.55  
PR7-Lot2 Salidroside:  30     15.10               2.22            0.09              0.33           0.08             0.5 
PR8-Lot1 Salidroside:  10      16.30              2.12              ND                ND              ND              ND 
PR8-Lot2 Salidroside:  30      46.36              4.71              ND                ND              ND              ND 
a  The data is present as average of triplicates 
b  ND = Not detected 
The abbreviation PR stands for Powder Rhodiola, the number behind PR stands for the number for 
the supplier and the lot stands for the batch we received from the specific supplier. 
 
3.6.1.2  Epimedium species 
 Epimedium plants have the distinctive four consecutive peaks, going from the lowest 
concentration of epimedin A, to a higher concentration of epimedin B, an even higher 
concentration epimedin C and lastly, the highest concentration is that of icariin.  The 
concentration of icariin in the plants is generally equal to the total concentration of 
epimedin A, B, C added together.  Epimedin C is approximately half of the concentration of 
icariin, therefore, the peak height of epimedin C is also half the height of icariin.  Epimedin B 
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is approximately 1/3 the concentration of epimedin C, as presented in Figure 3.65.  This 
figure shows the reference standards of epimedin A, B, C and icariin using the Phenomenex 
Luna column.   
 
 
Figure 3.65:  RRLC chromatograms of commercial Epimedium sample using the Phenomenex 
Luna Column and method 2.2.2.3. 
 
Ten commercial samples of Epimedium powder extracts collected from local stores 
were compared to evaluate differences between its determined active compound 
concentration versus its label claim.  Out of these ten commercial samples, seven did not 
meet the claims made on the respective labels.  Table 3.30 below shows the concentration 
detected using both the Phenomenex Luna column, as well as the Zorbax Eclipse column.  
The percentage is the comparison between the claims the label states and the actual 
concentration tested against its claims.  Samples EPE-001, EPE-004 and EPE-010 are the 
three samples tested that meet their claim.  EPE-002, EPE-003, EPE-005, EPE-006, EPE-007, 
EPE-008 and EPE-009 did not meet their label claim, and varied from only 22.8% of the label 
claim to 95.1% of the label claim. 
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Table 3.30:  Concentration of Epimedium species determined using both Phenomenex luna 
column and Zorbax eclipse column in percentages with comparison to its label claim 
Sample Name Label Claim    % Detected 
  (%)   Phenomenex Luna Column Zorbax Eclipse Column 
EPEb-001 Epimedium P.E.
a
 102.6%    103.5% 
  Icariin 10% 
EPE-002 Epimedium P.E.  86.5%    87.2% 
  Icariin 20%  
EPE-003 Epimedium P.E.  81.9%    82.3% 
  Icariin 20%  
EPE-004 Epimedium P.E.  123.8%    125.1% 
  Icariin 5% 
EPE-005 Epimedium P.E.  72.5%    73.4% 
  Icariin 10% 
EPE-006 Epimedium P.E.  22.8%    24.1% 
  Icariin 20% 
EPE-007 Epimedium P.E.  43.9%    45.3% 
  Icariin 10% 
EPE-008 Epimedium P.E.  84.6%    85.4% 
  Icariin 10% 
EPE-009 Epimedium P.E.  93.7%    95.1% 
  Icariin 10% 
EPE-010 Epimedium P.E.  100.8%    102.2% 
  Icariin 20% 
a
  P.E. = powder extract 
b EPE = Epimedium powder extract 
 
 
3.6.1.3  Eleutherococcus senticosus 
E. senticosus contains two major chemical constituents as shown on the HPLC 
chromatograph below (Fig. 3.66) by the two peaks.  These two peaks are similar height but, 
due to its peak width and from the tested results, it can be concluded that the 
concentration of eleutheroside E is 3 times of eleutheroside B.    
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Figure 3.66:  RRLC chromatograms of commercial E. senticosus sample using the 
Phenomenex Luna column and method 2.2.4.3. 
 
Five samples of E. senticosus commercial powder extracts were tested and the 
contents of eleutheroside B and eleutheroside E recorded.  All five commercial samples 
claim to be not less than 8 mg/g of total eleutheroside content and all of the commercial 
samples meet their label claim.  Samples ESPE-001 and ESPE-005 are very close to the label 
claim at 8.4 and 8.0 mg/g, respectively.  ESPE-002 and ESPE-004 are around 10% higher than 
the label claim at 9.2 and 9.4 mg/g, respectively.  Sample ESPE-003 even reached a total 
eleutheroside content of 11.8 mg/g, which is more than 30% over the label claim. 
 
Table 3.31:  Concentration of eleutherosides determined by using the Phenomenex luna 
column in mg/g with comparison to its label claim 
Sample Name  Label Claim Eleutherosides Content Detected 
   mg/g   B    E   Total   
ESPEa-001  Total  2.2   6.2   8.4 
  Eleutherosides ≥ 8 
ESPE-002  Total  2.4   6.8   9.2 
  Eleutherosides ≥ 8 
ESPE-003  Total  3.1   8.7   11.8 
  Eleutherosides ≥ 8 
ESPE-004  Total  2.5   6.9   9.4 
  Eleutherosides ≥ 8 
ESPE-005  Total  2.1   5.9   8.0 
  Eleutherosides ≥ 8 
a ESPE = Eleutherococcus senticosus powder extract 
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3.6.1.4  Panax species 
Nine P. ginseng roots and eleven P. quinquefolius roots have been analyzed by using 
method 2.2.3.4.  Figure 3.67 shows a distinctive RRLC chromatogram of authentic P. ginseng, 
P. quinquefolius and P. notoginseng roots.  The chromatogram of P. ginseng root (Figure 
3.67A) shows a profile with high but similar amount of Rc and Rb2 content.  In addition, 
ginsenoside Rf is also present in P. ginseng.  Figure 3.67B presents the chromatogram 
obtained from dried P. quinquefolius root.  The profile shows that ginsenoside Rc is 
approximately one third (1/3) the concentration of Rb1, and ginsenoside Rb2 has very 
minimal content and ginsenoside Rf is absent.  Figure 3.67C presents the chromatogram 
obtained from a dried P. notoginseng root.  The profile shows higher concentration of Rg1 
compared to Re, as well, the concentration of ginsenoside Rc and Rb2 is not significant and is 
absent in the chromatogram. 
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      A 
 
      B 
 
      C  
Figure 3.67:  RRLC chromatograms of (A)  P. ginseng roots (B)  P. quinquefolius roots (C)  P. 
notoginseng roots using the Phenomenex Luna Column and method 2.2.3.4. 
 
 
 A Zorbax Eclipse column was also used for the analysis and determination of 
compounds from Panax species.  Figure 3.68 below shows these for the commercial P. 
ginseng roots (A), P. quinquefolius roots (B), P. notoginseng roots (C) using method 2.2.3.5. 
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Figure 3.68:  RRLC chromatograms of (A)  P. ginseng roots (B)  P. quinquefolius roots (C)  P. 
notoginseng roots using the Zorbax Eclipse column and method 2.2.3.5. 
 
Fifteen commercial samples of P. quinquefolius powder extracts collected from local 
suppliers have been compared to evaluate differences between its actual active compound 
concentration versus their label claim (Table 3.32).  Out of these fifteen commercial samples, 
eight are P. ginseng powder extract.  In addition to this, three out of fifteen commercial P. 
quinquefolius powder extracts are mixtures of P. quinquefolius and P. ginseng powder 
extract.  The HPLC profile of the protopanaxadiol group enables the effective determination 
of the purity of the Panax species.  Represented on the profile of the HPLC chromatograph 
(Fig. 3.68B), the concentration of Rc is 1/3 of the concentration of Rb1, and has very minimal 
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concentration of Rb2 for P. quinquefolius, but in Figure 3.69, the concentration of Rc is almost 
½ of the concentration of Rb1, and significant increase of Rb2 concentration. 
 
Table:  3.32:  Concentration of each ginsenoside and the total ginsenoside of commercial 
samples purchased from local suppliers, all with a label claim of 10% of total ginsenoside. 
Sample Name   Ginsenoside (%) 
    Rg1 Re Rf Rb1 Rc Rb2 Rd Total 
PPEa-001   0.29 0.19 0.08 0.28 0.15 0.18 0.03 1.20 
PPE-002   0.33 0.14 0.10 0.22 0.21 0.20 0.08 1.28 
PPE-003   0.16 1.05 - 0.64 0.20 0.05 0.15 2.27 
PPE-004   0.38 0.34 0.22 0.48 0.48 0.44 0.34 2.68 
PPE-005   2.20 2.14 - 2.73 0.37 0.09 1.00 8.60 
PPE-006   0.40 2.40 - 1.89 0.90 0.10 1.12 6.81 
PPE-007   0.63 0.17 0.15 0.58 0.30 0.34 0.16 2.32 
PPE-008   0.62 0.59 0.26 0.64 0.40 0.52 0.25 3.30 
PPE-009   0.05 1.21 - 1.65 0.16 0.04 0.11 3.23 
PPE-010   0.14 3.21 - 2.76 0.34 0.08 0.63 7.20 
PPE-011   0.02 0.69 - 2.09 0.18 0.04 0.36 3.38 
PPE-012   0.53 0.25 0.13 0.46 0.24 0.31 0.10 2.03 
PPE-013   0.47 0.57 0.23 0.51 0.34 0.23 0.16 2.50 
PPE-014   0.14 1.78 - 0.82 0.21 0.05 0.49 3.50 
PPE-015   0.80 0.58 0.23 0.63 0.49 0.44 0.29 3.50 
a PPE = Panax powder extract 
 
 
Figure 3.69:  Representative HPLC chromatogram of a commercial P. quinquefolius root 
powder extract with Epimedium extract mixture that was identified as being contaminated 
with P. ginseng root powder using a Zorbax Eclipse XDB-C18 column and method 2.2.3.5. 
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3.6.2 Quantitative and Qualitative analysis for poly - raw herb and/or poly - 
formulated commercial products 
3.6.2.1  R. rosea and E. senticosus 
Chemical constituents from R. rosea have a similar polarity to the chemical 
constituents from E. senticosus, therefore, it is suitable, theoretically, to analyze these two 
herbs together.  Previous studies have shown that R. rosea and E. senticosus have different 
absorption wavelengths.  This is ideally suited to RRLC, as it can simultaneously analyze 
compounds at different wavelengths.  R. rosea has a maximum absorption at 205 nm and E. 
senticosus has a maximum absorption at 220 nm, therefore, chromatographs were 
produced running both absorption wavelengths at the same time, analyzing R. rosea at 205 
nm and E. senticosus at 220 nm.  Figure 3.70 below shows an authentic R. rosea root profile 
with two extra peaks in the middle of the chromatogram; these two peaks are identified by 
eleutheroside B and E reference standards and are viewed at 220 nm. 
 
Figure 3.70:  RRLC chromatograph of R. rosea reference and E. senticosus reference 
standard compounds. 
 
Method 2.2.5.2 was used to analyze six commercial samples of R. rosea and E. 
senticosus powder extracts.  Although the commercial sample capsules RE-001, RE-002, RE-
003, RE-004, RE-005 and RE-006 all contain active ingredients from R. rosea and E. 
senticosus,  variations in the contents of rosavins and total eleutherosides were noted.  The 
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contents of rosavins and total eleutherosides B and E detected in RE-001, RE-005 and RE-
006 were lower than their label claim (Table 3.33). 
 
Table 3.33:  The marker compounds content in six samples on commercial R. rosea and E. 
senticosus capsules 
Sample Name  Label Claim  Concentration (mg/capsule) 
   mg/Capsule  Rosavins  Total eleutherosides (TE) 
REa-001  Rosavins: 1.3  1.12   0.58 
   TE:  0.6 
RE-002   Rosavins: 3.0  3.15   0.46 
   TE:  0.44 
RE-003   Rosavins:  0.3  0.32   0.82 
   TE:  0.8 
RE-004   Rosavins:  0.9  0.85   0.075 
   TE:  0.08 
RE-005   Rosavins:  3.0  2.3   0.42 
   TE:  0.6 
RE-006   Rosavins:  2.1  1.71   0.45 
   TE:  0.6 
TE = Total Eleutherosides 
a RE = Rosavins and eleutheroside 
 
3.6.2.2  Panax and Epimedium species 
 Panax species contain ginsenosides that have a characteristic absorption at 203 nm, 
thus they have a significant weaker absorption compared to the flavonoids found in 
Epimedium, which have abosorption at both 270 nm as well as 205 nm.  Therefore, it is 
important to use ginsenoside’s maximum absorption for its analyzes.  In this situation, we 
have decided to use 203 nm for the detection of Panax and Epimedium species formulated 
capsules.   The retention time of the four consecutive Epimedium compound peaks 
appeared in between the proto-panaxadiol and proto-panaxatriol groups (Fig. 3.71).  P. 
quinquefolius has a standard profile with very low amount of Rb2, at almost one tenth of the 
content of Rb1, Rc has approximately one third the content of Rb1, and Rd similar to Rc.  The 
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HPLC profile presented here (Fig. 3.71), are characteristic peaks for P. quinquefolius.  P. 
ginseng is quite different from P. quinquefolius, as it contains very high content of Rc and Rb2, 
both Rb2 and Rc are approximately two thirds of the content of Rb1, with a slightly lower 
content of Rd, and therefore, the distinctive slope is the profile for P. ginseng.  P. 
notoginseng has very minimal content of Rc and Rb2, and consequently these two peaks are 
lacking in the chromatogram.  As well, the Rd content is approximately one third the content 
of Rb1, therefore, the standard profile of the proto-panaxadiol group of P. notoginseng 
consists of only the two major ginsenosides Rb1 and Rd.   
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Figure 3.71:  RRLC chromatograph for ginsenosides R1, Rg1 + Re, Rb1, Rc, Rb2, Rd, epimedin A, B, 
C and icariin reference (A), P. quinquefolius and Epimedium plant (B), P. ginseng and 
Epimedium plant (C) and P. notoginseng and Epimedium plant (D) using the Zorbax eclipse 
column. 
  
187 
 
       A 
 
       B 
 
       C 
 
       d 
188 
Figure 3.72:  RRLC chromatograph for ginsenosides R1, Rg1 + Re, Rb1, Rc, Rb2, Rd, epimedin A, B, 
C and icariin reference (A), P. quinquefolius and Epimedium plant (B), P. ginseng and 
Epimedium plant (C) and P. notoginseng and Epimedium plant (D) using the Phenomenex 
Luna column. 
 
Method 2.2.6.2 and 2.2.6.3 were used to analyze eight commercial samples of Panax 
and Epimedium species formulated capsules.  The analysis shows that some products sold 
on the market do not meet its claimed concentration(Table 3.34).   
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Table 3.34:  Percentage comparison of Panax species compounds using the Phenomenex 
Luna column (2.5 µm, 100 x 3.0 mm) with the Zorbax Eclipse column (1.8 µm, 4.6 x 50 mm) 
Sample Name     % compared to Claim 
Sample Label Claim   PL Column  ZE Column 
GEa-001 P. quinquefolius P.E 
  (10% ginsenosides)  90.8   92.5 
  Epimedium P.E. 
  (icariin 10%)   102.6   103.5 
GE-002 P. quinquefolius P.E 
  (10% ginsenosides)  71.3   70.7 
  Epimedium P.E. 
  (icariin 20%)   86.5   87.2 
GE-003 P. ginseng root powder 
  (3% ginsenosides)  36.4   35.8 
  Epimedium leaf extract 
  (icariin 20%)   81.9   82.3 
GE-004 P. quinquefolius P.E 
  (10% ginsenosides)  106.1   105.9 
  Epimedium P.E. 
  (icariin 5%)   123.8   125.1 
GE-005 P. quinquefolius P.E 
  (10% ginsenosides)  98.7   98.3 
  Epimedium P.E. 
  (icariin 10%)   100.2   99.8 
GE-006 P. quinquefolius P.E 
  (10% ginsenosides)  83.6   82.9 
  Epimedium P.E. 
  (icariin 5%)   100.5   100.0 
GE-007 P. quinquefolius P.E. 
  (10% ginsenosides)  102.4   102.1 
  Epimedium P.E. 
  (icariin 10%)   109.2   108.8 
GE-008 P. quinquefolius P.E. 
  (10% ginsenosides)  89.6   89.1 
  Epimedium P.E. 
  (icariin 10%)   98.2   97.7 
a GE = Ginseng extract 
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3.6.2.3  R. rosea, E. senticosus, Epimedium and Panax species 
Panax, Epimedium, R. rosea and E. senticosus are often used together due to their 
common properties.  A newly formulated commercial product is advertised as the “energy 
formula” to contain these four herbs.  A simultaneous method need to be used to 
determine the active ingredients both qualitatively and quantitatively.  All four of these 
herbs have different absorption wavelengths, hence, RRLC with the ability to simultaneously 
analyze compounds at different wavelengths was used.  Panax has a maximum absorption 
wavelength at 203 nm, Epimedium has maximum absorption wavelength at 270 and 205 nm, 
R. rosea has maximum absorption wavelength at 205 nm and E. senticosus has maximum 
absorption wavelength at 220 nm.  Since Epimedium has very strong absorption compared 
to the other three herbs, and compounds found in these plants have similar polarity 
compared to ginsenosides, similar absorption wavelengths can be used for both herbs.  Its 
maximum absorption wavelength will be used for R. rosea and E. senticosus.  The diagram 
below (Fig. 3.73) shows the typical profile of the nineteen active ingredients found in the 
combination of the four herbs, including salidroside, tyrosol, rosarin, rosavin, rosin, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, epimedins A, B, C, icariin, eleutheroside B and E. 
 
Figure 3.73: RRLC chromatograph of salidroside, tyrosol, rosarin, rosavin, rosin, 
ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, Rd, epimedins A, B, C, icariin, eleutheroside B and E 
reference standards. 
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Method 2.2.7.2 was used to analyze four commercial samples currently available to 
the public.  Each formulated product contains two, three or all four of the herbs.  All active 
ingredients of the four herbs in the products were quantified and the contents tested to 
determine if they meet their label claim (Table 3.35). 
 
Table 3.35:  The concentration of the marker compounds found in Panax, Epimedium, R. 
rosea and E. senticosus 
 
Sample Name  Lable Claim (%)  Tested Concentration (%) 
       Rosavins TE TG icariin 
T4a-001  Rosavins:  0.8%  0.88  0.14 3.55 0.36 
   TE:  0.14% 
   TG:  3.5% 
   Icariin 
T4-002   Rosavins:  1.0%  0.92  N/A 1.2 5.45 
   TG:  4.0% 
   Icariin:  10% 
T4-003   Rosavins:  0.5%  0.61  0.13 N/A 0.41 
   TE:  0.15% 
   Icariin:  0.3% 
T4-004   Rosavins:  0.8%  0.82  0.10 3.62 0.40 
   TE:  0.14% 
   TG:  3.5% 
   Icariin:  0.3% 
TE:  Total eleutherosides 
TG:  Total ginsenosides 
a T4 = Total of four herbs 
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3.7 Accelerated stability testing of extracts of Rhodiola rosea, 
Eleutherococcus senticosus, Epimedium and Panax species and their 
formulated products using the Equity Chamber 
 Stability testing is required by the FDA, Health Canada, and the European directorate 
for the quality of medicines and healthcare either in the form of either real time stability 
testing or accelerated stability testing.  Real time stability testing is when natural health 
products are stored under normal room temperature conditions for a period of three years, 
and then tested for the content of active compounds, to ensure that all products are still 
within their label claims.  Accelerated stability testing occurs inside a chamber, where the 
temperature and relative humidity are controlled at 40 °C and 75%, respectively, for a 
period of six months.  This time period of six months is equal to a real time of three years.  
The products are then taken out of the chamber and tested for the active compound 
content to ensure that it meets their label claim.  In this research programme, all stability 
testing was undertaken using accelerated stability testing. 
 The pH of liquid extracts containing citric acid or vitamin C were set at 3.70 and 4.00, 
respectively.  These acidic compounds can function as preservatives for formulations in the 
form of drinks. 
3.7.1 Panax quinquefolius extracts and its formulated capsules  
P. quinquefolius and its formulated capsules were prepared as described in sections 
2.2.12.1 – 2.2.12.4 and tested.  The results from the test are presented in Table 3.36 below.  
Five samples in methanol were prepared for each of the following:  P. quinquefolius, P. 
quinquefolius with Vitamin C and P. quinquefolius with Epimedium and were tested once a 
month for six consecutive months.  These samples were then examined by RRLC which 
showed that the total ginsenoside concentrations remained consistent during the study 
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period.  The data is also represented again as a line graph showing the variability range of 
the five samples tested, and the average concentration of these samples.  The line graph, 
with X-axis indicating time (months) and Y-axis concentration (%), shows the stability results, 
indicating the total ginsenoside concentration remains relatively unchanged, meaning there 
was no variation in content from the beginning of the six month stability testing to the end. 
 
Table 3.36: Concentration of total ginsenosides after six months in the equity chamber from 
accelerated stability testing 
Species sample   Average sample total ginsenoside concentration (%) 
Aliquot sample analysed  1 2 3 4 5 6 7  
P. quinquefolius   8.66 8.62 8.58 8.65 8.68 8.65 8.63 
P. quinquefolius + vitamin C  7.27 6.91 7.22 7.19 6.92 7.21 7.15 
P. quinquefolius + Epimedium 8.25 8.41 8.41 8.40 8.36 8.47 8.36 
 
 
 
 
Figure 3.74:  Comparison of the changes in the concentration of ginsenosides in pure P. 
quinquefolius powder extract, P. quinquefolius with vitamin C and P. quinquefolius with 
Epimedium with respect to time in months.  
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3.7.2 Panax quinquefolius and its formulated liquid extracts 
P. quinquefolius liquid extract and its formulated liquid extracts were prepared and 
tested for stability of the main constituents.  The results from the tests are presented in 
Table 3.37 below.  Five samples were prepared for each of the following:  P. quinquefolius 
liquid extract and P. quinquefolius with citric acid at a pH of 3.70 liquid extract, and were 
tested once a month for six consecutive months.  These results show that the total 
ginsenoside concentrations are consistent when initially prepare but, by the time the 
second sample was retrieved and tested, the concentration of ginsenosides in the presence 
of citric acid had already decreased by a significant amount and stayed at that concentration 
for the duration of the next six months.  The data is represented again in a line graph 
showing the variability range of the five samples tested, and the average concentration of 
these samples.  The line graph shows that the total ginsenoside concentration does not vary 
as indicated by the straight line, meaning there was no variation between the beginning of 
the six month stability testing until the end of the testing period for the pure P. 
quinquefolius liquid extract, but the ginsenoside concentration of the herb is markedly 
affected in the presence of citric acid where it drops to virtually zero. 
 
Table 3.37: Concentration of total ginsenosides after six months in the equity chamber from 
accelerated stability testing 
Species sample   Average sample total ginsenoside concentration (%) 
Aliquot sample analysed  1 2 3 4 5 6 7 
P. quinquefolius   13.53 13.81 14.33 12.89 14.02 13.58 13.68 
P. quinquefolius + citric acid  12.54 0.25 0.32 0.20 0.19 0.12 0.11 
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Figure 3.75:  Comparison line graph of the changes in the concentration of ginsenosides in 
pure P. quinquefolius liquid extract and P. quinquefolius with citric acid with respect to time 
in months. 
 
   
3.7.3 Accelerated testing of an extract mixture of Rhodiola rosea, Eleutherococcus 
senticosus, Epimedium and Panax quinquefolius  
 
 A mixture of the powdered extracts, R. rosea, E. senticosus, Epimedium species and P. 
quinquefolius, was subjected to accelerated stability testing.  Samples were taken at 
monthly intervals and extracted with methanol before examining the extracts by RRLC.  The 
chromatographs and the data obtained (Table 3.38) show that the active ingredients from 
all four herbs are consistent over time and that there is no interaction between them.  The 
data is also represented in a line graph (Fig. 3.76) showing the variability range of the five 
samples taken and tested, and the average concentration of these samples.  The line graph 
shows that there was no variation in concentration over the time that the experiment was 
conducted, thus, indicating that the concentration of the individual compounds from each 
herb stays unaltered from the start to finish of the six month study.  
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Table 3.38: Concentration of active compounds from R. rosea, E. senticosus, Epimedium and 
Panax species after six months in the equity chamber from accelerated stability testing 
Species sample  Concentration of the active compounds (%) 
Aliquot sample analysed 1 2 3 4 5 6 7 
Rosavins   0.88 0.82 0.83 0.86 0.86 0.88 0.84   
Eleutherosides  0.14 0.15 0.13 0.14 0.13 0.12 0.14 
Ginsenosides   3.55 3.52 3.56 3.53 3.53 3.55 3.54 
Epimedin & icariin  0.36 0.32 0.33 0.35 0.33 0.36 0.35 
 
 
 
 
 
Figure 3.76:  Comparison line graph of the changes in the concentration from accelerated 
testing of rosavins, eleutherosides, ginsenosides, epimedins and icariin in the “energy 
formula” containing R. rosea, E. senticosus, P. quinquefolius and Epimedium species powder 
with respect to time in months. 
 
 
 
3.7.4 Accelerated testing of a liquid extract mixture of Rhodiola rosea, Eleutherococcus 
senticosus, Epimedium and Panax quinquefolius 
 
A mixture of the liquid extracts containing R. rosea, E. senticosus, Epimedium species 
and P. quinquefolius was subjected to accelerated stability testing.  Samples were taken at 
monthly intervals and extracted with methanol before examining the extracts by RRLC.  The 
chromatographs and the data obtained (Table 3.39) show that the active ingredients of all 
four herbs are consistent over time and that there is no interaction between them.  The 
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data is also represented in a line graph (Fig. 3.77) showing the variability range of the five 
samples tested, and the average concentration of these samples.  The line graph shows that 
there was no variation in concentration over the time that the experiment was conducted, 
thus indicating that the concentration of the individual compounds from each herb stays 
unaltered from the start to finish of the six month study.  
 
Table 3.39:  Concentration of active compounds from liquid extracts of R. rosea, E. 
senticosus, Epimedium and Panax species after six months in the equity chamber from 
accelerated stability testing 
Species sample  Concentration of the active compounds (mg/mL) 
Aliquot sample analysed 1 2 3 4 5 6 7 
Rosavins   0.153 0.152 0.154 0.152 0.153 0.154 0.153   
Eleutherosides  0.021 0.021 0.020 0.021 0.021 0.020 0.021 
Ginsenosides   0.794 0.793 0.794 0.794 0.794 0.793 0.793 
Epimedin & icariin  0.073 0.073 0.073 0.072 0.073 0.072 0.073 
 
 
 
 
 
Figure 3.77:  Comparison line graphs of the changes in the concentration of rosavins, 
eleutherosides, ginsenosides, epimedins and icariin with respect to time in months for the 
“energy formula” containing liquid extracts of R. rosea, E. senticosus, P. quinquefolius and 
Epimedium species. 
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3.7.5 Liquid extract mixture of Rhodiola rosea, Eleutherococcus senticosus, Epimedium 
and Panax quinquefolius mixture at pH 3.70 with citric acid 
 
Since the concentration of ginsenosides dropped significantly by the first testing 
point with just P. quinquefolius and citric acid, a closer look at the degradation and 
concentration change in the four herb preparation with citric acid is necessary.  Another 
mixture was similarly prepared but this time the analysis was over a month of the mixture 
solution of Rhodiola rosea, Eleutherococcus senticosus, Epimedium and Panax quinquefolius 
liquid extract.   
Five samples of liquid extract, prepared from a mixture of the herbs R. rosea, E. 
senticosus, Epimedium species and P. quinquefolius was adjusted to pH 3.70 with citric acid 
and tested by accelerated stability.  The results from the tests are presented in Table 3.40 
below.  These show that the active ingredients of R. rosea, E. senticosus, Epimedium species 
remain at a constant level, but the ginsenosides of P. quinquefolius are very unstable.  By 
the third week, the ginsenosides have already degraded by 70%.  The data is also 
represented again in a line graph (Figure 3.78) showing the variability range of the five 
samples of this mixture tested, and the average concentration of these samples.  The line 
graph clearly shows that the stability of the active compounds of R. rosea, E. senitcosus, and 
Epimedium species are unaffected over the three weeks in the stability chamber.  However, 
the total concentration of the ginsenosides of P. quinquefolius is significantly decreased over 
the three week period.  
 
 
 
 
199 
Table 3.40: Concentration of active compounds in liquid extract of Rhodiola rosea, 
Eleutherococus senticosus, Epimedium and Panax quinquefolius adjusted to pH 3.70 with 
citric acid over three weeks in the equity chamber for accelerated stability testing 
Species sample  Concentration of the active compounds (mg/mL) 
Aliquot sample analysed 1  2  3  4  
Rosavins   0.062  0.061  0.062  0.062   
Eleutherosides  0.008  0.009  0.010  0.010  
Ginsenosides   0.370  0.317  0.311  0.111  
Epimedin & icariin  0.033  0.032  0.032  0.033  
 
 
 
 
Figure 3.78:  Comparison line graphs for changes in the concentration of rosavins, 
eleutherosides, ginsenosides, epimedins and icariin in the liquid extract “energy formula” 
containing R. rosea, E. senticosus, P. quinquefolius and Epimedium species adjusted with 
citric acid at a pH of 3.70 with respect to time in weeks. 
 
 
3.7.6 Liquid extract of Rhodiola rosea, Eleutherococcus senticosus, Epimedium and Panax 
quinquefolius at pH 4.00 with vitamin C 
 
Five samples of liquid extract, prepared from a mixture of the herbs R. rosea, E. 
senticosus, Epimedium species and P. quinquefolius liquid extract adjusted to pH 4.00 with 
vitamin C was tested by accelerated stability.  The results from the tests are presented in 
Table 3.41 below.  These show that the active ingredients of R. rosea, E. senticosus, 
Epimedium species remain at a constant level, but the ginsenosides of P. quinquefolius are 
very unstable.  By the third week, the ginsenosides have already degraded by approximately 
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45%.  The data is also represented again in a line graph (Fig. 3.79) showing the variability 
range of the five samples of this mixture tested, and the average concentration of these 
samples.  The line graph clearly shows that the stability of the active compounds of R. rosea, 
E. senticosus and Epimedium species are consistent over the three weeks in the stability 
chamber.  However, the total concentration of the ginsenosides of P. quinquefolius is 
significantly decreased over the three week period, as with the addition of citric acid.   
 
Table 3.41: Concentration of the active compounds in liquid extract of Rhodiola rosea, 
Eleutherococus senticosus, Epimedium and Panax quinquefolius adjusted to pH 4.00 with 
vitamin C over three weeks in the equity chamber for accelerated stability testing 
Species sample  Concentration of the active compounds (mg/mL) 
Aliquot sample analysed 1  2  3  4  
Rosavins   0.089  0.087  0.084  0.086   
Eleutherosides  0.010  0.009  0.009  0.011  
Ginsenosides   0.360  0.340  0.323  0.201 
Epimedin & icariin  0.031  0.033  0.033  0.034  
 
 
 
Figure 3.79:  Comparison line graphs for changes in the concentrations of rosavins, 
eleutherosides, ginsenosides, epimedins and icariin in the liquid extract “energy formula” 
containing R. rosea, E. senticosus, P. quinquefolius and Epimedium species with respect to 
time in weeks with vitamin C at a pH of 4.00. 
 
201 
Chapter 4  Discussion 
The botanical industry is experiencing unprecedented growth worldwide (Ma YC 
2009).  In order for any herb preparation to be considered medicinally effective, it must be 
given at a sufficient dosage level.  According to Traditional Chinese Medicine theory, the 
herb formula and dosage is adjusted depending on the clinical symptoms (Wei et al. 1991).  
This evolution is quite different from the development of synthetic drugs used in orthodox 
medicine.  For therapeutic purposes, the correct plant species is most important, however, 
many herb containing products that are made available to consumers on the market today 
contain misidentified plant species, counterfeit ingredients, insufficient quantity of the 
known active compounds and spiking with marker compounds (Ma YC 2009). 
 According to Health Canada, the FDA, the European Directorate for the Quality of 
Medicines and Healthcare, manufacturers of botanical products have an obligation to 
ensure that the products they sell are genuine, safe and effective.  Adulteration may occur 
accidentally or intentionally, by closely related or completely unrelated species.  To that end, 
the first step in quality control is identification.  Botanical medicinal materials are identified 
by their organoleptic, morphological or microscopic characteristics.  Someone who is 
inexperienced or not sufficiently knowledgeable of the plants in question will not be able to 
make an accurate identification.  Many closely related species may share morphological 
features and even common names, leading to confusion and accidental adulteration.  
Furthermore, most herbs are sold partially – processed, such as dried, cut into pieces, 
shredded or even powdered, such that morphological identification of the plant is no longer 
possible, though microscopic identification may still be employed. 
 In the 1990’s, one or two of the active compounds in a plant were used as marker 
compounds for the purpose of qualitative and quantitative quality control, which led to 
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spiking of low – quality or fraudulent botanical extracts with the marker compounds by 
unscrupulous producers (Ma YC 2009).  With the technological advances of the last 20 years, 
simultaneous analysis for multiple chemical constituents is available.  Thus, many herbs and 
botanical extracts are now analyzed for several marker compounds simultaneously as a 
means of circumventing the spiking issue.  This approach for the analysis is complimented 
by the multiple chemical components of an herb often being present in a consistent ratio to 
one another.  HPLC is commonly used to separate and quantify these constituents, which 
results in a characteristic profile, or fingerprint of the herb or extract. 
 Over the last 20 years, there have been many publications discussing the HPLC 
profile of popular herbs and many pharmacopoeias include HPLC methods and profiles as a 
reference and guide for quality control in the botanical industry.  With advances in 
technology, such as the development of RRLC, gradient elution, multi-wavelength detectors 
and other different types of detectors, analytical methods have become much more 
powerful and at the same time easy to operate.  RRLC offers significant time and cost 
savings over conventional HPLC, due to its shorter run times and concomitant reduced 
solvent usage.  Thus, returning to the example of the three Panax species, the RRLC profiles 
developed in this research programme are complete in only twenty minutes compared to 
more than an hour, but keep the same appearance as the earlier HPLC profiles.  With 
further development, one method has been established in which E. senticosus, R. rosea and 
Epimedium can be quantified in only 7.5, 6.5 and 2.5 minutes, respectively, in comparison to 
the usual time of more than one hour by means of an HPLC analytical system.    
RRLC is able to provide this due its advantages over the conventional HPLC, for example, five 
times more sensitivity, as well 60% more resolution and the analyses are 20 times faster 
compared to conventional HPLC.   It offers unlimited possibilities for automated method 
203 
development, as well as its ability to analyse thousands of samples per day.  As well, 
multiple wavelengths have been introduced, providing great advantage to the method 
developed in this programme for the formulated products.  All four of these herbs have 
different maximum absorbance, with the advantage of applying more than one wavelength 
at a time decreased the analysis time by a factor of four. 
 
4.1 Rhodiola rosea 
 
4.1.1 HPLC profile of phenylpropanoids, phenylethanol and monoterpenoids from R. 
rosea 
 
  The distribution and proportion of the major active compounds in R. rosea as well as 
a commercially popular species, R. crunalta, have been investigated (Chinese 
Pharmacopoeia 2010).  Though R. rosea is unique in that it is the one species that produces 
the rosavins and therefore it has a distinctive HPLC profile (Introduction, Section 1.2),  this 
valuable information can be used in the identification of Rhodiola species in commercial 
Rhodiola containing products, as well as its quality control (Ma YC 2011b). 
  In Chinese medicine, preparations with different pre-treatment processes, 
manufacturing procedures, dosage forms will be of different quality (Wei LX and Ma YC 
1991).  As well, the content of bioactive markers is also affected by plant origins, sources, 
cultivation year, harvest time, geographical climate and environment (Wei LX and Ma YC 
1991).  All of these could result in significant differences in the quality of R. rosea roots.  
However, from the eighteen commercial products containing R. rosea root powder extract 
that were examined (Results Section 3.6.1.1, Table 3.29), the concentration of rosavins 
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(rosarin, rosavin and rosin) was confirmed in twelve of these, of which only five of which 
are authentic R. rosea root samples.   
 
4.1.2 Method development for the analysis of phenylpropanoids, phenylethanol and 
monoterpenoids from R. rosea 
 
  Recently, with the development of rapid resolution liquid chromatography (RRLC), it 
has been possible to obtain more sensitive and baseline separation of the six main 
compounds of R. rosea with much improved faster analysis time.  For the first time, this 
newly designed RRLC is able to perform simultaneous analysis of a variety of classes of 
compounds by using multiple wavelengths which contributes to decreasing the analysis 
time as well as the amount of solvents required for each chromatographic run.  This newly 
developed technique was used for the analysis of rosiridin, as this compound has 
absorption at 270 nm, whereas salidroside, tyrosol, rosarin, rosavin and rosin all have 
maximum absorption at 205 nm.  In this research programme, many attempts have been 
used to establish baseline separation of salidroside, tyrosol, rosarin, rosavin, rosin and 
rosiridin in a single run by using a neutral mobile phase under gradient elution, with double 
wavelength detection with the RRLC system resulting in a significantly shorter retention 
time of 6 minutes.  This successfully developed method uses less solvent, faster analysis 
time with higher resolution compared to many reported methods using the conventional 
HPLC.  For example, one of the most renounced method developed by Dr. Khan uses 25 
mM phosphate buffer (A) adjusted to pH 7.0 and acetonitrile (B) with a gradient of 95 (A): 5 
(B) in 30 mins to 80 (A): 20 (B) (Ganzera et al. 2001).   
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The approach to the analysis of herbs with the RRLC development enables us to 
apply similar ideas and techniques to other herbs for a simultaneous analysis of their major 
active compounds.  The method developed is adequate for the quality control of natural 
health products production and the evaluation of the changes of active compounds caused 
by harvesting season and processing time.  This is illustrated with a batch of fresh R. rosea 
roots which was received and stored at room temperature for 24 hours.  The major active 
compound rosavin was found to have been partially enzymatically hydrolyzed by 
comparison of the chromatogram from this sample with that from dried roots.  Therefore, 
we can conclude that it is extremely crucial to either store fresh R. rosea roots in freezing 
condition, or dry it by rapidly removing moisture from it by heating it at a temperature 
regulated between 30 – 40 °C (Fig 4.1). 
 
 
Figure 4.1:  Chromatographs of R. rosea enzymatically hydrolized fresh root (top) and dried 
R. rosea root (bottom) were analyzed with RRLC under the gradient of 0 mins at 6%  
acetonitrile (B), 6 mins at 17% B, 7 mins at 20% B, 9 mins at 20% B, 10 mins at 100% B and 
11 mins at 6% B using a Phenomenex Luna column (2.5 µm, 100 x 3.0 mm), at 40 °C and 
wavelength settings of 205 nm 0 to 3.7 mins, 254 nm from 3.7 to 4 mins, 205 nm from 4 to 9 
mins 
 
Optimal extraction conditions of the biologically active compounds in R. rosea were 
compared.  Previous work by Ma et al. (2011) showed that refluxing and ultrasonication 
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using MeOH produced comparable extraction yields of rosavins.  In this study, 
ultrasonication was selected for its simplicity and shorter extraction time.  Variables in the 
extraction procedures, such as solvent strength and extraction time were optimized on an 
authentic R. rosea root sample.  Figure 4.2 below shows the extraction yield of rosavins 
increase as the concentration of MeOH in water (v/v) increased from 20% to 75%; further 
increases of MeOH concentration to 100% had a negative effect on rosavins extraction yield.  
Both 15 and 20 mins of ultrasonication resulted in comparable results for rosavins content, 
indicating that 15 mins of ultrasonication was sufficient for extraction of R. rosea roots.  The 
highest extraction effectiveness was achieved with 75% MeOH aq. solution with 15 mins of 
ultrasonication at 37 oC (Fig 4.2). 
 
Figure 4.2: Rosavins yields from R. rosea roots sample H3 using various extraction conditions 
at 37oC. X-axis consists of 5 blocks representing the extraction solvent strength varying from 
20% MeOH aq. solution to pure MeOH; y-axis shows the detected rosavins contents using 
different extraction conditions. Each block has 3 bars representing different ultrasonication 
times varying from 10 to 20 min. 
 
 The quantitative analytical results of R. rosea extracts as mentioned in the results 
section 3.6.1.1 indicates that variations in the content of the marker compounds in 
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commercial R. rosea powder extracts were high, even among the samples collected from 
the same supplier.  Analyses revealed that the characteristic rosavins peaks were not 
detected in about 33.3% of the commercial Rhodiola root powder extract samples that 
claimed to be R. rosea.  As well, the quantification analyses from this research programme 
revealed five out of the eighteen commercial R. rosea powder extracts showed variation 
between the actual rosavins content and the amount claimed by suppliers. 
 
4.2 Eleutherococcus senticosus  
4.2.1 HPLC profile of eleutherosides from E. senticosus 
  There are two main active compounds found in E. senticosus, namely, eleutheroside 
B and E.  E. senticosus, commonly known as Siberian ginseng, belongs to the Araliaceae 
family, just like Panax species, but it has been clarified by scientists that E. senticosus is not 
ginseng (Brekhman 1968).  Panax species possess saponins as its active compounds, 
whereas E. senticosus consists of eleutherosides.  Noted in the USP, the content of 
eleutheroside B and E is not less than 0.8% in E. senticosus powder (USP 2010).  The profile 
of E. senticosus obtained from analysis conducted in this project, for example, a peak ratio 
of eleutheroside B and E of 1:1.5, agree with that stated in the USP with a total analysis 
time of 60 mins.   
  
4.2.2 Method development for the analysis of eleutherosides from E. senticosus 
  Many publications have reported the identification eleutheroside B and E using 
conventional HPLC, and it is recorded in the 2010 edition USP as well using water: 
acetonitrile (95:5) (A): acetonitrile: water (60:40) (B) with a run time of 60 mins (USP 2010).  
In contrast, the RRLC method developed in this research programme is able to obtain 
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baseline separation in less than 7 mins.   Furthermore, under the conditions for the analysis, 
the polarity of eleutheroside B and E is between salidroside, tyrosol, rosarin, rosavin, rosin 
and rosiridin, which allows analysis of the major active compounds from two herbs in a 
single run.  Similar to the R. rosea method, the newly developed method here has 
considerable advantages over the most recently reported method shown in the USP, uses 
less solvent and the analysis time is significantly decreased while keeping the same profile. 
 
4.3 Epimedium species 
4.3.1 HPLC profile of flavonol glycosides in Epimedium species 
  Among the four active compounds, namely, epimedin A, B, C and icariin of 
Epimedium species, results as reflected from this research programme.  The quality criteria 
in the Chinese Pharmacopeia Commission (2010) is that total flavonoid content, calculated 
as icariin, must not be less than 5.0% and icariin content must not be less than 0.5%.  As 
well, the analysis of the results for all Epimedium samples show that epimedins A, B, C and 
icariin are the major compounds, therefore, the total epimedin A, B, C and icariin contents 
are important in evaluation of Epimedium species. 
  As mentioned in the introduction (section 1.3), epimedins A, B, C and icariin with a 
chemical structure of flavonol glycoside with isoprenyl group on carbon 8 contribute to the 
pharmacological activities.  However, to the best of our knowledge, there has been no 
study of the active compounds or metabolites of Epimedium extracts which produce the 
desired effect of alleviating erectile dysfunction, nor have Epimedium extracts or any of the 
components of such extracts been evaluated for PDE-5 activity (Lenoble et al. 2002). 
  In general, the contents of epimedin A, B, C and icariin in Epimedium leaf make up 
more than 50% of its total active compounds (Guo et al. 1996a,b), therefore, criteria can be 
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set up to evaluate the quality of the raw herb for traditional medicinal use and for the 
control of processing, namely, the total amount of epimedins A, B, C and icariin and cannot 
be for icariin content alone. 
  Many previously reported articles show that the epimedin A, B, C and icariin are 
analyzed by HPLC in at least 20 mins (Hong et al. 2009), but the research programme here 
is able to obtain successfully baseline separation within 2.5 mins using the Zorbax Eclipse 
column and 13 mins using the Phenomenex Luna column.  The latter was established 
initially mainly for the purpose of qualitatively and quantitatively analyzing the active 
compounds of both Epimedium and Panax species, but the procedure requiring 2.5 minutes 
is sufficient enough for qualifying both these of Epimedium species.  Due to the polarity of 
the flavonol glycoside, they elute in between the proto-panaxadiol and proto-panaxatriol 
compounds of Panax species, and therefore, after many attempts in this project, the profile 
of both Epimedium and Panax species that match previously reported articles have finally 
been established (Chinese Pharmacopeia Commission 2010, USP 2010). 
 
4.3.2 Method development for the analysis of flavonol glycosides in Epimedium species 
  The Introduction (section 1.3) showed that approximately 260 compounds have 
been isolated and identified from Epimedium species, but the major active compounds 
found in Epimedium species include epimedin A, B, C and icariin (Zhang et al. 2008).  Many 
conventional HPLC methods have been used for the identification of the four active 
compounds of Epimedium, but the mobile phase recommended either contains acetic or 
formic acids and are associated with long analysis time.  The RRLC method described here 
is able to obtain baseline separation for all four compounds using neutral mobile phase 
(acetonitrile and water) and a short analysis time of just 3 mins.  Epimedins A, B, C and 
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icariin have strong maximum wavelength absorption at 270 nm due to the aromatic ring 
but, with ultimate consideration of multi-herb analysis, it was decided that 203 nm is a 
better wavelength to use for the analysis developed here for convenience to match with 
the wavelengths used for Panax species. 
  Many RRLC methods developed in this research program can be extended to provide 
an excellent procedure for the identification and detection of other flavonol glycosides in 
plant extracts.  This technique has advantages, as mentioned before, including shorter 
analysis time, less solvent consumption over other available methods and will generally be 
useful in the separation and quantitative analysis of these naturally occurring plant 
conjugates. 
 
4.4 Panax species 
4.4.1 HPLC profile of ginsenosides in Panax species 
  From the HPLC profiles in USP as well as the results section 3.6.1.4 (Figure 3.67), it 
can be seen that the distribution and proportion of the major ginsenosides found in P. 
quinquefolius, P. ginseng and P. notoginseng roots are different in each species.  As noted 
in the 2010 USP edition (USP 2010) as well as in Ma et al. (1996), for P. ginseng, it 
recommends a determination of the ratio, from the absorbance, for the areas of 
ginsenoside Rb2 and ginsenoside Rb1, which should be more than 0.4.  In contrast, the ratio 
for the same two ginsenosides in P. quinquefolius it states a value that is less than 0.4.  In 
addition, for the latter species, the ratio for Rg1 (protopanaxatriol group) to Rb1 
(protopanaxadiol group) should be less than 0.3 (USP 2010, Ma et al. 1996).  Ginsenosides 
tend to be distributed throughout the Panax plant and occur in roots, stems, leaves and 
flowers (Ma et al. 1995).  The ginenoside profile can effectively identify the different 
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ginseng species and ginseng plant parts.  For example, the roots of P. quinquefolius show a 
Rc/Rb1 ratio < 0.3, while the leaves of this plant have a relatively large concentration of 
ginsenoside Rb3 (Ma et al. 1996, Qu et al. 2009).  Lim et al. (2005) discussed the newly 
discovered P. quinquefolius species from Maryland, USA, which has been highlighted to 
have a high Rg1/low Re ratio. This is in contrast to that stated in the USP (2010) and 
reported for the more extensively investigated type of P. quinquefolius, which has a low 
Rg1/ high Re ratio.  The Rg1/Re ratio between the two types of this species will vary according 
to the place of cultivation.  However, the ratio for protopanaxadiol ginsenosides is 
relatively stable.  Therefore, both the method developed with the Zorbax Eclipse column as 
well as the Phenomenex Luna column is sufficient for the identification and quantification 
of Panax species. 
 
4.4.2 Method development for the analysis of ginsenosides from Panax species 
  Many compounds have been isolated from Panax species, but only eight major 
ginsenosides from the three major Panax species, P. quinquefolius, P. ginseng and P. 
notoginseng are considered to give pharmacological effects, namely; R1, Rg1, Re, Rf, Rb1, Rc, 
Rb2 and Rd (USP 2010).  Many attempts have been made to assay the eight active 
compounds via conventional high performance liquid chromatography (HPLC), mainly in 
reverse – phase mode.  More recently, with the development of rapid resolution liquid 
chromatography (RRLC) it is possible to achieve a more sensitive and faster analysis time 
for the eight compounds.  We have tried to use different ratios of mobile phase for the 
achievement of baseline separation of R1, Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd in a single run by 
using a neutral mobile phase under gradient elution with RRLC in under both 5 and 15 mins 
with the Zorbax Eclipse column and Phenomenex Luna column, respectively.  For 
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comparison, as noted in the 2010 USP, it takes 77 mins in total to simultaneously analyze 
the eight major ginsenosides with a mobile phase of water (A) and acetonitrile:water (8:2) 
at a gradient elution of 0 mins at 76% A, 12 mins at 75% A, 28 mins at 65% A, 51.5 mins at 
56.5% A, 52.5 mins at 0% A, 64.5 mins at 76% A, 77 mins at 76% A. 
 
4.5 Analysis of phenylpropanoids, phenylethanol, monoterpenoids, eleutherosides, 
flavonol glycosides and ginsenosides in R. rosea, E. senticosus, Epimedium and 
ginseng containing products 
 
The method development for the HPLC fingerprinting of formulated or combination 
products represents a breakthrough in the quality control of botanical products.    Individual 
herbs may be analyzed by different methods, using different HPLC columns, solvent 
gradients or detection wavelengths.  Mao et al. (2007), Peng et al. (2009), Yu et al. (2008), 
Tolonen et al. (2003b), Petsalo et al (2006) used HPLC with photodiode array detector, HPLC 
and LC/MS, HPLC, LC/MS respectively, for the analysis of Rhodiola species, all of which takes 
either more than twenty minutes analysis time or uses acidic mobile phase.  The method 
developed in this programme successfully achieved baseline separation within 7.5 minutes 
using a neutral mobile phase.  E. senticosus has been analysed by many authors, such as 
Zgorka and Kawka et al. (2001), Feng et al. (2006), Zhu et al. (2011), as well as USP (2010), 
and in all instances an analysis time of at least 40 minutes to one hour was required.  The 
method developed in this programme successfully achieved a baseline separation within 7 
minutes.  Epimedium has been extensively studied by many, but some of the more recent 
studies recorded in Chinese Pharmacopeia (2010), Xie et al. (2010), Zhao et al. (2008), Ding 
et al. (2011), Wu et al. (2011) completes the analysis in either 85 minutes or uses an acidic 
mobile phase.  Compared to the method developed in this programme, only 3 minutes are 
required to achieve baseline separation with a neutral mobile phase using RRLC.  Panax 
213 
species have been used for more than two thousand years, many studies and methods have 
been applied to its analysis, some of the more recent studies include United States 
Pharmacopeia (2010), Cheng et al. (2011), Toh et al. (2010).  In all of these studies, either a 
long analysis time of 77 minutes or an acidic mobile phase such as formic acid was required.  
The method developed in this programme allowed baseline separation within 18 minutes 
using neutral mobile phases.  The profiles of these four herbs may overlap, hence new 
methods must be developed that will distinguish the profile for each herb, yet still allow for 
analysis within a reasonable time frame.  The complexity of this task necessarily increases 
with the numbers of herbs present in the combination product.  The final methods 
described in this research programme show that the baseline separation was achieved for 
all 20 major active compounds found in R. rosea, E. senticosus, Epimedium and ginseng with 
a retention time of 25 min.  The multiple wavelengths and gradient mobile phase were used 
for this simultaneous analysis of these 20 compounds, it allowed the identification of the 
plant species to be compared by the profile and the peak ratios, which allowed for a more 
efficient analysis.   
 The four herbs used in this research programme, namely, R. rosea, E. senticosus, 
Epimedium and Panax species is used as a Western – style “energy formula”.  The RRLC 
profile for R. rosea, E. senticosus and Epimedium species has a run time ranging from 4 mins 
for Epimedium to 8 mins for R. rosea and E. senticosus.  The analysis of phenylpropanoids, 
phenylethanol, monoterpenoids, eleutherosides, flavonol glycosides and ginsenosides in 
one injection using reverse – phase RRLC were adequate for evaluating the quality of the 
four herbs individually as well as their finished formulated products (Results sections 3.2 – 
3.5) and are considered the most important biological markers of R. rosea, E. senticosus, 
Epimedium and ginseng for quality control purposes.  The combination HPLC profile in a 
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single injection can definitely provide us with information in regards to the plant species, 
the amount of different herb and their proportion in the formulated product.   The HPLC 
profiles obtained from previous reported articles (USP 2010) and the profiles obtained from 
the newly developed RRLC methods of the four herbs are stable and repeatable.  One single 
injection can effectively identify the plant species, the HPLC profile of R. rosea, E. senticosus, 
Epimedium and Panax species that are used for the formulated products, clearly show the 
unique fingerprint of each herb, and the quantification of more than 20 compounds in only 
22 mins in a single run.  This establishment of constituent profiles and quality evaluation 
criteria for R. rosea, E. senticosus, Epimedium and Panax species and their formulated 
products will help the industry to produce consistent and high quality products, and will 
support research scientists to evaluate their pharmacological activities and clinical efficacy 
accurately and properly.  The analysis of this formulated commercial product also indicated 
that the constituents in these herbs do not influence the analysis of the 20 active 
compounds. 
The industry standard is the current standard, with Health Canada, the FDA and 
many other natural health product regulatory affairs departments involved, which can and 
will change and improve according to market demands.  It is crucial to establish an RRLC 
profile not only to differentiate one species from other species, but also to evaluate and 
control the quality of commercial products and the industry must take the lead and set the 
benchmark for the quality control of botanical extracts and traditional Chinese medicine, to 
counteract the erroneous belief that herbal medicines are unregulated, untested and 
ineffective.  Combining the application, reliable and practical complementary techniques of 
chemical profiling for the quality control of herbal products from raw herb to extract to 
finished product will assure delivery of high - quality, safe and efficacious products to the 
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market.  Furthermore, establishing a consistent quality of botanical products will enable 
robust pharmacological and clinical investigations into the action and efficacy of herbal 
materials. 
 Reliable analytical methods are needed to supplement organoleptic identification of 
botanical medicinal materials.  Chemical profiling using TLC and HPLC is common and such 
profiles are documented in herbal monographs found in sources such as USP (2010), 
Chinese pharmacopeia (2010) and many other similar literature sources.  However, it must 
be considered that the chemical profile of an herb may vary due to factors such as growing 
stage, plant part, geography and post – harvest processing and storage (Wei and Ma 1991). 
The challenges today for the quality control of formulated botanical products in the 
market is for effective methodological development of the simultaneous quantification of 
multi-chemical constituents.  This research work is a breakthrough in today’s 
pharmaceutical market, promoting stricter rules for safety and efficacy. 
 
4.6 Stability testing of single and formulated products containing R. rosea, E. 
senticosus, Epimedium and Panax species 
 
Stability testing for R. rosea, E. senticosus, Epimedium and Panax species containing 
products are analysed using the developed HPLC methods mentioned in this research 
programme (method 2.2.12).  After six months of accelerated stability testing for a few 
products, it has been determined that the majority of the active ingredients found from 
these four herbs are consistent, with the exception of ginsenosides.  Under acidic conditions, 
ginsenosides undergo hydrolysis, causing degradation of all of the major ginsenosides found 
in all Panax containing formulated products.  This degradation happens considerably fast; 
within one week of storage in the stability chamber there was a noticeable amount of 
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degradation, therefore, drinks on the market containing Panax species under acidic 
conditions are for taste purposes. 
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Chapter 5 Conclusion 
Currently, Health Canada, the FDA, the European Directorate for the Quality of 
Medicines and Healthcare and many other natural health product agencies have set strict 
regulations for the management of natural health products.  As the botanical industry grows 
unprecedentedly, the demand for management and quality is a necessity.  For example, 
many herb containing products that are made available to consumers on the market today 
contain misidentified plant species either accidentally or intentionally with either closely 
related or completely unrelated species, counterfeit ingredients, insufficient quantity of the 
known active compounds and spiking with marker compounds.  Spiking of natural health 
products or herbs is a practice that can disguise substandard herbs where only one of two 
active compounds are used for the identification, and qualitative and quantitative control of 
the herb or product.  Now, instead of reliance on only one or two active compounds, 
multiple active compounds are analysed simultaneously to prevent spiking.  This is easily 
monitored by examination of the HPLC profiles of the extract of the herb/formulation with 
that of the popular herbs.  Many research articles and pharmacopoeias have started 
publishing profiles as a reference of tightening the quality control in the botanical industry.   
The liquid chromatography herb profiles of the four herbs included in this research 
programme are Rhodiola rosea, Eleutherococcus senticosus, Epimedium and Panax species.  
The RRLC technique offers significant reduction in time and cost for analysis of extracts over 
the conventional HPLC.  For instance, the time required for separation of the extract from 
the Panaxspecies is halved, but also providing the same separation profile as for the 
reported HPLC profiles for each of the herbs, while for E. senticosus, R. rosea and 
Epimedium the sample runs can be quantified in only 7.5, 6.5 and 2.5 mins, respectively.   
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 The four herbs used in this research program, namely, R. rosea, E. senticosus, 
Epimedium and Panax species, are widely utilised together as a Western – style “energy 
formula”.  Consequently, it contains a combination of the following classes of active natural 
product compounds, phenylpropanoids, phenylethanol, monoterpenoids, eleutherosides, 
flavonol glycosides and ginsenosides.  With one injection with reverse – phase RRLC, it has 
been demonstrated in this programme that it is possible to evaluate not just the quality of 
the four herbs individually, but as well as their combined finished formulated products 
which in addition have similar HPLC profiles to previously reported methods.  Therefore, 
one single injection can effectively identify the plant species, even when present in a 
formulated product and as well, in this program, more than 20 compounds were analysed in 
only 22 mins in a single run.  This idea will lead the natural health product industry on a new 
path to produce consistent and high quality products which are of a reliable and high 
standard to match more closely with those used in conventional medicines.   
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An RRLCmethod capable of simultaneous identiﬁcation and rapid quantiﬁcation of six biologically active
compounds (salidroside, tyrosol, rosarin, rosavin, rosin, rosiridin) in Rhodiola rosea L. and two active
compounds (eleutheroside B and eleutheroside E) in Eleutherococcus senticosus Maxim. was developed.
The chromatographic analyses were performed on a reversed phase Phenomenex C18 (2)-HST column
at 40 ◦C with a neutral mobile phase (puriﬁed water and acetonitrile) gradient system at a ﬂow rateeywords:
hodiola rosea L.
leutherococcus senticosus
apid resolution liquid chromatography
RRLC)
olyherbal formulation
of 1.0ml/min and UV detection at 205 and 220nm simultaneously. Baseline separation of eight active
compoundswas achievedwithin 8min. This developedmethod provides good linearity (R>0.9997), pre-
cision (RSD<1.99%) and recovery of the bioactive compounds. The RRLC method developed is capable of
controlling the quality of R. rosea and E. senticosus raw herbs, commercial extracts, as well as polyherbal
formulations containing R. rosea and E. senticosus as ingredients. This RRLC method is accurate and sen-
sitive; in addition, it greatly increases sample analysis throughput with reduced analysis time, which is
ty consuitable for routine quali
. Introduction
Adaptogens are natural bio-regulators that increase the abil-
ty of an organism to adapt to environmental factors and to avoid
amage from such factors; example of these are Eleutherococcus
enticosus Maxim. and Rhodiola rosea L. [1]. A number of studies
ave demonstrated the efﬁcacy of these adaptogens in stress-
nduced disorders of central nervous, cardiovascular and immune
ystems, and they have been used as adjuvants to other medicines
o enhance curative effects in conditions such as, chronic pneumo-
ia, chronic tuberculosis, vascular dystonia, cancer (reduction of
etastasis), and in reducing the debilitating effects of radiotherapy
nd chemotherapy [2].Please cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcatio
rococcus senticosusMaxim. using rapid resolution liquid chromatography (R
R. rosea has been categorized as an adaptogen by Russian
esearchers due to its observed ability to increase resistance to
variety of chemical, biological, and physical stressors [3,4].
he pharmacological effects of R. rosea have been studied
∗ Corresponding author at: Canadian Phytopharmaceuticals Corp., 12233 River-
ide Way, Richmond, BC V6W 1K8, Canada. Tel.: +1 604 3037782;
ax: +1 604 3037726.
E-mail address: jiem0121@gmail.com (J. Ma).
731-7085/$ – see front matter © 2011 Published by Elsevier B.V.
oi:10.1016/j.jpba.2011.03.013trol analysis.
© 2011 Published by Elsevier B.V.
extensively, including the CNS stimulating, neuro-, cardio- and
hepato-protective effects, life-span increasing, MAO-A inhibitory,
immunotropic, antiviral, anti-inﬂammatory and antibacterial
activity [5]. E. senticosus grows in abundance in northeastern China,
particularly in theHeilongjiang province, aswell as InnerMongolia,
North Korea, and Siberia [6]. It is adaptogenic and an effective,
anti-aging medicinal herb [7]. In addition, E. senticosus regulates
endocrine secretions, adrenal cortex, and blood sugar levels [7].
Phytochemical investigations show that there are three impor-
tant classes of bioactive constituents in R. rosea: phenylethanoids
(salidroside, p-tyrosol), phenylpropanoid glycosides (rosarin,
rosavin, rosin), andmonoterpene (rosiridin) that are responsible for
the bioactivity of R. rosea [8]. Characteristic feature of R. rosea is the
presence of phenylpropanoids rosavin, which was not detected in
21 other genus Rhodiola species morphologically similar to R. rosea
[9,10]. On the market, the term rosavins refers to three phenyl-
propanoid glycosides: rosavin, rosin and rosarin [11,12]. In present
days, commercialR. rosea extracts are standardized for the contentsn of polyherbal formulations containing Rhodiola rosea L. and Eleuthe-
RLC), J. Pharm. Biomed. Anal. (2011), doi:10.1016/j.jpba.2011.03.013
of both salidroside and rosavins. Besides this, rosiridin is contained
in R. rosea in an amount of about 3% and should also be considered
as a marker compound [13].
Isolation and structural studies on several diterpenoids [14],
triterpenoid saponins [15], and phenolic components [16] from
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leutherococcus species have been reported previously. Among
hese, the lignan compounds, eleutheroside B (syringin) and
leutheroside E ((−) syringaresinol-di-O-13-Dglucoside) havebeen
dentiﬁed as the key bioactive compounds for E. senticosus.
Literature survey reveals that a variety of methods have
een reported to analyze the active constituents in R. rosea
sing analytical methods including capillary zone electrophoresis
17–19], liquid chromatography (LC) coupled with UV [8,12,20,21]
r MS [21–23]. All of the listed methods suffer from longer
nalysis time of over 30min and subsequently much solvent
onsumption. For E. senticosus analysis, several methods have
een reported to analyze the bioactive active compounds, such
s thin-layer chromatography-densitometry [24], HPLC [25]. An
PLC analysis method for E. senticosus was provided in USP
26] using H2O and acetonitrile as mobile phase; however, this
ethod takes longer than 30min to complete. With the objec-
ive of reducing analysis time and maintaining good efﬁciency,
here has been substantial focus on high-speed chromatographic
eparations.
RRLC is a relativelynewtechniquegivingnewpossibilities in liq-
id chromatography, especially concerning decrease of time and
olvent consumption. A study conducted by Guillarme et al. has
hown that rapid resolution technology is capable of obtaining very
igh resolution in both isocratic and gradient modes for a wide
ange of compounds from molecular weight 160–1000gmol−1
27]. As efﬁciency and speed of analysis has become of a great
mportance in many application of liquid chromatography, espe-
ially in the ﬁeld of pharmaceutical analysis, where it is important
o increase throughput and reduce analysis costs, RRLC could play
signiﬁcant role in the future of liquid chromatography. Therefore,
n effective and reliable method, which is capable of analyzing the
ajor bioactive compounds in R. rosea and E. senticosus to ensure
ts quality and efﬁcacy, is necessary for qualitative and quantitative
nalysis of polyherbal formulations.
In today’s natural health products market, polyherbal formu-
ations that contain two or more herbal ingredients are very
opular because of the joint contributions of multi-components.
n this study, we have established an RRLC method to examine
he contents of the active compounds, i.e. salidroside, tyrosol,
osarin, rosavin, rosin, rosiridin, eleutheroside B and eleuthero-
ide E simultaneously in R. rosea and E. senticosus. A back pressure
f 420bar was observed during analyses and hence an RRLC
ystem, which is capable of running up to 600bar is neces-
ary. This method is intended not only to evaluate the quality
f R. rosea and E. senticosus raw materials, but also be efﬁ-
ient in the quality control of commercial polyherbal formulated
roducts.
. Materials and methods
.1. Chemicals and materials
The reference standards of salidroside (purity: 98.3%), tyrosol
purity: 98.1%), rosarin (purity: 98.6%), rosavin (purity: 99.2%), and
osin (purity: 98.1%) were purchased from ChromaDex (Irvine,
SA); eleutheroside B (purity: 99.6%), eleutheroside E (purity:
9.1%) and rosiridin were purchased from Biopurify (Chengdu,
hina), where rosiridin reference standard was used for identiﬁ-
ation purpose only. Four samples of dried R. rosea roots (H1, H2,
3 and H4) were provided by Alberta Agriculture Canada and a
upplier in Shanxi province, China; one fresh R. rosea root sam-Please cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcatio
rococcus senticosusMaxim. using rapid resolution liquid chromatography (R
le (H5) was provided by a Canadian supplier. Twelve commercial
hodiola extracts samples (P1-Lot1, P2-Lot1, P2-Lot2, P3-Lot1, P3-
ot2, P4-Lot1, P5-Lot1, P5-Lot2, P5-Lot3, P5-Lot4, P5-Lot5, P5-Lot6)
nd 5 commercial E. senticosus powder extracts samples (E1, E2,
3, E4 and E5) were collected from 8 suppliers in China. Seven PRESS
Biomedical Analysis xxx (2011) xxx–xxx
other Rhodiola commercial extracts samples (P6-Lot1, P6-Lot2, P6-
Lot3, P7-Lot1, P7-Lot2, P8-Lot1 and P8-Lot2) were provided by
three Canadian suppliers. Six commercial polyherbal formulated
capsules (RE1, RE2, RE3, RE4, RE5 and RE6) containing R. rosea
and E. senticosus ingredients were purchased from a local drug
store.
CH3CN and methanol (MeOH) was of HPLC grade (Fisher Scien-
tiﬁc, Ottawa, Canada). Deionized H2O was puriﬁed by a Nanopure
Ultrapure water system (Barnstead, USA) for all solutions and dilu-
tions.
2.2. Preparation of standard solutions and samples
The stock reference standard solution of salidroside, tyrosol,
rosarin, rosavin, and rosin were prepared at concentration of
1.0mg/ml in pure methanol (MeOH), stock solution of eleuthero-
side B and eleutheroside E were prepared at 0.1mg/ml in pure
MeOH.Reference standard rosiridinwasused for identiﬁcationpur-
pose only. The mixture of the reference compounds stock solution
was also prepared. All the reference standard solutionswere stored
at 4 ◦C in a refrigerator. The reference standards in solution were
stable at least for 24h at room temperature.
Dried R. rosea roots, commercial R. rosea extracts, E. senticosus
extracts and commercial polyherbal formulated capsuleswere kept
in the desiccator. Fresh R. rosea roots were stored in a freezer at
−10 ◦C and dried in an oven at 50 ◦C for 24h before analysis. About
5g of dried R. rosea roots were ground into ﬁne powder and 0.1 g
were accurately weighed and transferred into a 10ml volumetric
ﬂask, ultrasonic extracted at 37 ◦C with 75% MeOH aq. solution for
15min and then made up to volume. For Rhodiola and E. sentico-
sus extracts, the same procedures were followed except using pure
MeOH as extraction solvent for efﬁciency. Prior to RRLC analysis all
samples were ﬁltered through a 0.20m membrane ﬁlter. Every
sample was injected in triplicates and the relative standard devia-
tion (RSD) was calculated for all the samples. For the commercial
polyherbal formulated capsules, the contents of 20 capsules were
transferred to a ﬂask and 0.10g of capsule powder was accurately
weighed into a 10ml volumetric ﬂask andultrasonic extractedwith
pure MeOH as stated above.
2.3. Chromatography conditions
Analysis was carried out using an Agilent series 1200 RRLC
instrument (Agilent, CA, US) equipped with a binary pump, a
micro vacuum degasser, a multi-wavelength (MW) detector, an
autosampler, and a thermostated column. Optimum resolution and
peak shape were obtained on a Luna C18-HST (High Speed Tech-
nology) column (2.5m, 100mm×3.0mm) from Phenomenex
(Torrance, CA, U.S.A.). The mobile phase consisted of puriﬁed
water (H2O) (A) and acetonitrile (CH3CN) (B). At a ﬂow rate of
1.0ml/min, the linear gradient was as follows: 0–6min, 6–17% B;
6–7min, 17–19.7% B; 7–9min, 19.7–19.7% B, 9–10min, 19.7–100%
B. The detection wavelength varies as follows: 0–3.5min, 205nm;
3.5–6.5min, 220nm; 6.5–8min, 205nm. The column temperature
was 40 ◦C and the injection volume was 1l. Each run was fol-
lowed by a 2min post run and an equilibration period for 5min.
The injection volume was 1l for all analysis. Data acquisition
and processing were performed by ChemStation revision B.01.01
software.
3. Results and discussionn of polyherbal formulations containing Rhodiola rosea L. and Eleuthe-
RLC), J. Pharm. Biomed. Anal. (2011), doi:10.1016/j.jpba.2011.03.013
3.1. Method development
Basic chromatographic conditions, such as, mobile phase
composition, elution gradients, column temperature andUVdetec-
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tig. 1. Chemical structures of six bioactive compounds in Rhodiola rosea roots: (1)
ompounds in Eleutherococcus senticosus (3) eleutheroside B, (4) eleutheroside E.
ion wavelength were optimized while developing the RRLC
ethod. In conventional HPLC, it is a common practice to add
onization suppressants, such as phosphoric acid (H3PO4) and
ormic acid (HCO2H) to mobile phases to improve chromato-
raphic separations. In this study, various mobile phases including
2O–methanol (MeOH), 0.05% (v/v) H3PO4 solution–MeOH,
2O–acetonitrile (CH3CN), 0.1% HCO2H solution–CH3CN, and
.05% H3PO4 solution–CH3CN, were evaluated and compared.
H3CN was chosen over MeOH for its ability to reduce back-
ressure and achieve better separation. Ionization suppressants
id not improve the peak shape and resolution of the six
ctive compounds, hence H2O–CH3CN was selected as the mobile
hase.
Selecting a proper detection wavelength is vital to ensure the
ctive compounds are detected precisely. The active compounds
, 2, 5, 6, 7 and 8 in R. rosea had characteristic absorption atPlease cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcatio
rococcus senticosusMaxim. using rapid resolution liquid chromatography (R
05nm; active compounds 3 and 4 in E. senticosus had maximum
bsorption at 220nm. For the quality control of commercial poly-
erbal formulated capsules, detection wavelength was selected as
05nm (0–3.5min), 220nm (3.5–6.5min), and 205nm (6.5–8min)
o simultaneously analyze all bioactive compounds in polyherbaloside, (2) tyrosol, (5) rosarin, (6) rosavin, (7) rosin, (8) rosiridin and two bioactive
formulations containing R. rosea and E. senticosus (Fig. 1).
3.2. Optimization of extraction conditions
Prior to sample analysis, the optimal extraction conditions of
the biologically active compounds in R. rosea roots were examined.
Previous work by Ma et al. [8] showed that reﬂuxing and ultra-
sonication using MeOH produced comparable extraction yields of
rosavins. In this study, ultrasonication was selected for its sim-
plicity and shorter extraction time. Variables in the extraction
procedures, such as solvent strength and extraction timewere opti-
mized on an authentic R. rosea root sample (H3). As shown in Fig. 2,
the extraction yield of rosavins increased as the concentration of
MeOH in H2O (v/v) increased from 20 to 75%; further increases
of MeOH concentration to 100% had a negative effect on rosavinsn of polyherbal formulations containing Rhodiola rosea L. and Eleuthe-
RLC), J. Pharm. Biomed. Anal. (2011), doi:10.1016/j.jpba.2011.03.013
extractionyield. Fig. 2 shows thatboth15and20minofultrasonica-
tion resulted in comparable results for rosavins content, indicating
15min of ultrasonication was sufﬁcient for R. rosea root extraction.
The highest extraction effectiveness of R. rosea roots was achieved
with 75%MeOHaq. solutionwith 15min of ultrasonication at 37 ◦C.
ARTICLE IN PRESSGModelPBA-8088; No.of Pages8
4 Y.-C. Ma et al. / Journal of Pharmaceutical and Biomedical Analysis xxx (2011) xxx–xxx
Table 1
Calibration curves, limit of detection (LOD), limit of quantiﬁcation (LOQ) (n=3) and recovery data (n=3) for seven reference compounds: salidroside, tyrosol, rosarin, rosavin,
rosin, eleutheroside B and eleutheroside E in Rhodiola rosea and Eleutherococcus senticosus.
Compounds Salidroside Tyrosol Rosarin Rosavin Rosin Eleutheroside B Eleutheroside E
Regression equation y=351.24X−0.97 y=864.60X−0.61 y=725.16X+0.87 y=1081.57X+1.95 y=953.07X+1.10 y=1400.21X+1.10 y=953.07X+1.10
R 0.9997 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
LOD (g/ml) (n=3) 0.36 0.85 0.52 0.69 0.65 0.19 0.25
RSD% 0.14 0.36 0.24 0.09 0.23 0.13 0.19
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rLOQ (g/ml) (n=3) 0.86 1.78 1.14
RSD% 0.19 0.42 0.31
Recovery % (n=3) 99.6 100.3 98.9
RSD% 1.12 1.15 1.23
.3. Method validation
.3.1. Calibration, sensitivity, linearity, and accuracy
The quantitative method was assessed by linearity, sensitivity,
nd accuracy. Calibration curves were prepared by plotting the
eak area of marker compounds against the corresponding con-
entrations. The regression lines are linear in the concentration
ange studied and the corresponding coefﬁcients of correlation are
hown in Table 1. Peaks were assigned by spiking the samples
ith standard compounds, and comparing of the UV spectra and
etention time. Good linear relationships (R=0.9997 for salidro-
ide, and 0.9999 for tyrosol, rosarin, rosavin, rosin, eleutheroside B
nd E) are demonstrated over a range of 50–800g/mL. The mean
egression equations for the sevenmarker compounds are listed in
able 1. Fig. 5A shows the separation of mixed marker compounds
1) salidroside, (2) tyrosol, (3) eleutheroside B, (4) eleutheroside E,
5) rosarin, (6) rosavin, (7) rosin and (8) rosiridin.
Limits of detection (LOD) and quantiﬁcation (LOQ) under the
resent chromatographic conditions were determined on the basis
f response and slope of each regression equation at a signal to
oise ratio (S/N) of 3 and 10, respectively. The LOD for the seven
arker compounds ranged from 0.19 to 0.85g/ml (n=3, RSD
anged from 0.09 to 0.24%); the corresponding LOQ ranged from
.55 to 1.78g/ml (n=3, RSD ranged from 0.14 to 0.42%).
The accuracy of the analytical method was evaluated using the
ecovery test. The recovery tests of this method were studied by
piking a known quantity of the references to 0.1 g of the R. rosea
amples and E. senticosus samples. The fortiﬁed samples were thenPlease cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcatio
rococcus senticosusMaxim. using rapid resolution liquid chromatography (R
xtracted and quantiﬁed as described before. Each samplewas ana-
yzed in triplicate. The recovery valueswere obtainedby comparing
he results from samples and fortiﬁed samples. The mean recov-
ries are from 98.9 to 100.9% with RSD less than 1.42% for seven
eference compounds.
ig. 2. Rosavins yields from R. rosea roots sample H3 using various extraction con-
itions at 37 ◦C. x-Axis consists of ﬁve blocks representing the extraction solvent
trength varying from20%MeOHaq. solution to pureMeOH; y-axis shows the tested
osavins contents using different extraction conditions. Each block has three bars
epresenting different ultrasonication times varying from 10 to 20min..59 1.62 0.55 0.71
.14 0.30 0.15 0.19
00.9 99.5 100.5 99.7
.01 1.42 1.11 0.98
3.3.2. Precision, tailing factors, and resolution
The precision of the assay was determined by repeatability
(intra-day) and intermediate precision (inter-day). Repeatability
was evaluated by testing a commercial polyherbal formulated
capsules RE-1 at the same condition during the same day. The
intermediate precision was studied by analyzing and comparing
the assays on each of the 3 successive days. As shown in Table 2,
the intra-day and inter-day RSD of retention time ranged from 0.04
to 0.92% and 0.18–1.98%, respectively. The intra-day and inter-day
RSD of peak area ranged from0.34 to 1.91% and 0.71–1.99%, respec-
tively. The results show that the variance for both retention time
and peak area for triplicate injections of the same sample analyzed
on 3 successive days tended to be higher than the variance for a sin-
gle day. The tailing factor of 7 reference compounds ranged from
1.01 to 1.07; the resolution ranged from 1.57 to 3.66.
3.4. Sample analysis
Four samples of dried and one sample of fresh Rhodiola roots,
as well as 18 batches of commercial R. rosea roots extracts and
5 batches of commercial E. senticosus extracts were tested. Six
batches of commercial polyherbal formulated capsules were also
tested for the contents of seven active compounds. All investigated
compounds were identiﬁed by comparing the retention times of
the peaks with those of the reference compounds eluted in parallel
under the same conditions and spiking the sample with stock stan-
dard solutions of the reference compounds further conﬁrmed the
identities of the peaks.
3.4.1. R. rosea roots and extract testing
Five samples of Rhodiola roots and 18 batches of Rhodiola com-
mercial extract have been analyzed by the described method.
Fig. 3A–C show the characteristic RRLC chromatogram of authentic
R. rosea dried roots (H3), fresh roots (H5), and commercial extract
(P5-Lot3), respectively. The optimum extraction and RRLC analysis
method were applied to 18 samples of commercial R. rosea roots
extracts collected from 8 suppliers to calculate and compare the
contents of the 5 marker compounds.
Table 3 shows that 6 out of 18 (33.3%) commercial Rhodiola
extracts namely, P1-Lot1, P3-Lot1, P6-Lot1, P6-Lot2, P8-Lot1, and
P8-Lot2 are not R. rosea species as claimed by suppliers since the
marker compounds of R. rosea species: rosarin, rosavin, and rosin
were not detected in these samples. Five out of 18 (27.8%) commer-
cial R. rosea extracts namely, P3-Lot2, P4-Lot1, P5-Lot2, P7-Lot1,
and P7-Lot2 did not meet the claimed bioactive compounds’ con-
tents standards. Speciﬁcally, in these ﬁve samples, two samples
(P4-Lot1and P7-Lot2) contained lower salidroside content than the
claimedone; three samples (P3-Lot2, P5-Lot2, and P7-Lot1) containn of polyherbal formulations containing Rhodiola rosea L. and Eleuthe-
RLC), J. Pharm. Biomed. Anal. (2011), doi:10.1016/j.jpba.2011.03.013
lower rosavin or rosavins content.
3.4.2. E. senticosus extract testing
Table 4 summarizes the contents of eleutheroside B and
eleutheroside E in ﬁve samples of commercial E. senticosus extracts.
Please cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcation of polyherbal formulations containing Rhodiola rosea L. and Eleuthe-
rococcus senticosusMaxim. using rapid resolution liquid chromatography (RRLC), J. Pharm. Biomed. Anal. (2011), doi:10.1016/j.jpba.2011.03.013
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Table 2
Precision, tailing factor and resolution (n=3).
Retention
time (min)
Peak area Tailing factor Resolutiona
Salidroside
Intra-day Mean 2.37 41.58 1.07 1.57
RSD (%) 0.29% 0.34% 0.14% 0.71%
Inter-day Mean 2.39 52.36 1.07 1.57
RSD (%) 1.54% 1.06% 0.15% 0.84%
Tyrosol
Intra-day Mean 2.88 15.23 1.02 1.84
RSD (%) 0.92% 1.56% 0.46% 0.65%
Inter-day Mean 2.89 15.54 1.02 1.84
RSD (%) 1.13% 1.89% 041% 0.93%
Rosarin
Intra-day Mean 6.79 26.41 1.01 2.41
RSD (%) 0.48% 0.96% 0.05% 1.12%
Inter-day Mean 6.82 26.87 1.02 2.40
RSD (%) 0.95% 1.14% 0.14% 1.27%
Rosavin
Intra-day Mean 7.01 54.46 1.03 2.41
RSD (%) 0.27% 0.65% 0.84% 1.12%
Inter-day Mean 7.04 54.11 1.03 2.40
RSD (%) 1.98% 0.71% 1.21% 1.27%
Rosin
Intra-day Mean 7.37 17.12 1.05 1.97
RSD (%) 0.04% 0.81% 0.86% 0.93%
Inter-day Mean 7.37 17.93 1.05 1.98
RSD (%) 0.63% 1.25% 1.78% 1.24%
Eleutheroside B
Intra-day Mean 3.38 37.16 1.03 1.78
RSD (%) 0.07% 1.91% 0.47% 1.01%
Inter-day Mean 3.39 37.62 1.03 1.78
RSD (%) 0.18% 1.99% 0.65% 1.39%
Eleutheroside E
Intra-day Mean 6.45 38.62 1.04 3.66
RSD (%) 0.14% 1.42% 0.81% 0.87%
Inter-day Mean 6.44 38.45 1.04 3.67
RSD (%) 0.27% 1.96% 1.31% 1.29%
a Resolution is calculated using the most adjacent peak.
Table 3
The contents of 6 marker compounds: salidroside, tyrosol, rosarin, rosavin, rosin, rosavins in 18 claimed R. rosea roots extracts collected from 8 suppliers (n=3).
Sample Claim (mg/g) Contents (mg/g)
Salidroside Tyrosol Rosarin Rosavin Rosin Rosavins
P1-Lot1 Salidroside: 0 10.1 ± 0.01 NDa ND ND ND ND
P2-Lot1 Rosavins: 30 40.9 ± 0.02 4.65±0.01 7.12±0.02 19.64±0.01 5.75±0.01 32.51±0.04
P3-Lot1 Salidroside: 30 30.18 ± 0.01 5.14±0.02 ND ND ND ND
P3-Lot2 Rosavins: 30 36.5 ± 0.02 2.49±0.01 6.84±0.01 15.7±0.01 5.67±0.01 28.21±0.03
P4-Lot1 Salidroside: 10 2.97 ± 0.01 0.52±0.005 1.28±0.01 2.48±0.01 0.68±0.006 4.44±0.026
P5-Lot1 Salidroside: 30 42.9 ± 0.02 2.27±0.01 2.72±0.01 5.32±0.007 1.47±0.005 9.51±0.022
P5-Lot2 Rosavin: 30 36.55 ± 0.02 2.64±0.01 9.39±0.03 26.2±0.02 6.32±0.01 41.91±0.06
P5-Lot3 Salidroside: 0; Rosavins: 30 22.35 ± 0.02 1.81±0.01 6.39±0.01 20.68±0.01 4.41±0.01 31.48±0.03
P5-Lot4 Rosavins: 30 21.56 ± 0.01 1.84±0.01 6.86±0.01 20.15±0.02 4.68±0.01 31.69±0.04
P5-Lot5 Salidroside:100 132 ± 0.04 9.35±0.02 2.33±0.01 3.22±0.006 1.86±0.004 7.41±0.02
P5-Lot6 Salidroside: 30 36 ± 0.02 2.42±0.01 9.32±0.01 27.12±0.03 6.31±0.01 42.75±0.05
P6-Lot1 Salidroside: 30 31.59 ± 0.01 2.83±0.01 ND ND ND ND
P6-Lot2 Salidroside: 20 32.3 ± 0.01 2.83±0.01 ND ND ND ND
P6-Lot3 Salidroside: 10 17.4 ± 0.01 1.39±0.01 3.52±0.01 6.02±0.01 2.94±0.006 12.48±0.026
P7-Lot1 Rosavin: 30 27.73 ± 0.01 4.16±0.01 10.86±0.01 26.1±0.02 6.59±0.01 43.55±0.04
P7-Lot2 Salidroside: 30 15.1 ± 0.01 2.22±0.01 0.09±0.001 0.333±0.002 0.08±0.001 0.5±0.004
P8-Lot1 Salidroside: 10 16.3 ± 0.01 2.12±0.01 ND ND ND ND
P8-Lot2 Salidroside: 30 46.36 ± 0.02 4.71±0.01 ND ND ND ND
a Not detected.
Table 4
The contents of two marker compounds: eleutheroside B and eleutheroside E in ﬁve commercial E. senticosus extracts (n=3).
Sample Claim (mg/g) Eleutheroside B
(mg/g)
Eleutheroside E
(mg/g)
Total eeutherosides
(mg/g)
E1 Total eleutherosides≥8 2.2 ± 0.01 6.2 ± 0.01 8.4 ± 0.02
E2 Total eleutherosides≥8 2.4 ± 0.01 6.8 ± 0.01 9.2 ± 0.02
E3 Total eleutherosides≥8 3.1 ± 0.02 8.7 ± 0.02 11.8 ± 0.04
E4 Total eleutherosides≥8 2.5 ± 0.01 6.9 ± 0.01 9.4 ± 0.02
E5 Total eleutherosides≥8 2.1 ± 0.01 5.9 ± 0.01 8.0 ± 0.02
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sFig. 3. RRLC chromatograms of (A) dried R. rosea roots (H3), (B
he ﬁve samples claim not less than 8mg/g of total eleutherosides
ontent and the results are satisfactory. A typical RRLC chro-
atogram of E. senticosus extract (E1) is shown in Fig. 4.
.4.3. Results of commercial polyherbal formulated productsPlease cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcatio
rococcus senticosusMaxim. using rapid resolution liquid chromatography (R
esting
The RRLC method developed was successfully applied to simul-
aneous determination of the eight marker compounds in six
amples of commercial polyherbal formulated capsules. Fig. 5
hows the RRLC proﬁle of (A) mixed marker compounds reference
Fig. 4. RRLC chromatogram of a commR. rosea roots (H5), (C) commercial R. rosea extract (P5-Lot3).
standards and (B) commercial polyherbal formulated capsule RE-2
(Table 5).
Although the commercial polyherbal formulated capsules RE-1,
RE-2, RE-03, RE-4, RE-5 and RE-6 all contain R. rosea and E. sentico-
sus ingredients, they show considerable variations in the contentsn of polyherbal formulations containing Rhodiola rosea L. and Eleuthe-
RLC), J. Pharm. Biomed. Anal. (2011), doi:10.1016/j.jpba.2011.03.013
of rosavins and total eleutherosides. The contents of rosavins and
total eleutherosides B and E detected in RE-1, RE-5 and RE-6 were
lower than claimed contents; in other words, three out of six sam-
ples failed the quality tests. This might be caused by variations in
the manufacturing process. The developed RRLC method in this
ercial E. senticosus extract (E1).
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Fig. 5. RRLC chromatograms of (A) marker compounds reference standard mixture, (B) commercial formulated product capsule (RE-2).
Table 5
The marker compounds contents in six samples of commercial formulated capsules (n=3).
Sample Claims (mg/capsule) Rosavins
(mg/capsule)
Total eleutherosides
(mg/capsule)
RE-1 Rosavins: 1.3 Total eleutherosides: 0.6 1.12 ± 0.01 0.58 ± 0.005
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rRE-2 Rosavins: 3.0Total eleutherosides: 0.44
RE-3 Rosavins: 0.3 Total eleutherosides: 0.8
RE-4 Rosavins: 0.9Total eleutherosides: 0.08
RE-6 Rosavins: 2.1 Total eleutherosides: 0.6
tudy could be used for fast simultaneous determination of all eight
arker compounds in commercial polyherbal formulated products
ontaining R. rosea and E. senticosus.
. Conclusion
R. rosea and E. senticosus are two of the most extensively stud-
ed adaptogens in both pharmacological and clinical studies. In the
resent study, we have successfully developed an RRLC method
o control the quality of commercial formulated products which
ontain R. rosea and E. senticosus components. This RRLC method
s capable of simultaneously analyzing six biological compounds,
.e. salidroside, tyrosol, rosarin, rosavin, rosin, rosiridin in R. rosea
nd two biological compounds, i.e. eleutheroside B and eleuthero-
ide E in E. senticosus with high resolution in a single run within
min. Additionally, this method was fully validated with respect
o precision, repeatability and accuracy.
This method allows strict quality control not only for raw
aterial R. rosea and E. senticosus extracts, but also for commer-
ial polyherbal formulated products. The analyses revealed that
he quality issue of commercial R. rosea extracts was a big con-
ern because the characteristic bioactive compounds, i.e. rosarin,
osavin and rosin of R. roseawere not detected in 33.3% of the com-
ercialR. rosea extract samples tested. Furthermore, therewas also
big variation between the actual rosavins content and the amountPlease cite this article in press as: Y.-C.Ma, et al., Simultaneous quantiﬁcatio
rococcus senticosusMaxim. using rapid resolution liquid chromatography (R
laimed by suppliers. No deviationwas observed in the ﬁve batches
f commercial E. senticosus extracts quantitatively. This method
as further applied to analyze six samples of commercial poly-
erbal formulated capsules collected on the market that contain R.
osea and E. senticosus ingredients.3.15 ± 0.01 0.46 ± 0.005
0.32 ± 0.006 0.82 ± 0.008
0.85 ± 0.008 0.075 ± 0.001
1.71 ± 0.01 0.45 ± 0.004
Our results also showed that this readily available, rapid and
reliablemethod is suitable for routine analysis and effective quality
control of raw materials and ﬁnished products. The main advan-
tage of RRLC is particularly a signiﬁcant reduction of analysis
time, which meant also reduction in solvent consumption. Our
experiments showed four times analysis shortening, while solvent
consumption decreased four times. According to GMP regulations,
routine tests should be performed by quality control (QC) labora-
tory on every batch of raw materials and ﬁnished products. From
this point of view, RRLC is more convenient for complex analyti-
cal determination of pharmaceutical preparations because analysis
duration, solvent consumption and consequently analysis cost is a
very important aspect in many QC laboratories. Therefore, RRLC is
an attractive alternative to conventional HPLC technique in routine
QC analysis, especially in situationswhere high sample throughput
and fast analytical speed are needed.
Health Canada, FDA and many other Natural Health Product
Regulatory Affairs departments are becoming more strict with the
identiﬁcation of herbs and botanical products; therefore in natural
health product industry, it is crucial to establish a rapid analyti-
cal method not only to analyze a single herb, but also to evaluate
and control the quality of commercial polyherbal natural health
products [28].
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A simple, sensitive and reliable reversed phase Rapid Resolution Liquid Chromatography (RRLC) method was developed and validated for 
six biologically active compounds (salidroside, tyrosol, rosarin, rosavin, rosin and rosiridin) in Rhodiola rosea L. roots and powder extracts. 
The method uses a Phenomenex C18 (2)-HST column at 40oC with a neutral gradient system mobile phase (H2O and acetonitrile), a flow rate 
of 1.0 mL/min, and UV detection wavelengths set at 205 and 254 nm, simultaneously. Baseline separation of the six active compounds was 
achieved within 8 minutes. The average percentages of rosavins (rosarin, rosavin, and rosin) in authentic R. rosea roots and root powder 
extracts were quantitatively determined and a characteristic R. rosea roots RRLC profile was established.  The RRLC method is accurate and 
sensitive; in addition, it effectively increases the sample analysis throughput compared with conventional HPLC.  
 
Keywords:  Rhodiola rosea L., rapid resolution liquid chromatography (RRLC), HPLC profile, salidroside, rosavin, rosavin. 
 
 
 
The Rhodiola genus consists of more than two hundred 
species, at least twenty of which have been used in 
traditional Chinese medicine [1]. Among them, R. rosea L. 
(also known as golden root and Arctic root) is the best 
known species. R. rosea is a perennial plant with a thick 
rhizome and a rose-like fragrance when cut [2]. The plant 
is distributed in Arctic regions of Europe, Asia and North 
America. For centuries it has been used in eastern 
European and Asian cultures as a tonic and adaptogen to 
aid physical endurance, extend longevity, protect against 
altitude sickness and help to treat fatigue, depression, 
anemia, impotence, gastrointestinal ailments, infections 
and nervous system disorders [3,4]. 
 
The traditional medicinal uses of R. rosea have been well-
established, and numerous in vitro and in vivo studies have 
been conducted on animals. For example, the CNS 
stimulating, neuro-, cardio- and hepato-protective effects, 
life-span increasing, immunotropic, antiviral, anti-
inflammatory and antibacterial activities of R. rosea have 
been demonstrated [5].  
 
Phytochemical investigations showed the existence of 
three classes of important active constituents in R. rosea, 
namely, phenylethanoids (salidroside, tyrosol), 
phenylpropanoid glycosides (rosarin, rosavin, rosin), and a 
monoterpene (rosiridin) [6].  In the 1970s, salidroside was 
believed to be the compound responsible for the 
pharmacological properties in R. rosea roots; therefore, the 
first generation of R. rosea root tinctures and root powder 
extracts were standardized to a minimum of 0.8% 
salidroside content (w/w) [7]. Salidroside is present in 
many species including R. rosea, R. quadrifida, R. algila, 
R. sachalinensis, R. kirilowii, R. crenulata, R. heterodonta 
and R. semenovii [5]. Similarly, tyrosol has also been 
found in all studied species of Rhodiola [8,9].  A 
characteristic feature of R. rosea is the presence of 
rosavins, which has not been detected in the other 21 
Rhodiola species that are morphologically similar to R. 
rosea [5]. On the market, the term rosavins is used to 
identify the three phenylpropanoid glycosides:  rosarin, 
rosavin and rosin [10,11]. Recently, rosavins has attracted 
particular interest because of its antidepressant, anticancer, 
neurotropic, immune-stimulating and hepato-protective 
properties in some animal experiments [5]. Current market 
production of commercial R. rosea root powder extracts is 
standardized for the contents of both salidroside and 
rosavins. In addition, the rosiridin content of R. rosea is 
about 3% (w/w) and should also be used as a diagnostic 
marker compound [12]. 
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Figure 1:  Chemical structures of the six bioactive compounds in R. rosea 
roots: (1) salidroside, (2) tyrosol, (3) rosarin, (4) rosavin, (5) rosin and (6) 
rosiridin.      
 
Literature survey reveals that a variety of methods have 
been reported to analyze the active constituents of R. rosea 
using capillary zone electrophoresis [13-15], liquid 
chromatography (LC) coupled with UV [4,16-17], and MS 
[18-21]. Unfortunately, all of these methods use acid in the 
mobile phase and suffer from both a long analysis time of 
more than 30 minutes and large quantities of solvent 
consumption. With the objective of reducing analysis time 
while maintaining efficiency, RRLC became one of the 
most frequently applied methods due to its high sensitivity 
and high-speed detection with reduced analysis cost. In 
this study, a RRLC method was established and validated 
for the quantitative and qualitative analysis of the six 
active compounds in R. rosea: (1) salidroside, (2) tyrosol, 
(3) rosarin, (4) rosavin, (5) rosin, and (6) rosiridin.  
 
Basic chromatographic conditions, such as, mobile phase 
composition and UV detection wavelength, were 
optimized while developing the RRLC method. In 
conventional HPLC, it is a common practice to add 
ionization suppressants, such as phosphoric acid (H3PO4) 
and formic acid (HCO2H), to mobile phases to improve 
chromatographic separations. In this study, various mobile 
phases including H2O - methanol (MeOH), 0.05% (v/v) 
H3PO4 solution - MeOH, H2O - acetonitrile (CH3CN), 
0.1% HCO2H solution - CH3CN, and 0.05% H3PO4 
solution - CH3CN, were evaluated and compared. CH3CN 
was chosen over MeOH for its ability to reduce 
backpressure and achieve better separation.  Ionization 
suppressants did not improve the peak shape and 
resolution of the six active compounds, hence H2O - 
CH3CN was selected as the mobile phase. When 
comparing the UV absorptions in the mobile phase, the 
reference compounds rosarin, rosavin, and rosin had 
characteristic absorption at 254 nm, while rosiridin had 
absorption only at 205 nm (Figure 2). In addition, the 
absorption of salidroside at 254 nm was very weak, and 
tyrosol was under the limit of quantification (LOQ). 
Therefore, a detection wavelength was selected at 205 nm 
to analyze the six bioactive compounds in R. rosea 
products in a single run. 
Figure 2: Chromatogram of R. rosea extract at a UV wavelength of 205 
nm (A) and 254 nm (B) using the proposed method. (Column:  
Phenomenex Luna C18-HST, (2.5 μm, 100 × 3.0 mm), kept at 40oC, 
mobile phases: A- H2O and B- CH3CN in the following gradients: 0 to 6 
min, 6 to 17% B; 6 to 7 min, 17 to 19.7% B, 7 to 9 min, kept at 19.7% B, 
9 to 10 min, 19.7 to 100% B, flow rate: 1.0 mL/min, injection volume: 1 
μL). UV detection: A: 205 nm, B: 254 nm. 
 
Prior to sample analysis, the optimal extraction conditions 
of the biologically active compounds in R. rosea were 
compared. Previous work by Ma et al. [6] showed that 
refluxing and ultrasonication using MeOH produced 
comparable extraction yields of rosavins. In this study, 
ultrasonication was selected for its simplicity and shorter 
extraction time [22]. Variables in the extraction 
procedures, such as solvent strength and extraction time 
were optimized on an authentic R. rosea root sample (H3). 
As shown in Figure 3, the extraction yield of rosavins 
increased as the concentration of MeOH in H2O (v/v) 
increased from 20% to 75%; further increases of MeOH 
concentration to 100% had a negative effect on rosavins 
extraction yield. Figure 3 shows that both 15 and 20 
minutes of ultrasonication resulted in comparable results 
for rosavins content, indicating that 15 minutes of 
ultrasonication was sufficient for R. rosea root extraction. 
The highest extraction effectiveness was achieved with 
75% MeOH aq. solution with 15 minutes of ultrasonication 
at 37oC.  
 
 
Figure 3: Rosavins yields from R. rosea roots sample H3 using various 
extraction conditions at 37oC. X-axis consists of 5 blocks representing the 
extraction solvent strength varying from 20% MeOH aq. solution to pure 
MeOH; y-axis shows the tested rosavins contents using different 
extraction conditions. Each block has 3 bars representing different 
ultrasonication times varying from 10 to 20 min. 
 
Calibration curves were prepared by plotting the peak area 
against the corresponding concentrations of analytes.  The 
regression lines are linear in the concentration range 
studied and the corresponding coefficients of correlation 
are shown in Table 1. Rosiridin reference standard was 
used only for identification purposes in the analysis. Peaks 
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Figure 4: HPLC chromatograms of (A) reference standards mixture, (B) 
dried R. rosea roots (H3), (C) fresh R. rosea roots (H5), (D) commercial 
R. rosea powder extract (P5-Lot3). The chromatographic conditions are 
the same as in Figure 2 and UV detection was performed at 205 nm.   
 
were assigned by spiking the samples with standard 
compounds, and comparing the UV spectra and retention 
time. Good linear relationships (r=0.9997 for salidroside, 
0.9999 for tyrosol, rosarin, rosavin and rosin) were 
demonstrated over a range of 50-800 μg/mL. Figure 4A 
shows the separation of the mixed marker compounds: (1) 
salidroside, (2) tyrosol, (3) rosarin, (4) rosavin, (5) rosin 
and (6) rosiridin.  
 
The precision of the developed method was determined by 
analyzing the same mixed standard solution in triplicate. 
As shown in Table 1, the relative standard deviation (RSD) 
of the relative retention time and relative peak area were 
less than 0.79%, indicating that this RRLC method was 
precise for the quantitative analysis of the major active 
compounds in R. rosea. The accuracy of this method was 
evaluated by using the recovery test, which was performed 
by spiking a known quantity of the five references to 0.1 g 
of authentic R. rosea root extract (P5-Lot3). The fortified 
samples were then extracted and analyzed in triplicate. The 
results of the recovery tests were obtained by comparing 
the results of the original samples with the fortified 
samples. The mean recoveries were from 98.9% to 
100.9%, with RSD less than 1.42%. These results suggest 
that the RRLC method has good repeatability, precision, 
accuracy and recovery, making RRLC a reliable and useful 
method for the quality control of R. rosea roots. 
 
Nine samples of Rhodiola roots have been analyzed by the 
described method.  Figures 4B, 4C, and 4D show the 
characteristic RRLC chromatograms of authentic R. rosea 
dried roots (H3), fresh roots (H5), and commercial powder 
extract (P5-Lot3), respectively. The optimum extraction 
and RRLC analysis method were applied to 18 commercial 
samples of R. rosea root powder extracts collected from 
eight suppliers to calculate and compare the contents of the 
five marker compounds. As shown in Table 2, the 
characteristic marker compounds rosarin, rosavin, and 
rosin were not detected in six out of eighteen (33.3%) 
commercial Rhodiola powder extracts (P1-Lot1, P3-Lot1, 
P6-Lot1, P6-Lot2, P8-Lot1, and P8-Lot2). In addition, five 
out of eighteen (27.8%) commercial R. rosea powder 
extracts (P3-Lot2, P4-Lot1, P5-Lot2, P7-Lot1, and P7-
Lot2) did not meet the claimed contents standards for the 
marker compounds. Among these five samples, two 
contained less salidroside than the label claim; the other 
three had either lower rosavin or rosavins content. This 
allows us to conclude that the establishment of this RRLC 
analysis method is necessary to monitor and regulate the  
quality of products in the Natural Health Products industry. 
 
The quantitative analytical results indicate that the 
variations in the content of the marker compounds of the 
commercial R. rosea powder extracts were high, even 
among the samples collected from the same supplier. 
 
Analyses revealed that the characteristic rosavins peaks 
were not detected in about 33.3% of the commercial 
Rhodiola root powder extract samples. In addition, the 
quantification analyses revealed a large variation between 
the actual rosavins content and the amount claimed by 
suppliers. Health Canada, FDA and many other Natural 
Health Product Regulatory Affairs departments are 
becoming stricter with the identification of herbs and 
botanical products.  In the Natural Health Product industry, 
it is crucial to establish an RRLC profile not only to 
differentiate R. rosea from other species, but also to 
evaluate and control the quality of commercial R. rosea 
related products. 
 
It is well known that Chinese medicine preparations     
with different pretreatment processes, manufacturing 
procedures, and dosage forms will be of different quality. 
As well, the content of bioactive markers is also affected 
by plant origins, sources, cultivation year, harvest time, 
geographical climate and environment. All of these could 
result in significant differences in the quality of R. rosea 
roots. However, as shown in Figure 5, the percentages of 
rosavins (rosarin, rosavin, and rosin) in twelve confirmed 
R. rosea root powder extract samples and five authentic R. 
rosea roots samples are relatively constant, except for 
sample P5-Lot5, which was claimed to have a 10% 
salidroside content. The average percentages of rosarin, 
rosavin and rosin are 24.3%, 59.3% and 16.4%, 
respectively. Furthermore, no significant difference was 
observed in the composition of rosavins between 
confirmed commercial R. rosea root powder extracts and 
authentic R. rosea roots, indicating that the chemical 
profile of R. rosea roots does not change during the 
extraction process. 
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Table 1: Regression equations, linearity, LOD, LOQ, retention time, peak area, and recovery test for the five reference compounds. 
 
Compounds Salidroside Tyrosol Rosarin Rosavin Rosin 
Regression equation y=351.24X-0.97 y=864.60X-0.61 y=725.16X+0.87 y=1081.57X+1.95 y=953.07X+1.10 
r 0.9997 0.9999 0.9999 0.9999 0.9999 
LOD (ug/ml) 0.36 0.85 0.52 0.69 0.65 
LOQ (ug/ml) 0.86 1.78 1.14 1.59 1.62 
tR (min) 2.37 ± 0.012 2.84 ± 0.077 6.79 ± 0.017 7.01 ± 0.016 7.37 ± 0.014 
RSD % 0.29 1.11 0.16 0.14 0.12 
Peak Area 563.43 ± 3.81 854.52 ± 4.69 735.86 ± 4.64 1996.55 ± 8.66 966.07 ± 8.14 
RSD % 0.64 0.53 0.61 0.40 0.79 
Recovery 99.6 100.3 98.9 100.9 99.5 
RSD % 1.12 1.15 1.23 1.01 1.42 
 
Table 2: Marker compound contents of 18 claimed R. rosea root powder extracts collected from 8 suppliers. 
 
Contents (mg/g)a 
Sample 
Claim 
(mg/g) Salidroside  Tyrosol Rosarin Rosavin Rosin Rosavins 
P1-Lot1 Salidroside: 10  10.1 NDb ND ND ND ND 
P2-Lot1 Rosavins: 30 40.9 4.6 7.1 19.6 5.7 32.5 
P3-Lot1 Salidroside: 30 30.2 5.1 ND ND ND ND 
P3-Lot2 Rosavins: 30 36.5 2.5 6.8 15.7 5.7 28.2 
P4-Lot1  Salidroside: 10 3.0 0.5 1.3 2.5 0.7 4.4 
P5-Lot1  Salidroside: 30 42.9 2.3 2.7 5.3 1.5 9.5 
P5-Lot2 Rosavins: 30 36.5 2.64 9.4 26.2 6.3 41.9 
P5-Lot3  Salidroside: 10 
Rosavins: 30 
22.3 1.81  6.4 20.7 4.4 31.5 
P5-Lot4 Rosavins: 30 21.6 1.8 6.9 20.1 4.7 31.7 
P5-Lot5  Salidroside: 10 132.0 9.3 2.3 3.2 1.9 7.4 
P5-Lot6  Salidroside: 30 36.0 2.4 9.3 27.1 6.3 42.7 
P6-Lot1 Salidroside: 30 31.6 2.8 ND ND ND ND 
P6-Lot2 Salidroside: 20 32.3 2.8 ND ND ND ND 
P6-Lot3  Salidroside: 20 17.4 1.4 3.5 6.0 2.9 12.5 
P7-Lot1  Rosavin: 30 27.7 4.2 10.9 26.1 6.6 43.5 
P7-Lot2  Salidroside: 30 15.1 2.2 0.09 0.33 0.08 0.5 
P8-Lot1 Salidroside: 10 16.3 2.1 ND ND ND ND 
P8-Lot2 Salidroside: 30 46.4 4.7 ND ND ND ND 
a The data was present at average of triplicates  
b Not detected 
 
 
 
Figure 5: The percentages of rosavins (rosarin, rosavin, and rosin) in 12  
Rhodiola root powder extracts (confirmed as R. rosea.) and 5 authentic R. 
rosea. roots 
 
Our results also showed that the established RRLC method 
enjoyed the practical advantages of shorter analysis times 
and reduced quantity of solvent consumption. This makes 
the RRLC method an attractive alternative to the 
conventional HPLC technique for routine QC analysis, 
especially when high sample throughput and fast analytical 
speed is required. 
Experimental 
 
Chemicals and materials: The reference standards of 
salidroside, tyrosol, rosarin, rosavin, and rosin were 
obtained from ChromaDex (Irvine, USA). The purities 
of these 5 standards were not less than 98%.  The 
reference standard of rosiridin was obtained from 
Biopurify (Chengdu, China), which was used only for 
identification purpose. Four samples of dried R. rosea 
roots (H1, H2, H3 and H4) were provided by Alberta 
Agriculture Canada and Shanxi, China; one fresh R. 
rosea roots sample (H5) was provided by a local 
supplier. Eighteen commercial Rhodiola powder extract 
samples (P1-Lot1, P2-Lot1, P2-Lot2, P3-Lot1, P3-Lot2, 
P4-Lot1, P5-Lot1, P5-Lot2, P5-Lot3, P5-Lot4, P5-Lot5, 
P5-Lot6, P6-Lot1, P6-Lot2, P6-Lot3, P7-Lot1, P7-Lot2, 
P8-Lot1, P8-Lot2)  were collected from 8 global 
suppliers. HPLC grade CH3CN and MeOH were 
purchased from Fisher Scientific (Ottawa, Canada). 
Deionized H2O was prepared by a Nanopure Ultrapure 
water system (Barnstead, USA) for preparing samples 
and mobile solution. 
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Standard solutions and sample preparation: The stock 
reference standard solution of salidroside, tyrosol, 
rosarin, rosavin, and rosin was prepared at a 
concentration of 1.0 mg/mL in MeOH. Further 
calibration levels were prepared by diluting the      
above reference standard solution to 0.2, 0.4, 0.6, and 
0.8 mg/mL. All solutions were stored in a refrigerator at 
4oC.              
 
About 5 g of dried R. rosea roots was ground into fine 
powder and accurately weighed into a 10 mL 
volumetric flask, ultrasonic extracted at 37oC with 75% 
MeOH aq. solution for 15 min, and then made up to 
volume. Prior to RRLC analysis, all samples were 
filtered through a 0.20 μm syringe filter purchased from 
VWR International (Mississauga, Canada). Every 
sample was injected in triplicate and the RSD was 
calculated for all the samples.  For Rhodiola powder 
extracts, the same procedures were followed except 
using pure MeOH as extraction solvent.  
 
Chromatography conditions: RRLC analysis was 
carried out using an Agilent series 1200 RRLC 
instrument (Agilent, CA, US) equipped with a binary 
pump, a micro vacuum degasser, a multi-wavelength 
(MW) detector, an autosampler, and a thermostated 
column. Optimum resolution and peak shape were 
obtained on a Luna C18-HST column (2.5 μm, 100 × 
3.0 mm) from Phenomenex (Torrance, CA, USA). The 
mobile phase consisted of purified H2O (A) and CH3CN 
(B). The linear gradient was as follows: 0-6 min, 6-17% 
B; 6-7 min, 17-19.7% B; 7-9 min, 19.7-19.7% B, 9-10 
min, 19.7-100% B at a flow rate of 1.0 mL/min. The 
column temperature was 40oC, detection wavelength 
205 and 254 nm, and injection volume 1 µL. Each run 
was followed by a 2 min post run and an equilibration 
period of 5 min. 
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Two Rapid Resolution Liquid Chromatography (RRLC) methods have been developed and validated for simultaneous quantification of eight 
major ginsenosides from Panax species, namely, R1, Rg1, Re, Rf, Rb1, Rb2, Rc, and Rd, and flavonoids from Epimedium species, namely, 
epimedins A, B, and C and icariin.  The analyses were performed using an Agilent 1200 series RRLC system with Phenomenex Luna C18-
HST and Zorbax Eclipse XDB columns.  The separation was performed with a gradient mobile phase of A (pure water) and B (acetonitrile) 
at a flow rate of 1.0 mL/ min and 2.5 mL/min, respectively.  Both columns were kept at 40oC with the detection wavelength set at 203 nm.  
Specific eluted compounds were identified by using reference samples of ginsenosides R1, Rg1, Re, Rf, Rb1, Rc, Rb2, and Rd, and epimedins A, 
B, C and icariin.  Baseline separation was achieved in less than 15 minutes for the Phenomenex Luna column and 4 minutes for the Zorbax 
Eclipse column.  Characteristic RRLC profiles were established for complex mixtures of ginsenosides from Panax species and flavonoids 
from Epimedium species.  Both methods developed here are effective for the quality control of formulated products containing both Panax 
and Epimedium varieties. 
 
Keywords:  Rapid Resolution Liquid Chromatography, RRLC, Panax, ginsenoside, Epimedium, epimedin, icariin. 
 
 
 
Panax and Epimedium species have been used in 
Traditional Chinese Medicine for thousands of years and 
are frequently combined as the most popular “energy 
formula” in today’s Natural health product market.  Due to 
multiple ingredients, interferences in the chemical analysis 
occur; therefore, it is necessary to develop a rapid 
analytical method to evaluate Panax and Epimedium 
formulated products simultaneously.  Moreover, there are 
three main species of Panax, namely Panax ginseng C.A. 
Meyer (Asian ginseng), P. notoginseng Burkill and P. 
quinquefolius L. (North American ginseng). The health 
benefits of these species are different:  P. ginseng has a 
traditional use as a stimulating tonic, while P. 
quinquefolius has a calming and nourishing effect [1a].  P. 
notoginseng is highly prized in China for its therapeutic 
effects in treating, for example, cardiovascular diseases, 
inflammation, body pains, trauma, and internal and 
external bleeding due to injury [1b].   
 
Up to date, over 60 species of Epimedium have been 
reported, but only five of these are recorded in the  
Chinese Pharmacopeia, namely, Epimedium bravicornum 
Maxim., E. sagittatum (Sieb. et Zucc) Maxim., E. 
koreanum Nakai, E. pubescens Maxim. and E. wushanense 
T.S. Ying [1c]. Epimedium species have been used 
extensively in Traditional Chinese Medicine for their 
warming or “Yang” tonic effect, which shows great 
therapeutic properties for the kidney [2a,2b], enhances the 
immune system [2c], and increases sperm production, 
therefore being useful for sexual enhancement [2d,2e].  
 
The active constituents of ginseng roots, known as 
ginsenosides (triterpenoid saponin glycosides), contribute 
primarily to the pharmacological effects [3a-3c].  There are 
two types of ginsenosides, both with a similar dammarane 
chemical skeleton, 20S- protopanaxadiol compounds,   
such as Rb1, Rb2, Rc and Rd, and 20S-protopanaxatriol 
compounds, which include Rg1, Re, Rf and R1 [Figure 1] 
[3d].  More than 30 ginsenosides have been identified in 
Panax species [3e], but Rb1, Rb2, Rc, Rd, Re and Rg1 are the 
six major ginsenosides that represents more than 90% of 
the total ginsenoside content in ginseng roots, with Rf  
used for identification of P. ginseng and R1 to identify     
P. notoginseng [3f-3h]. 
 
Flavonoids are the main active chemical constituents of 
Epimedium species, the four major flavonoids contributing 
to their effects being epimedins A, B, and C, and icariin  
[4a,4b]. These biologically active constituents are flavonol 
glycosides with an isoprenyl group substituted on carbon 8 
[Figure 2] [4c].  
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Ginsenoside               R1                 R2 R3 R4 
Rb1             Glc-Glc-     Glc-Glc- - - 
Rb2             Glc-Glc-    Ara(p)-Glc- - - 
Rc             Glc-Glc-    Ara(f)-Glc- - - 
Rd             Glc-Glc-          Glc- - - 
Rg3             Glc-Glc-           H- - - 
Rh2                Glc-               H-      - - 
Re                  -                  -                 Rha-Glc-      Glc- 
Rg1                   - -                Glc-           Glc- 
Rf                           -  -               Glc-Glc-        H- 
R1                    - -            Glc-Xyl-        Glc-   
Figure 1: Structures of ginsenosides found in Panax species (protopanaxadiol-
type) (20S) (Left), (protopanaxatriol-type) (20S) (Right), Glc, glucose; Ara(p), 
arabinose in pyranose form; Ara(f), arabinose in furanose form; Rha, 
rhamnose; H, hydrogen; Xyl, Xylose [3d]. 
 
     
                   (1)             (2) 
  
 (3)             (4) 
 
 (5) 
 
Figure 2: (1) Example of flavonol glycoside with isoprenyl group on carbon 8; 
R representing different sugar substituents; structures of the 4 major flavonol 
glycosides in Epimedium species: (2) epimedin A; (3) epimedin B; (4) 
epimedin C; and (5) icariin [4c]. 
 
Recently, many analytical methods, including HPLC–ESI-
MS/MS [5a,5b], and MEKC [6a,6b], have been developed 
and used for both Panax and Epimedium species.  Many 
publications recommend identification of Panax species by 
confirming either the presence or absence of different 
ginsenosides; for instance, based on either ginsenoside Rf 
or 24(R)-pseudoginsenoside F11 [6c,6d], while some 
consider as many different ginsenosides as possible in 
conjunction with HPLC analysis [7a-7c].  The USP 
method for the identification of P. quinquefolius and P. 
ginseng relies upon analysis of the seven major 
ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1 and Rf by means of 
HPLC and by comparing the ratio of the ginsenosides [3g].  
Ma et al. claimed that consideration of these seven major 
ginsenosides, along with R1, can identify all three 
commonly used Panax species [7d].  Since the 2009 
edition, the USP has published HPLC chromatograms of 
Panax species, thereby minimizing adulterated products on 
the market.  For P. ginseng, it recommends determination 
of the ratio, from the absorbance, for the areas of 
ginsenoside Rb2 and ginsenoside Rb1, which should be 
more than 0.4.  In contrast, the ratio for the same two 
ginsenosides in P. quinquefolius gives a value that is less 
than 0.4.  In addition, for the latter species, the ratio of Rg1 
(protopanaxatriol group) to Rb1 (protopanaxadiol group) 
should be less than 0.3 [3g,7d].  Ginsenosides tend to be 
distributed throughout the Panax plants and occur in roots, 
stems, leaves and flowers [3a].  The ginsenoside profile 
can effectively identify the different ginseng species and 
ginseng plant parts. For example, the roots of P. 
quinquefolius show a Rc/Rb1 ratio < 0.3, while the leaves of 
this plant have a relatively large concentration of 
ginsenoside Rb3 [7d,8a].  Epimedium species provide 
similar profiles, with icariin as the main chemical 
constituent [8b,8c].  Analysis of natural health products 
available on the market relies mostly on the presence of 
icariin for confirmation of products containing Epimedium 
species.  There is a need and scope to expand this 
methodology, as indicated by a gradient HPLC method 
that has successfully separated the four major flavonoids 
of Epimedium species in around 30 minutes [8c]. 
 
A new type of P. quinquefolius from Maryland, USA, has 
been highlighted to have a high Rg1/low Re ratio [3b,8d].  
This is in contrast to that stated in the USP and reported 
for the more extensively investigated type of P. 
quinquefolius, which has a low Rg1/high Re ratio [3g].  The 
Rg1/Re ratio between the two types of this species will vary 
according to the place of cultivation. However, the ratio 
for protopanaxadiol ginsenosides is relatively stable.  In 
this communication, a new rapid analytical method has 
been developed, which mainly focuses on the qualitative 
and quantitative analysis of the protopanaxadiol group that 
is sufficient for the identification of the commonly used 
Panax species.  
 
As mentioned earlier, herbs are often used in combination 
and, therefore, methods developed for single herb analysis 
may not be suitable for formulated products. Rapid 
Resolution Liquid Chromatography (RRLC) enables 
simultaneous analysis of multiple compounds.  This 
technique has been proven for high sensitivity, better 
resolution and a rapid analysis compared with the 
conventional HPLC system [7b,8e].  One of the methods 
reported here was developed after consideration of both 
the active ingredients and the HPLC profiles of extracts of 
Panax and Epimedium species.  It allows separation of 
ginsenosides Rg1 and Re and requires fifteen minutes to 
complete the analysis.  Another method that relies on the 
protopanaxadiol group identification within formulated 
products can be completed in even a shorter time of only 
four minutes. Both methods are sufficient for the 
identification of the formulated products containing Panax 
and Epimedium species. 
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Whilst developing the RRLC method, scrutiny of the 
literature reports indicated a preference for a UV detector 
and a mobile phase commonly employing formic acid 
(HCO2H) to achieve better chromatographic separation 
[7b].  In this study, H2O - acetonitrile (CH3CN) was 
chosen as the mobile phase since their combination allows 
for good chromatographic separation while having the 
advantage of being non-acidic. In the mobile phase for the 
ginsenosides, characteristic UV absorption was obtained at 
203 nm, while flavonoids in Epimedium had a maximum 
absorption at 270 nm and another at 205 nm.  The 
flavonoids from Epimedium have a relatively stronger 
absorption due to their aromatic nature, and, therefore, the 
detection wavelength at 203 nm was selected to analyze 
the twelve bioactive compounds in Panax and Epimedium 
species in a single run. 
 
The linearity for each of the eight ginsenosides, epimedins 
A, B, and C, and icariin were established by plotting the 
peak area (Y) versus concentration (X), expressed by the 
equations given in Table 1.  Correlation study verified the 
linearity of the calibration curves and the correlation 
coefficients were all above 0.999.  Peaks were assigned   
by comparing the retention time of samples with   
reference standards and were demonstrated over a range of 
10 – 2208 μg/mL.  The limit of detection (LOD) and limit 
of quantification (LOQ) for the eight ginsenosides, 
epimedins and icariin were estimated at signal-to-noise 
ratios (S/N) of 3 and 10, respectively.  The LOD and LOQ 
for the bioactive compounds in Panax and Epimedium 
species were ≤ 6.7 µg/mL and less than 12.2 µg/mL using 
the Phenomenex Luna column and ≤ 3.1 µg/mL and less 
than 8.6 µg/mL for the Zorbax Eclipse column, 
respectively.  All LOD and LOQ were obtained with 1 µL 
sample injections.  Figure 3 shows the profile of the major 
chemical constituents from Panax and Epimedium species 
using the Phenomenex Luna column.  Twelve marker 
compounds, namely ginsenosides R1, Rg1, Re, epimedins 
A, B, and C, icariin, Rf, Rb1, Rc, Rb2 and Rd with Rg1 and Re 
were successfully separated.  Figure 3A shows the profile 
of the reference standards.  Figures 3B-D show the 
separation of active compounds of three different Panax 
species and Epimedium species. 
 
The mixed reference standard solution was analyzed in 
triplicate to determine the reproducibility of the method 
developed.  Table 1 shows the relative standard deviation 
(RSD) for both retention time and recovery rate:  it is ≤ 
0.42 % using the Phenomenex Luna column and ≤ 0.38 % 
using the Zorbax Eclipse column. This shows that the 
methods are precise for the analysis of both Panax and 
Epimedium species.  Accuracy was tested via the recovery 
test. Known quantities of the reference standards were 
spiked into 0.03 g of authentic Panax and Epimedium 
powder extract claiming 10% ginsenosides and 10% icariin 
contents; the sample was then extracted and analyzed in 
triplicate.  The results were collected and compared      
with the original Panax and Epimedium powder extract 
and the spiked sample.  The recoveries for the bioactive 
 
 
 
 
 
Figure 3:  HPLC chromatograms of (A) Reference standard mixture, (B)       
P. quinquefolius + Epimedium powder extract. (C) P. ginseng + Epimedium 
powder extract, and (D) P. notoginseng + Epimedium powder extract using 
Phenomenex Luna C18-HST column (for details, see Experimental). 
 
compounds were between 98.3 – 100.7%, with RSD less 
than 1.9% using the Phenomenex Luna column and 96.1 – 
102.9%, with RSD less than 2.8% using the Zorbax 
Eclipse column.   
 
The Phenomenex Luna and Zorbax Eclipse columns were 
compared with each other in triplicate to ensure that 
similar results were obtained.  The percentage of 
concentration tested on the Zorbax Eclipse column to the 
Phenomenex Luna column was 98.1 – 102.5%.  Therefore, 
these results show precision, accuracy, recovery and good 
repeatability. 
 
The existence of the two types of P. quinquefolius roots 
with high Rg1/low Re and low Rg1/high Re, suggests that 
Rg1 and Re from the protopanaxatriol group cannot be 
relied upon for identification of Panax species.  However, 
the Zorbax Eclipse column can be employed to distinguish 
and identify the three commonly used Panax species by 
comparison of the HPLC profiles of the protopanaxadiol 
group ginsenosides, namely Rb1, Rc, Rb2 and Rd (Figure 4). 
Figure 4 shows the profile of the major chemical 
constituents of Panax and Epimedium species using the 
Zorbax Eclipse column.  Ten marker compounds, namely, 
ginsenosides R1, epimedins A, B, and C, icariin, Rf, Rb1, 
Rc, Rb2 and Rd are presented.  Figure 4A shows the profile 
of the reference standards.  Figures 4B-D show the 
separation of active compounds of three different Panax 
species and Epimedium species.  Unfortunately, 
compounds Rg1 and Re cannot be separated using the 
Zorbax Eclipse column, but the total concentration of the 
protopanaxatriol and protopanaxadiol group can aid in the 
determination of the type of P. quinquefolius.  For the 
A
B
C 
D
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Maryland P. quinquefolius (high Rg1/low Re ratio), in the 
28 samples tested, the total ginsenoside content of the 
protopanaxadiol group was around 45%, which is       
lower than the protopanaxatriol Rg1 + Re ratio (normally 
about 55%) [3b]. For the traditional P. quinquefolius    
(low Rg1/high Re ratio), in the ten samples tested, the 
protopanaxadiol group was around 54%, which is higher 
than the protopanaxatriol group, at around 46%.  
 
Next, the RRLC method was applied to four commercial 
samples of Panax and Epimedium formula products by 
using the Phenomenex Luna and Zorbax Eclipse columns 
(Table 3) to compare the contents of the twelve marker 
compounds.  Figures 3 and 4 show the standard RRLC 
chromatograms of these compounds. 
 
There is evidence that P. ginseng and P. quinquefolius 
have opposing effects [1a], but many commercial ginseng 
products containing both Panax species do exist on the 
market.  Figure 5 shows the chromatogram of the ginseng 
product claiming to be pure North American ginseng 
extract.  However, according to the rapid analysis using the 
Zorbax Eclipse XDB column, the product does contain 
North American ginseng roots, but is contaminated with 
Asian ginseng roots.  The Rb2/Rb1 ratio for P. quinquefolius 
should be less than 0.1, but analysis shows that the ratio is 
around 0.3, and, in addition, there is the clear presence of 
Rf in the HPLC chromatogram (Figure 5). 
 
The analysis shows that some products (CPC-GE-001, 
CPC-GE-002, CPC-GE-003) available on the market do 
not meet claimed concentrations.  Many organizations, 
such as Health Canada, the FDA and other Natural Health 
Product Regulatory Affairs departments are demanding 
identification of the herbs and botanical products.   
Therefore, for the Natural Health Product industry to meet 
these requirements, rapid analysis methods are crucial for 
the identification of Panax and Epimedium species, as well 
as to evaluate the quality of the commercial ginseng and 
Epimedium products.  The two methods developed and 
described in this communication are essential for such 
identification and evaluation of Panax species.  The 
Phenomenex Luna column was able to fully separate eight 
major ginsenosides in Panax and four flavonoids in  
Epimedium species for both quantitative and qualitative 
analysis in less than 15 minutes. 
 
The existence of a different type of P. quinquefolius with a 
high Rg1/ low Re ginsenoside ratio has excluded quality 
control reliance on this parameter for identification of 
Panax species.  Nevertheless, the content ratio of 
protopanaxadiol to protopanaxatriol can be used to 
distinguish preparations containing mature ginseng roots, 
fiber and also identifying the two types of P. quinquefolius 
roots.  In the latter case, the HPLC profile of the 
protopanaxadiol group enables effective determination of 
the Panax species purity.  Many commercial ginseng 
products claim to be North American ginseng, but      
Asian ginseng is added to the formulated product as well. 
The Rb2/Rb1 ratio for North American ginseng, which is 
 
 
 
 
 
Figure 4: HPLC chromatograms of (A) Reference standard mixture;   
reference standards ratio of ginsenosides Rg1:Re was prepared at 1:3, (B) P. 
quinquefolius + Epimedium powder extract, (C) P. ginseng + Epimedium 
powder extract, (D) P. notoginseng + Epimedium powder extract, using 
Zorbax Eclipse XDB-C18 column (for details, see Experimental).   
 
 
Figure 5: Representative HPLC chromatogram from an Agilent         
1200 series RRLC system with a Zorbax Eclipse XDB column of a 
commercial P. quinquefolius root powder extract with Epimedium extract 
mixture that was identified as being contaminated with P. ginseng root powder 
using a Zorbax Eclipse XDB-C18 column (for details, see Experimental).  
 
expected to be less than 0.1, allows us to conclude that the 
protopanaxadiol group is enough for the identification of 
the Panax species; therefore, the method using the Zorbax 
Eclipse XDB column was established to complete the 
analysis rapidly in only four minutes. 
 
Experimental 
 
Materials and reagents:  Acetonitrile and methanol of 
HPLC grade were from Fisher Scientific Canada. 
Deionized water was purified by Barnstead’s Nanapure 
ultrapure water system (Barnstead, USA).  Ginsenoside 
standards Rg1, Re, Rb1, Rc, Rb2, Rd, Rf and icariin standard 
were purchased from Sigma (USA), ginsenoside R1 was 
purchased from the National Institute of drug control and 
biological products (China) and epimedins A, B, C were 
from Biopurify (Chengdu, China).  Epimedium plants were 
collected from local growers.  P. quinquefolius, fresh and 
dried root samples, were mostly from plants grown in 
North America. P. ginseng roots were collected from 
ginseng growers in Korea and China.  P. notoginseng 
samples were from Kunming Institute of Botany in China.  
Membrane filters were purchased from VWR International 
(Mississauga, Canada). 
 
 
A 
B 
C 
D 
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Table 1:  Linearity, regression equation, LOD, LOQ, retention time, and peak area for the 12 reference compounds using the Phenomenex Luna column. 
Compounds Regression Equation r2 LOD (µg/mL)  LOQ (µg/mL)      tR (min)   RSD%       Recovery      RSD% 
R1             83.95X+0.48             1.0000       0.51              1.08                    6.53           0.11             99.4              1.01 
Rg1           109.54X+0.071             0.9995         3.21             9.24                      9.67           0.42             98.3              1.88 
Re                   93.68X+0.10             0.9999        1.67             4.40                    10.10           0.40             98.9              1.45  
EA           600.64X+0.63             0.9999         0.17             0.48                    11.03           0.17             99.7              1.06 
EB           561.73X+1.76             0.9998         0.19             0.48                    11.17           0.15             99.6              1.09 
EC           667.55X+2.22             0.9999         0.21             0.60                    11.33           0.19           100.2              1.13 
I           986.88X+3.34             1.0000       0.18  0.49         11.56           0.18           100.7              0.98 
Rf               101.64X+0.57             1.0000         0.10             0.24                    12.64           0.22             99.9              1.05 
Rb1                   88.23X+0.06             0.9999         0.68             1.56                    13.36           0.19           100.6              1.15 
Rc              96.46X+0.10             0.9994         0.74              2.18                    13.63           0.16             99.9              1.20             
Rb2               92.54X-0.02             0.9998        0.62             1.46                    13.87           0.18             99.5              1.19 
Rd          110.87X-0.05             0.9998        0.52             1.35                    14.46           0.21             98.7              1.18 
R2, Correlation coefficient of regression equations; LOD, limit of detection (S/N = 3); LOQ, limit of quantification (S/N = 10). 
 
Table 2:  Linearity, regression equation, LOD, LOQ, retention time, peak area for the 12 reference compounds using Zorbax Eclipse column 
Compounds Regression Equation r2 LOD (µg/mL) LOQ (µg/mL) tR (min)    RSD%       Recovery      RSD% 
R1              21.73X-0.001             0.9994        0.97              2.09                 0.97             0.12               97.2            1.42 
Rg1+Re*             44.34X-0.14             0.9995        3.10              8.60                  1.41             0.38               96.1            2.81 
EA           327.20X+0.06             1.0000         0.15              0.44                 2.42          0.16              99.8            1.14 
EB           301.03X+0.10                 1.0000        0.14              0.47                2.52          0.20              99.3            1.23 
EC           357.25X+0.19             1.0000                0.18              0.56                 2.60          0.17            100.4            1.16 
I           403.63X+0.30             1.0000                0.14   0.48         2.68          0.18             102.3            0.97 
Rf                   6.81X-0.01             0.9995        0.13            0.33                  3.04             0.14             100.4            1.19 
Rb1                  33.84X+0.29             0.9999         0.64              1.55                  3.30             0.19             102.9            1.25 
Rc              36.04X+0.18             0.9996         0.73               1.97                  3.40             0.17             100.2            1.36             
Rb2               36.32X+0.14             0.9994         0.59              1.62                 3.50             0.16               99.6            1.29 
Rd            41.85X+0.14             0.9991         0.57             1.59                 3.74             0.19               98.9            1.78 
R2, Correlation coefficient of regression equations; LOD, limit of detection (S/N = 3); LOQ, limit of quantification (S/N = 10). 
*, Ginsenoside Rg1/Re Reference standard was prepared in the ratio of 1/3. 
 
Table 3: Concentration of the active compound analysis in four commercial formulated ginseng and Epimedium products. 
   Products  Labeling Claim   % Compared with that claimed  % Compared with that claimed 
       (Phenomenex Luna column)  (Zorbax Eclipse column) 
 CPC-GE-001 North American Ginseng P.E. (105 mg)  
(10% ginsenosides)      90.8      92.5   
   Epimedium P.E. (87.5 mg)  
icariin (10% )    102.6    103.5 
 
 CPC-GE-002* North American Ginseng P.E. (200 mg) 
(10% ginsenosides)      71.3      70.7 
   Epimedium P.E. (55 mg) 
icariin (20% )      86.5      87.2 
 
 CPC-GE-003 Asian Ginseng Root Powder (100 mg) 
(3% ginsenosides)      36.4      35.8 
   Epimedium Leaf Extract (15 mg)  
icariin (20% )      81.9      82.3 
 
 CPC-GE-004 North American Ginseng P.E. (105 mg) 
(10% ginsenosides)    106.1    105.9 
   Epimedium P.E. (175 mg) 
                   icariin (5% )    123.8    125.1 
All samples tested in triplicate. All commercial products only claimed icariin and ginsenosides and did not claim epimedins A, B and C. 
* Sample tested contained  P. ginseng instead of P. quinquefolium. 
 
Sample and Reference standard solution preparation:  
Panax species powder extract (50 mg), claiming to contain 
10% ginsenosides, and Epimedium powder extract 
claiming 10% icariin were accurately weighed and 
dissolved in 100% methanol in a 10 mL volumetric flask 
and made to volume, then ultra-sonicated at 37oC for 20 
min.  Panax species root powder (100 mg) was accurately 
weighed and dissolved in 75% aqueous methanol in a 10 
mL volumetric flask, made to volume, then ultra-sonicated 
at 37oC for 20 min.  The extract solutions were cooled to 
room temperature, the supernatant collected, and filtered 
through a membrane filter (0.2 µm) for further analysis.  
Each of the prepared solutions (1 µL) was injected into the 
RRLC system.  Each sample was injected in triplicate and 
the RSD calculated for all the samples. Each of the 
individual standards (R1, Rg1, Re, Rf, Rb1, Rc, Rb2, and Rd,  
epimedins A, B, and C, and icariin) were accurately 
weighed and dissolved in pure methanol to yield 
concentrations of 179.00, 29.55, 89.10, 37.37, 223.58, 
37.42, 30.45, 45.00, 23.98, 39.58, 60.18 and 90.00 µg/mL, 
respectively.  All the solutions were stored at 4oC in a 
refrigerator. Each of these (1 µL) was injected into the 
RRLC system.  All analyses were performed on an Agilent 
1200 Series Rapid Resolution Liquid Chromatography 
(RRLC) system (Agilent, CA, USA) equipped with a 
binary pump SL, vacuum degasser from a high-speed, 
high-performance auto plate-sampler SL for high area 
precision, and a thermostated column compartment SL that 
reaches up to 100oC.  This system was controlled by an 
Agilent ChemStation revision B.01.01. A Phenomenex 
Luna 2.5 µm C18 (2)-HST (3.0 mm x 100 mm) column, 
and a Zorbax Eclipse XDB-C18 1.8 µm (4.6 mm x 50 mm) 
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column were employed at 40oC.  Gradient elution with 
mobile phase A (pure water) and B (acetonitrile) was used 
at a flow rate of 1.00 mL/min for the Phenomenex Luna 
column and 2.50 mL/min for the Zorbax Eclipse XDB 
column.  For the Phenomenex Luna column, gradient 
elution was employed as follows:  19.7% - 19.7% B at      
0 – 9 min; 19.7% - 30% B at 9 – 10 min; 30 – 30% B at  
10 – 11 min; 30 – 50% B at 11 – 16 min; 50 – 100% B at 
16 – 18 min, followed by a re-equilibration for another 2 
min.  For the Zorbax Eclipse XDB column gradient elution 
was employed as follows:  22 – 22% B at 0 – 1.6 min; 22 – 
40% B at 1.6 – 3.5 min; 40 – 50% B at 3.5 – 5 min; 50 – 
100% B at 5 – 6 min, followed by a re-equilibration period 
of 2 min. 
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